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“What we observe is not nature itself, but nature exposed to our method of questioning” 
Werner Heisenberg (1901-1976) 
 
“Some men have constitutions that are like wooded mountains running with springs, others like 
those with poor soil and little water, still others like land rich in pastures and marshes, and yet 
others like the bare, dry earth of the plain.” 
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There are over 100,000 human diseases of which only around 10,000 are known to be 
monogenic, resulting from modification in a single gene. Many multifactorial diseases, such as 
cancer and lung cancer in particular, are outcomes of the interplay between genetic and 
environmental factors. It is well known that smoking is the major environmental risk factor in 
lung cancer. 
In recent years, great progress in genotyping technology and cost control has enabled 
researchers to perform large-scale association studies, involving thousands of individuals 
genotyped on millions of markers. To date, genome-wide association studies (GWAS) have 
identified hundreds of genetic risk factors in complex diseases. However, the detected variants 
explain only a small part of the total heritability. Unexplained phenotypic variance may be 
partly attributed to undetected gene-environment (G×E) interactions. Therefore, there has been 
a rapid evolution in the development of statistical tools to discover biologically credible G×E 
interactions in a genome-wide context. 
The analysis of G×E interactions remains one of the greatest challenges in the post-genome-
wide-association-studies era. Uncovered population stratification in large association and 
interaction studies may lead to false positive results or masks true signals via under (over)-
estimation of the true effects. In this dissertation, we began by evaluating the robustness or the 
magnitude of the bias due to population stratification in case-control studies of G×E interaction. 
A simple equation was derived to measure the population stratification bias of the interaction 
effect for the case-control estimator of G×E interaction. 
Another great challenge to G×E interaction research remains the ability to maintain adequate 
power, while accounting for gene-environment (G-E) correlation in the source population. G-
E correlation occurs when exposure to the environmental condition depends on the individual’s 
genotype or vice versa, irrespective of the disease status of that individual. The empirical 
hierarchical Bayes approach to G×E interaction (EHB-GECHI) benefits from greater power than 
the classical case-control test, while accounting for population based G-E correlation. We 
developed extensions of EHB-GECHI with respect to covariate adjustment, general exposure 
and genotype and to performance under an additive mode of inheritance. 
In this dissertation, we finally introduce an alternative to EHB-GECHI which is computationally 
more efficient, using a more stable model to obtain the posterior estimates of G-E correlation 
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in controls. Incorporating a parametric Bayes inference framework, with a normal distribution 
in a hierarchical model, we developed an approach that corrects for G-E correlations, gathering 
information across all markers simultaneously (as does EHB-GECHI). We named it the 
empirical hierarchical Bayes approach for G×E interaction EHB-GENN. Our simulation study 
demonstrates that EHB-GENN controls type I error better than EHB-GECHI while remaining 
powerful. 
The last objective of this thesis is to consider the joint tests for genetic marginal and G×E 
interaction effects. Previous studies suggest that G×E interactions might help to detect genetic 
variants missed by a test for association with main effects. Specifically, some SNPs may have 
a moderate genetic and a G×E interaction effect and thus joint tests for marginal association 
and G×E interaction were developed to gain additional power over tests of main effects. Here 
we present how EHB-GENN can be adopted for joint testing, resulting in the EHB-GENNJ test. 
The application of EHB-GENN and joint tests on four lung cancer GWASs from the 
ILCCO/TRICL consortia is presented and the results are discussed. We detected known 
markers for lung cancer, e.g. rs1051730 in CHRNA3, rs8034191 in AGPHD1 and suggestive 
signals, e.g. rs7982922 in ENOX1, rs2736100 in TERT, applying joint tests, using either case-
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Charles Darwin in his opus “On the Origin of Species” stated that there are two factors 
responsible for biological variation-“the nature of the organism and the nature of the 
conditions” (Darwin 1869). Darwin represents the idea of genes and environment as being two 
forces acting synergistically to design our individual characteristics. Nowadays, it is well 
known that most of the multifactorial human traits and diseases, such as asthma, diabetes, 
cardiovascular diseases, depression, rheumatoid arthritis, and cancer, result from a complex 
interplay of the individual genetic and various environmental factors. 
Cancer is the leading cause of worldwide mortality. All cancer forms together were responsible 
for 8.2 million deaths and 14.1 million new cancer cases around the globe in 2012 (WHO) 
(http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx). Even though the cancer mortality rate 
has continued to decline within the last two decades, the prognosis remains poor (Jemal, Simard 
et al. 2013). In the European Union, the predicted number of cancer deaths for 2013 is 1.3 
million (Malvezzi, Bertuccio et al. 2013) 
Lung cancer is the most lethal malignant disease, having caused 1.37 million deaths worldwide 
annually according to figures from 2008 (WHO) (World Health Organization Report on the 
Global Tobacco Epidemic, 2008). Lung cancer alone is responsible for more cancer-related 
deaths than breast, prostate, and colon cancers together (Jemal, Siegel et al. 2008). In Germany, 
it is the third most common cancer type after prostate, colon, and breast cancers. According to 
the population-based cancer registries in Germany, 35,040 men and 17,030 women newly 
developed lung cancer in 2010 (Krebsregister and (GEKID) 2013). Lung cancer is a complex 
disease of the uncontrolled cancer cell growth in tissues of the lung. Lung cancer is classified 
in two main types: small cell (SCLC) and the more common non-small cell (NSCLC) lung 
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cancer. These two types differ in their growth rates and are treated differently. The most 
abundant of the three histological forms of NSCLC is adenocarcinoma, which is also the most 
common type of lung cancer in lifelong non-smokers, so-called “never smokers” (Subramanian 
and Govindan 2007). 
Various environmental factors may affect the risk of lung cancer development, such as 
exposure to tobacco smoke, radon, asbestos, arsenic, diesel exhaust, silica, and chromium. 
Lung cancer in non-smokers may occur due to a combination of genetic factors (Gorlova, Weng 
et al. 2007) with radon (Catelinois, Rogel et al. 2006), asbestos (O'Reilly, McLaughlin et al. 
2007) and air pollution (Chiu, Cheng et al. 2006, Coyle, Minahjuddin et al. 2006, Kabir, 
Bennett et al. 2007), including second-hand smoke (WHO , Smoking and and Health 2006). 
In USA, the major environmental risk factor for lung cancer is exposure to tobacco smoke. 
Smoking contributes to 80% and 90% of lung cancer deaths in women and men, respectively 
(US Department of Health and Human Services, 2004). In Germany, 90% of lung cancer cases 
in men and 60% in women are attributed to active smoking (Robert Koch-Institut und die 
Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. 2012). 
However, not only smoking alone increases the risk of developing lung cancer. Nowadays, it 
is well recognized that genetic factors also play a role in lung cancer development. Single 
nucleotide polymorphisms (SNPs) in a number of genome regions have been reported as being 
associated with lung cancer. Mutations in the genes CHRNA5, CHRNA5, CHRNB4 located on 
chromosome 15q25.1 (Amos, Wu et al. 2008, Hung, Christiani et al. 2008, Thorgeirsson, Geller 
et al. 2008), SNPs on chromosome 5p13.3 (McKay, Hung et al. 2008, Wang, Broderick et al. 
2008, Landi, Chatterjee et al. 2009), mutations in BAT3 on chromosome 6p21.33 (Wang, 
Broderick et al. 2008), RAD52 on 12p13.3 (Shi, Chatterjee et al. 2012), and in the 
CDKN2A/CDKN2B genes on chromosome 9p21.3 (Timofeeva, Hung et al. 2012) were 
discovered to affect the risk of lung cancer in genome-wide association studies (GWAS). Even 
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though active smoking is the lead environmental risk factor in lung cancer, only 10% of heavy 
smokers are known to develop the disease (Sauter, Rosenberger et al. 2008). This together with 
the discovery of genetic causes of the disease suggests that the inter-individual genetic 
variability affects the metabolism of tobacco-smoke carcinogens and leads to risk modification 
for some groups (Matakidou, Eisen et al. 2005, Amos 2007, Sun, Schiller et al. 2007). 
Therefore, studies of G×E interactions play an important role in public health, especially in the 
context of cancer research. They may further help to understand the nature of many complex 
diseases (Thomas 2010a, Thomas 2010b) and more specifically of the above lung cancer, for 
which smoking has such a considerable impact. 
The initial completion and ongoing development of the International HapMap Project 
(International HapMap Consortium 2003, International HapMap Consortium 2005) and 
Human Genome Project (International Human Genome Sequencing Consortium 2004) lists 
human genetic variation at millions of polymorphic locations in several human populations, 
supporting more powerful association study designs. Recent advances in genotyping 
technologies, together with a significant reduction in the associated costs, has enabled 
researchers to genotype millions of common and rare single nucleotide polymorphisms (SNPs) 
both rapidly and accurately (International HapMap Consortium 2005, Frazer, Murray et al. 
2009, Spencer, Su et al. 2009). A direct consequence is the opportunity to perform genome-
wide association studies (GWAS), investigating the role of individual genetic variability in the 
etiology of complex diseases such as cancer. The genome-wide association study was 
originally designed to investigate DNA variations associated with common diseases (Hardy 
and Singleton 2009, Manolio, Collins et al. 2009). Nowadays, a new generation of GeneChips 
(Affymetrix) and BeadChips (Illumina) not only target common and rare SNPs but also known 
copy number variations (CNV), based on the maps available for the human genome (Redon, 
Ishikawa et al. 2006, McCarroll 2008, Itsara, Cooper et al. 2009). Recently, a lot of effort was 
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undertaken in developing methods for low-cost whole-genome next generation sequencing 
(NGS) (Mardis 2008, Schuster 2008, von Bubnoff 2008), which will capture even more rare 
variants, previously missing. 
In addition to the technological advances in the field, genetic association studies and studies of 
gene-environment interactions can benefit from improvements in study design and the 
development of novel statistical approaches. In the following, I list statistical methods 
commonly used in G×E interaction studies for a case-control design. Consider a case-control 
study with a total of N individuals. Let G denote a genotype, E denote the exposure variable, 
and D the disease outcome variable. Many of the existing association tests including interaction 
tests are based on logistic regression models such as 
logit (P(D = 1| G)) = α0 + βGG+ βZZt     (1.1) 
logit (P(D = 1| G, E)) = α0CC + βG_CCG + βE_CCE + βCCG×E+ βZCCZt (1.2) 
Equation (1.1) models the association between D and G, therefore βG = 0 tests for the presence 
of a genetic main effect, while equation (1.2) includes genetic, environmental, and G×E 
interaction effects. Both (1.1) and (1.2) are adjusted for the covariate Z. 
The classic case-control (CC) method for G×E interactions estimates the corresponding 
coefficient βCC per SNP, which is equal to the natural logarithm of the odds ratio for G×E 
interaction from a logistic regression model (1.2). 
The case-control test analyzes G×E interaction as departure from the multiplicative odds ratio 
model. It is often underpowered to detect G×E interactions, especially in situations in which 
genetic and environmental factors are rare and the interaction effect is weak (Mukherjee, Ahn 
et al. 2012). 
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Some researchers have addressed the lower power issue of the case-control test for G×E 
interactions by developing statistical tools designed to increase power to detect such 
associations besides marginal genetic effects. One powerful proposal is the case-only design, 
in which tests for G×E interaction are performed without considering controls (Piegorsch, 
Weinberg et al. 1994, Khoury and Flanders 1996). Under the assumption of the absence of 
population-based gene-environment correlation (G-E), the case-only (CO) test provides a valid 
procedure to test for G×E interaction, characterized by the more precise estimate of G×E 
interaction and therefore more powerful alternative to the CC test. As proposed by the case-
only method, under G-E independence the odds ratio of G×E interaction can be estimated using 
information only from cases (Piegorsch, Weinberg et al. 1994). However, when the assumption 
of G-E independence is violated, the CO test produces a large number of false positive results; 
in other words the CO test has a highly inflated type I error rate. 
Generally, on genome-wide level one would expect to see only a small number of genes and 
therefore a moderate number of SNPs with true detectable G-E correlation. However, this may 
be different for diseases such as lung cancer with a strong behavioral component. It is also well 
known that population stratification leads to such spurious dependence between genotype and 
environment in the general population (Thomas 2010a). Therefore, in the presence of 
population stratification thousands of markers may induce population-based G-E correlation. 
These correlations result from the difference in the  genetic origin of individuals, i.e. 
differences in minor allele frequencies across the subgroups and cultural differences leading to 
the specific behavior and favor of the specific exposures, resulting in differences in the 
environment distribution. Since confounding owing to the population stratification leads to 
biased G×E effect estimates, it is important to control for the ancestry covariates in the analyses 
(Bhattacharjee, Wang et al. 2010). 
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In recent years, further methods to test for G×E interaction have been proposed, aiming to 
increase the power while keeping type I error at the nominal 5% level, mainly exploiting the 
assumption of G-E independence or trying to account for G-E correlation. 
The two-step approach to scan for G×E interactions was developed by Murcray in 2009 
(Murcray, Lewinger et al. 2009), which we will refer to as Murcray’s two-step test (MUR). 
During the first step, the approach screens for G-E correlation in the combined sample of cases 
and controls. Then only a subset of SNPs that exceed a given significance threshold in step one 
is selected and tested for G×E interaction in step two. This test combines power protection 
from bias of the case-control estimator in a two-step procedure with the test statistics being 
independent from each other. A disadvantage of MUR is that the power of the first step depends 
on the case-control ratio. A large number of controls compared to cases leads to a decrease in 
power in step one and hence a loss of power for the overall procedure (Murcray, Lewinger et 
al. 2011). 
The empirical Bayes type shrinkage estimator (MUK-EB) proposed by Mukherjee and 
Chatterjee (Mukherjee, Ahn et al. 2008, Mukherjee and Chatterjee 2008) combines the robust 
case-control estimator with the efficient case-only estimator in a single Bayes type shrinkage 
estimator. This estimator is approximately robust to the presence of G-E correlation in the 
source population and performs comparably to the case-control estimator under large 
departures from independence. This method does not strictly adhere to nominal type I error 
rate level under violation of the G-E independence assumption and moderate sample size. 
However, it does maintain a smaller mean squared error (MSE) compared to the other 
estimators listed above irrespective of the true state of the G-E correlation. 
Recently Sohns and colleagues developed the empirical hierarchical Bayes approach to G×E 
interaction (EHB-GECHI) (Sohns 2012, Sohns, Viktorova et al. 2013). EHB-GECHI is based on 
a two-level hierarchical model with a parametric distribution assigned to the parameters during 
7 
 
both stages; the chi distribution and a mixture distribution with the point mass at zero. EHB-
GECHI does not require the assumption of G-E independence. In fact, the approach estimates 
the G-E correlation effect by borrowing information across all SNPs. 
The EHB-GECHI test has inflated type I error in the presence of a large number of G-E 
correlations. The approach is therefore not recommended for significance testing. EHB-GECHI 
is however proposed as a powerful ranking method to identify biologically plausible signals 
worth further detailed investigation (Sohns, Viktorova et al. 2013). “Rank power” is defined as 
the percentage of simulated replicates in which the true interacting SNP is within the top 
ranking positions, according to the absolute value of the corresponding test statistics, for 
example top 25 (Sohns, Viktorova et al. 2013). EHB-GECHI was shown to be the most powerful 
procedure in most of the cases in terms of rank power (Kuo and Zaykin 2011) when compared 
to the other G×E methods listed above. 
 All the approaches discussed above were designed specifically to study G×E interactions and 
therefore do not involve the estimation of genetic marginal or joint effects. Nevertheless, it is 
also interesting to know if G×E interaction may help to uncover additional genetic variants 
associated with disease, markers with moderate G×E interaction and main effects.  This idea is 
based on the belief that even though a disease locus only modifies the disease risk in presence 
of the environment, the locus may still have a detectable marginal effect on the disease (Clayton 
and McKeigue 2001). Joint tests were recently investigated by some research groups in terms 
of achieved power and type I error (Chatterjee, Kalaylioglu et al. 2006, Kraft, Yen et al. 2007, 
Dai, Logsdon et al. 2012). Joint tests are performed to address simultaneous testing for the 
presence of a genetic main effect combined with a test for G×E interaction (Vanderweele, Ko 
et al. 2013). 
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Genome-wide studies of G×E interactions are challenging, since there are many pitfalls that 
can arise. We attempted to address some of these pitfalls. As a rule of thumb in case-control 
samples, the detection of an interaction requires a sample size at least four times larger than 
that required for the detection of a main effect of comparable size (Smith and Day 1984). 
Therefore, non-homogeneity of the study sample usually arises as an issue. The presence of 
population stratification in the study sample is the first problem in studies of G×E interactions, 
as it leads to a loss of power to identify true signals, spurious association signals, and can mask 
true associations. Principal component analysis (PCA) is currently the most powerful 
procedure to correct for population stratification in genetic main effects case-control GWASs 
(Price, Patterson et al. 2006). PCA was also shown to be an attractive approach to correct for 
the bias in studies of gene-gene (G-G) interactions (Bhattacharjee, Wang et al. 2010). In case-
control studies of G×E interactions, we investigated the bias due to population stratification, 
deriving an analytical measure of the population stratification bias for case-control studies of 
G×E interactions. PCA was performed to correct for population stratification. We proposed 
PCA as a useful tool to correct for population stratification bias in GWAS of G×E interactions. 
Another prominent problem in the study of G×E interactions is the occurrence of population-
based G-E correlation for as many as thousands of markers. In a genome-wide context, the 
assumption of G-E independence cannot be surely stated and therefore statistical tools need to 
be able to relax this constraint. In this dissertation, we generalized the originally proposed 
EHB-GECHI method in three important ways: with respect to covariate adjustment; 
performance under the additive risk model assumption; and regarding applications with 
multilevel or continuous exposure, or genotype variables. However, some limitations remain, 
such as, for example, the complexity of the EHB-GECHI method and its relatively poor 
performance in the GWAS context and last but not least the inappropriateness of the approach 
to significance testing. Therefore, we proposed an alternative empirical hierarchical Bayes 
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approach for G×E interactions, naming it EHB-GENN. All three extensions mentioned above 
are valid in our modified EHB-GENN. Just as its predecessor EHB-GECHI, this novel approach 
does not require any assumption of independence between genotype and environment in the 
general population. It is characterized by a smaller number of hyperparameters requiring 
estimation on the dataset and by the ability to derive an exact equation for the posterior variance 
of the statistics. The asymptotic distribution of EHB-GENN test statistics is available as well. 
We propose EHB-GENN as a powerful tool keeping type I error rate at an approximately 
nominal level in contrast to EHB-GECHI and MUK-EB in samples in which a large number of 
G-E correlation signals with moderate to large effect size are suspected to occur. Moreover, to 
address the joint testing issue, we constructed a joint test EHB-GENNJ similar to that proposed 
by Dai and colleagues (Dai, Logsdon et al. 2012). 
This thesis is motivated by lung cancer GWAS data from the International Lung and Cancer 
Consortium (ILCCO) and the Transdisciplinary Research in Cancer of the Lung (TRICL) 
consortium and is illustrated on four GWASs (Holle, Happich et al. 2005, Wichmann, Gieger 
et al. 2005, Amos, Wu et al. 2008, Hung, Christiani et al. 2008, Hung, McKay et al. 2008, 
Sauter, Rosenberger et al. 2008, Wang, Broderick et al. 2008) with smoking as the exposure 
factor. On analysis, we searched for G×E interactions applying the EHB-GENN approach. 
Findings following the application of competing methods on the same data including EHB-
GECHI can be found in (Sohns 2012, Sohns, Viktorova et al. 2013). The discovery and 
understanding of G×E interactions clearly is a key to the future of personalized medicine. Novel 
findings in this area of research will very likely prove to be a direct benefit to public health, as 
they have the potential to lead to the future development of individualized treatments. 
This dissertation is structured as follows: Chapter 2 includes a review of the literature and 
presents the necessary definitions and methods. Chapter 3 discusses issues concerning bias 
resulting from population stratification in studies of G×E interaction. A simple equation is 
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presented to evaluate the degree of population stratification bias in case-control studies of G×E 
interaction. A description and the results of the calculation as well as a simulation study are 
presented. The advantage of applying PCA to correct for population stratification in G×E 
interaction studies is discussed. Chapter 4 introduces the EHB-GECHI approach (Sohns 2012, 
Sohns, Viktorova et al. 2013) and describes limitations of the originally proposed method. 
Newly developed generalizations of the EHB-GECHI method are also presented in this chapter. 
Chapter 5 introduces our alternative approach “Empirical hierarchical Bayes approach for G×E 
(EHB-GENN)” to studies of G×E interaction in the presence of many population-based G-E 
correlation signals with moderate to strong effect size. A description and the results of a 
simulation study comparing EHB-GENN versus other G×E interaction methods are presented. 
The same chapter describes the joint tests for genetic main and G×E interaction effects. Joint 
tests as proposed in (Dai, Logsdon et al. 2012) are described. Similarly, a joint EHB-GENNJ 
test was built. In Chapter 6, we present the lung cancer analyses and results. We applied EHB-
GENN and four joint tests on four GWASs from the ILCCO/TRICL consortia. The data are 
described and the methods and results of these genome-wide studies are discussed. The thesis 





2. Fundamentals of Human Genetics and Association Studies 
This chapter reviews basic concepts of population genetics as well as case-control genetic 
association and gene-environment interaction (G×E) studies. This chapter also presents the 
necessary definitions and principles to understand the main challenges in the area of case-
control genome-wide G×E interaction studies and our approach to addressing some of them. 
The statistical methods described in this chapter are standard methods to analyze G×E 
interactions in genome-wide association studies (GWAS) for a case-control design. Later in 
this thesis, these methods are employed in a comparative performance evaluation of our novel 
EHB-GENN approach to studies of G×E interaction, and are applied to analyze lung cancer 
GWAS data. 
 
2.1. Population Genetics 
 
2.1.1. Hardy-Weinberg Equilibrium 
A keystone of population genetics is outlined in the Hardy-Weinberg law, a principle 
independently formulated by G.H. Hardy and W. Weinberg in 1908. The Hardy-Weinberg law 
relies on the assumption of random mating in a population. A random mating represents the 
situation, in which a mating occurs between individuals at random and implies absence of 
selection. The Hardy-Weinberg law describes the mathematical relationship between 
frequencies of alleles and frequencies of genotypes in a population at a locus (l). To illustrate 
the law, assume that qA and qa are the corresponding frequencies of alleles A and a at a biallelic 
locus l, so that qA+qa=1. The Hardy-Weinberg law postulates that in a random mating 
population the allele and genotype frequencies are in stable equilibrium, which is called Hardy-
12 
 
Weinberg Equilibrium (HWE). The frequencies of the corresponding genotypes AA, Aa and aa 
are qA2, 2qAqa, and qa2, respectively. It indicates that the frequencies remain stable from 
generation to generation. On the other hand, allele frequencies can be derived from genotype 
frequencies under HWE by allele counting. 
To check if population allele and genotype frequencies satisfy HWE, a χ2 -test can be 
performed, which compares expected genotype frequencies derived from allele frequencies 
with those observed. Deviation from HWE may suggest e.g. the presence of selection or 
admixture of different populations. All markers, including single nucleotide polymorphisms 
(SNPs), are often tested for HWE during the quality control (QC) steps to avoid possible 
genotyping errors. Only control samples are used when testing for deviations from HWE. The 
threshold for declaring SNPs to be outside HWE varies significantly among studies; p-values 
between 0.001 and 5×10-8 (Zeggini and Morris 2010) are common depending on the number 
of SNPs under consideration. 
 
2.1.2. Minor Allele Frequency 
The minor allele frequency (MAF) refers to the frequency at which the least common allele 
occurs in a population or in the sample at hand. The frequency of alleles in the population can 
be estimated from their frequencies in a reference population, such as HapMap samples 
(International HapMap Consortium, Frazer et al. 2007). More often, MAF is estimated on the 
data on hand, and thus is only representative of cases or of controls. One of the alleles appears 
less frequently than the other and therefore is called minor allele. For a locus that is in Hardy-
Weinberg Equilibrium in a diploid population, an allele that is at a frequency of 0.3 will be 
present in 51% of the population [1 - (1 - 0.3)2] and absent in 49% of the population [(1 - 0.3)2]. 
Low MAF leads to poor performance of the genotype-calling algorithms (Weale 2010). 
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Therefore, during quality control of the data, it is reasonable to exclude markers with a MAF 
≤ 5% from further consideration depending on the sample size (Ziegler, König et al. 2008). 
 
2.1.3. Linkage Disequilibrium 
Genetic linkage represents violation of Mendel’s Second Law, the law of independent 
assortment of genes, and is reflected in segregation of alleles at loci located close to each other 
on the same chromosome. Under independence, the frequency of haplotypes, for close loci 
defined as pairs of alleles at different loci on the same gamete, is the product of their respective 
allele frequencies. Therefore, when an excess or deficiency of some haplotypes exist, the loci 
are said to be in linkage disequilibrium (LD) (Khoury, Beaty et al. 1993). In other words, LD 
may be defined as an existing correlation between alleles located at nearby loci, owing to the 
possible joint inheritance (Ardlie, Kruglyak et al. 2002). For simplicity, assume that we have 
only two loci l1 and l2 with corresponding alleles A/a and C/c and allele frequencies qA, qa, qC, 
qc. Four haplotypes can be present for these two loci: AC, Ac, aC, and ac, with corresponding 
frequencies qAC, qAc, qaC, and qac. Hence, l1 and l2 are in equilibrium if  
qAC = qAqC, qAc = qAqc, qaC = qaqC, qac = qaqc.  
LD can be measured by the disequilibrium coefficient DAC = qAC - qAqC, which deviates from 0 
in the presence of LD. Another measure of LD, which does not depend on the allele frequency 
is the squared correlation coefficient, r2 (Ardlie, Kruglyak et al. 2002). It is defined as 
r2=D2/( qAqaqCqc)  
and ranges from 0 to 1. The HapMap database (http://www.hapmap.org) provides LD 
information across the whole human genome including the position of recombination hotspots 




2.1.4. Population Stratification 
A confounder is a variable that is not itself the object of a study, but is associated with the 
phenotype and at the same time with the variable under consideration. For example, a person’s 
ethnicity can be a confounder associated with the marker allele under investigation. If the 
confounder is the ethnic affiliation of the individual, this is termed confounding by ethnicity or 
population stratification (PS) (Ziegler and König 2006). PS in case-control studies can occur 
when cases and controls are sampled from different populations in different proportions and 
the allele frequencies of genetic markers, often SNPs, are distributed unequally in these 
populations (Ziegler and König 2006). 
Population stratification can act as a confounder when the genetic effect is assumed to be 
uniform across admixed subpopulations. On the other hand, PS can act as an effect modifier 
when the existing genetic effect is different in the subpopulations. In other words, the 
homogeneity of genetic effects in all subpopulations is assumed for a confounder, whereas for 
an effect modifier, heterogeneity across subpopulations is present. In addition to producing 
false-positives, population stratification might also mask a true association, thus reducing the 
power to detect a genetic effect (Ziegler and König 2006). 
To test for the presence of population stratification in the study sample, Pritchard and 
Rosenberg (Pritchard and Rosenberg 1999) proposed to select randomly a set M of neutral 
markers in linkage equilibrium and construct χ2-statistics for each marker, testing for 
association between the phenotype and the marker. Then, the sum of all statistics (χ𝑙
2, l=1..M) 
is formed χ𝑃𝑆
2 = ∑ χ𝑙
2𝑀
𝑙=1  and it is asymptotically distributed as χ
2 with M degrees of freedom 
(df) under the null hypothesis. Failure to reject the null hypothesis by this test means that the 
sample is assumed to be homogeneous. 
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There are three well-known approaches in the literature to test for association in case-control 
studies while adjusting for unobserved population stratification. The first approach is the 
method of Genomic Control (GC), proposed by Devlin and Roeder (Devlin and Roeder 1999). 
The idea of GC is to use additionally genotyped marker loci (“null loci”) to estimate empirically 
the variance inflation under the null hypothesis of no association. For this, an inflation factor λ 








in which 0.4549 is the median of the χ1𝑑𝑓
2  distribution. It is assumed that this remains constant 
across the genome. Then, the test statistic for any locus l is corrected to χ𝑙
2/?̂?. 
The second approach proposed is the structured association (SA), (Pritchard, Stephens et al. 
2000, Pritchard, Stephens et al. 2000). SA is a two-step procedure. The first step involves 
inferring details of the population structure from the sample using unlinked loci. The number 
of subpopulations and allele frequencies in each of them, as well as the mixed genetic ancestry 
of each individual are estimated employing a Monte-Carlo method at this step. In the second 
step, the information obtained is used to test for association within subpopulations (Ziegler and 
König 2006). Several different SA methods were subsequently proposed, for example as in 
(Köhler and Bickeböller 2006). 
The third approach to correct for population stratification, which is applicable to genome-wide 
association case-control studies, is based on principal component analysis (PCA) and was 
proposed by Price and colleagues (Price, Patterson et al. 2006). To perform a PCA, more than 
10,000 SNPs are necessary for the principal components estimation. The analysis is therefore 
only applicable in the GWAS context. The advantage of PCA over GC or SA is that the ancestry 
adjustment is performed per SNP. This allows us to correct for both false positive and false 
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negative associations (Weale 2010). Nowadays, PCA is the most commonly used and the most 
appropriate method to correct for PS in genetic association studies. We implemented PCA to 
account for population stratification in our study and as such, it is explained in more detail 
below. 
 
2.1.5. Principal Component Analysis 
Principal component analysis is a method of data dimensionality reduction. It is a roadmap of 
how to transform a large set of related variables into a new smaller set of independent variables 
to reveal hidden substructure in the original data. The main idea of PCA is that most of the 
variance in the original dependent variables, in the GWAS context genotypes, can be explained 
by a significantly smaller number of independent variables, termed principal components. 
Principal components are ordered according to the amount of the variance in the full set of 
original variance that they explain. 
PCA can be performed on case-control data and can be summarized in the following steps. Let 
a GWAS dataset be coded in the form of a large n×m matrix with one row i=1,...,n for an 
individual and one column j=1,…,m for every SNP. Each cell ij of the original data matrix is 
the genotype of individual i at a particular SNP j, coded as (0,1,2) according to the minor allele 
count (gij). 
Step 1 Normalize the original n×m matrix by subtracting column means and dividing by 
standard deviation. 
Step 2 Calculate the covariance matrix for the normalized data variables. Assume Σ to be the 
m×m covariance matrix of M=(m1…mm), so that Σjj’=cov(mj,mj’), where mj  =(g1j…gnj)t is a jth 
SNP column-vector, j=1,…,m, j’=1,…,m, gij is each cell entry in n×m matrix. 
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Step 3 Calculate the eigenvectors and eigenvalues of Σ. To do so, let a1∈ℝM be the first 
eigenvector and λ to be an eigenvalue, then we search for the vector maximizing 
 𝑣𝑎𝑟(𝑎1
𝑡 𝑀) = 𝑎1
𝑡 𝛴𝑎1 
with 𝑎1
𝑡𝑎1 = 1. This defines an optimization problem with one constraint and can be solved 
using the method of Lagrange multipliers. Consider the function 
 𝑎1
𝑡 𝛴𝑎1 = 𝜆(𝑎1
𝑡 𝑎1 − 1) 
where λ is a constant termed the Lagrange multiplier. Differentiating the equation above with 
respect to a1 leads to 𝛴𝑎1 − 𝜆𝑎1 = (𝛴 − 𝜆𝐼𝑀)𝑎1 = 0, with IM being the M×M identity matrix. 
From this it follows that λ is an eigenvalue of Σ and a1 is corresponding eigenvector. From the 
above and the fact that λ ∈ ℝ , the equation below follows 
 𝑎1
𝑡 𝛴𝑎1 = 𝑎1
𝑡 𝜆𝑎1 = 𝜆𝑎1
𝑡 𝑎1 = 𝜆. 
Therefore, λ is the largest eigenvalue of Σ and a1 is the first eigenvector, explaining the largest 
proportion of variance. Once a1 is derived, the transformation 𝑎1
𝑡 𝑀 yields the first principal 
component. To obtain the second, third and finally mth principal components, we proceed in 
the same manner, choosing vector a2∈ℝM maximizing the variance, such that 𝑎2
𝑡 𝑀 and 𝑎1
𝑡 𝑀 are 
uncorrelated, i.e. orthogonal. Then, 𝑎2
𝑡 𝑀…𝑎𝑀
𝑡 𝑀 are m principal components. Mathematically 
speaking, this process is equivalent to a singular value decomposition of the original data 
matrix. In 2006, Price and colleagues demonstrated in application on case-control genetic data 
that the inclusion of the set of significant principal components as covariates into the analysis 
corrects for population stratification in genome-wide association studies, of the genetic main 
effect (Price, Patterson et al. 2006). PCA for GWAS data is integrated in the EIGENSOFT 




2.2. Case-Control Association Studies 
 
2.2.1. Genome-Wide Association Studies 
In a case-control design, the aim of a GWAS is to compare genetic variants in cases to those in 
controls and answer the question as to whether there is any association of these variants with 
the outcome status (cases/controls) (Witte 2010). Even though there is an increasing tendency 
to apply GWA methodologies to population-based cohorts, most published GWASs employ 
the case-control design (McCarthy, Abecasis et al. 2008). Genetic variation in such studies is 
often measured using single nucleotide polymorphisms (SNPs). GWASs are possible 
nowadays because millions of SNPs in the human genome have been identified. 
 
2.2.2. Measures of Association  
Consider the following data representation in an epidemiological study. Let G=(0, 1, 2) 
represent the minor allele count for an individual genotype. Let D denote the disease status 
with 1 for cases and 0 for controls. Let nij denote the number of subjects with D=i, G=j and N 
is the total number of individuals. Replacing any subscript with a dot (.) denotes summation 
over the subscript. We can summarize our data for each SNP in Table 2.1. 
Table 2.1 Data representation in a case-control study with a SNP 
 G=0 G=1 G=2  
D=1 n1 n11 n12 n1. 
D=0 n0 n01 n02 n0. 
 n.0 n.1 n.2 N 
 
The most common measure of association between a categorical characteristic and a disease 
the “relative risk” (RR) of a member with the characteristic developing the disease compared 
to a member without this characteristic. For example, genetic association represents association 
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between a specific genotype and the disease and can be measured by the relative risk of a person 
with such a genotype developing the disease compared to a person with the reference genotype. 
To identify risk factors for disease development, the risks of contracting or developing the 
disease among people exposed to potential risk factors, such as genotype or environment, and 
those of an unexposed individual, such as wild-type genotype or absence of environment, are 
related to each other. The corresponding measure of risk is the relative risk.  
The relative risk is the probability that a member of an exposed group will develop a disease 
(D=1) relative to the probability that a member of an unexposed group will develop that same 
disease. 








,  ?̂?1 =
𝑛11
𝑛.1




from the data presented in Table 2.1, where a penetrance is the disease risk given a specific 





























The genetic risk of a specific mode of inheritance is defined according to the relationship 
between the corresponding genotype RRs. 
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The dominant mode of inheritance satisfies   RRG=2=RRG=1>1. 
The co-dominant mode of inheritance satisfies RRG=2≠RRG=1>1. 
The recessive mode of inheritance satisfies   RRG=2>1, RRG=1=1. 
The additive mode of inheritance satisfies   RRG=2=(2RRG=1 - 1)>1 (additive scale). 
The multiplicative mode of inheritance satisfies  RRG=2=(RRG=1)2>1. 
In a prospective cohort study, the numbers of individuals in the exposed and non-exposed 
groups are representative of the whole population. This is not the case in retrospective case-
control studies, since the number of individuals in each group is decided upon by the 
investigator and can therefore differ from the population case-control ratio. It is therefore 
impossible to estimate risks and thus relative risks from case-control data directly. However, 
association can then be measured by the so-called odds ratio (OR). 
If an event takes place with probability P, the odds in favor of that event are P to (1-P). The 
odds ratio relates two odds to each other. In our example, OR is the odds of exposed individuals 
among cases divided by the odds of exposed individuals among controls: 
 𝑂𝑅 =  
𝑃(𝑒𝑥𝑝𝑜𝑠𝑒𝑑|𝑑𝑖𝑠𝑒𝑎𝑠𝑒)/(1−𝑃(𝑒𝑥𝑝𝑜𝑠𝑒𝑑 |𝑑𝑖𝑠𝑒𝑎𝑠𝑒))
𝑃(𝑒𝑥𝑝𝑜𝑠𝑒𝑑|𝑛𝑜𝑛 − 𝑑𝑖𝑠𝑒𝑎𝑠𝑒)/(1−𝑃(𝑒𝑥𝑝𝑜𝑠𝑒𝑑|𝑛𝑜𝑛 − 𝑑𝑖𝑠𝑒𝑎𝑠𝑒))
  














Generally, OR overestimates RR when RR>1 and underestimates it when RR<1. The two 
converge with decreasing disease prevalence. Under the assumption of a rare disease in the 
population, OR is a good approximation of RR and is therefore often implemented in case-
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control studies. In practice, even with a disease prevalence of 10%, scientists estimate 𝑂?̂? from 
the data collected by a case-control study and use it to approximate RR. 
 
2.2.3. Case-Control and Case-Only Studies 
In a case-control study, sampling data are collected retrospectively and conditional on the 
disease status of the individuals. The common practice in association studies is to analyze such 
data ignoring the fact of the retrospective nature of the sampling. In 1956, Cornfield 
demonstrated that prospective and retrospective odds ratios are equivalent. Therefore, odds 
ratios estimation based on the case-control data is valid as according to (Cornfield 1956). 
The efficiency of the approach was established in two other research papers by Andersen 
(Andersen 1970) and Prentice and Pyke (Prentice and Pyke 1979). They demonstrated that 
classic prospective analysis of the case-control data yields the correct maximum-likelihood 
estimates of the odds ratio parameter under the retrospective sampling design when the 
distribution of the underlying covariates is nonparametric. 
Later, in 1994, Piegorsch and colleagues proposed the case-only approach to estimate the G×E 
interaction effect (Piegorsch, Weinberg et al. 1994).  Under the population-based G-E 
independence assumption, it was shown that efficient estimates of G×E interaction for the 
categorical exposure and binary genotype variables can be derived through logistic regression 
in a case-only approach (Piegorsch, Weinberg et al. 1994, Umbach and Weinberg 1997). The 
CO approach was later extended to continuous environment and categorical genotype variables 
employing logistic, ordinal, and multinomial regression techniques (Albert, Ratnasinghe et al. 




2.2.4. Single Nucleotide Polymorphism 
Molecular markers revealing polymorphisms at the deoxyribonucleic acid (DNA) level are 
essential in human genetic studies. Over the last ten years, the revolution in biological science, 
advanced genotyping and sequencing technologies, together with a substantial reduction in 
their cost, have enabled the research community grow significantly in terms of knowledge 
regarding genetic and genomic variation, as more and more genomes have been sequenced. 
One of the essential steps towards greater knowledge was the completion of the Human 
Genome Project in 2003 (Collins, Green et al. 2003). As a consequence of this, great progress 
in the discovery of genes influencing the risks of contracting and/or developing monogenic and 
complex human diseases has been made (Johnson 2009). The post-genome era is beginning to 
unravel the function of the human genome and explain how the circa 21,000 human genes 
interact with each other and the environmental conditions. Comparison of genomic DNA 
sequences in a variety of people reveals many positions at which two or sometimes more 
different nucleotide bases can be observed (Syvanen 2001). Such variation at a single position 
of a DNA sequence is called a single nucleotide polymorphism, or simply SNP. SNPs are very 
abundant in the human genome and are estimated to appear approximately once within every 
thousand bases (Sachidanandam, Weissman et al. 2001, Syvanen 2001, Venter, Adams et al. 
2001). The effect of a SNP on a phenotype depends on the genome position at which the SNP 
occurs, be it a non-coding region or the coding region of a gene or its regulatory region. 
Multifactorial human diseases do not follow a simple Mendelian mode of inheritance, but are 
the result of the complex interplay between a number of genetic and environmental factors 
(Buselmaier and Tariverdian 1999, Thomas and Kejariwal 2004). There is increasing evidence 
that many complex diseases demonstrate association with various SNPs and a number of 
environmental factors. Identifying the molecular causes of multifactorial diseases has become 
the focus of many researchers. Association studies are rapidly gaining ground for human traits, 
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with the human Haplotype Map Project (International HapMap Consortium 2003) being funded 
to support these findings (Thomas and Kejariwal 2004). 
 
2.2.5. Gene-Environment Interaction and Gene-Environment Correlation 
The vast majority of common diseases occur as a result of the complex interplay between 
genetic and environmental factors. In genetic studies, gene-environment interaction (G×E) is 
present when genetic and environmental factors interact to cause a disease. In other words, the 
effect of the genotype and particular environment together on the disease risk differs from the 
separate effects of these factors (Ober and Vercelli 2011). For example, in cancer biology the 
susceptibility to particular external toxic elements depends on the efficiency of the DNA repair 
process, which can be different among the people with a different genetic signature. Another 
example is individual response to drug therapy or nutrition. Genetics may affect the response 
to a particular medication via drug metabolism and can also lead to medication or therapy 
intolerance (Hunter 2005). So far, numerous gene-environment associations with various 
complex diseases have been discovered through candidate gene or genome-wide association 
studies. For example, the GST superfamily polymorphisms have been demonstrated to be 
associated with an elevated risk of smoking-related lung cancers (Haugen, Ryberg et al. 2000, 
Raimondi, Paracchini et al. 2006). It was also demonstrated that female smokers develop a 
substantially higher expression level of CYP1A1 in the lung when compared to males (Haugen, 
Ryberg et al. 2000). The variant alleles of the NAT2 gene increase the risk of colorectal cancer 
only in combination with red meat consumption (Chen, Stampfer et al. 1998). Furthermore, 
variants of the MC1R gene, responsible for skin color, combined with UV radiation result in 
an increased skin cancer risk (Rees 2004), while on their own the genetic and environmental 
factors have no effect on the disease risk. 
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To understand the scope of this dissertation, it is of at most importance to distinguish between 
G×E interaction and gene-environment (G-E) correlation in the source population. In this 
dissertation, G×E interaction will always refer to gene-environment interaction and G-E 
correlation to gene-environment correlation. Population-based G-E correlation occurs when 
exposure to the environmental condition depends on an individual’s genotype or vice versa, 
irrespective of the disease status of the individual. This can be either causal or spurious. An 
example of a causal G-E correlation would be smoking addiction genes, which favor smoking, 
such as GPR51 and CYPR51 (Caporaso, Gu et al. 2009), or the genes GABRA2 and ADH1C 
correlated with alcohol addiction (Online Mendelian Inheritance in Man 2012). Generally, one 
would expect only a small number of genes to have a true causal G-E correlation, detectable 
on a genome-wide level. However, this can be different for some diseases such as lung cancer 
for which many SNPs may correlate with nicotine addiction. It is also well known that 
population stratification leads to a spurious dependence between genotype and environment in 
a general population, owing to non-causal mechanisms (Thomas, Lewinger et al. 2012), and 
may lead to a large number of G-E correlations. Understanding the difference between G×E 
interaction and G-E correlation is crucial to this dissertation. It is therefore important to 
separate these two terms. However, G×E interaction and G-E correlation are not mutually 
exclusive in reality and can occur simultaneously. 
To introduce the approach to measure G×E interaction and G-E correlation in case-control 
studies, we restrict to the binary disease (D), a binary exposure (E) and the three level genotype 
(G) variables. As previously introduced, let G=(0, 1, 2) be an individual genotype. Let E denote 
an exposure variable with 1 for exposed subjects and 0 otherwise. Let D denote the disease 
status with 1 for cases and 0 for controls. Let nijk denote the number of subjects with D=i, G=j 
and E=k and N is the total number of individuals. Then, data for each SNP may be presented 
in a 2×6 contingency table (Table 2.2). 
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Table 2.2 Data representation in a case-control study with a SNP and a single environment as 
factor 
 E=1 E=0  
 G=0 G=1 G=2 G=0 G=1 G=2  
D=1 n101 n111 n121 n100 n110 n120 n1.. 
D=0 n001 n011 n021 n000 n010 n020 n0.. 
 n.01 n.11 n.21 n.00 n.10 n.20 N 
 
The observed vector of cell counts for cases in the sub table n1=(n121, n111, n101, n120, n110, n100) 
and respectively for controls n0=(n021, n011, n001, n020, n010, n000) can be seen as realizations from 
two independent multinomial distributions n1∼MN(n1, p1) and n0 ∼MN(n0, p0), where p1=(p121, 
p111, p101, p120, p110, p100) and p0=(p021, p011, p001, p020, p010, p000) are the cell probabilities of the 

































 joint effect of genotype and 
environment. 





Where ORG is for G=1 or 2, likewise for ORGE. 




positive G × E, increasing disease risk
no G × E
negative G × E, decreasing disease risk
 
Gene-environment correlation separately within cases or controls, respectively, can also be 

























If G-E correlation is absent for a SNP in cases or in controls, then ORcontrols=1 or ORcases=1 for 
that SNP. As before, departure from 1 indicates the presence of G×E interaction. 
It is very important for this thesis that G×E can be expressed by the ORs measuring G-E 




















Therefore, if ORG×E = 1, G×E is absent if 𝑂𝑅𝑐𝑎𝑠𝑒𝑠= 𝑂𝑅𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 = 1 or if 𝑂𝑅𝑐𝑎𝑠𝑒𝑠 =
 𝑂𝑅𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 ≠ 1. And G×E is present if 𝑂𝑅𝑐𝑎𝑠𝑒𝑠 ≠ 1 and 𝑂𝑅𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 = 1 or if 𝑂𝑅𝑐𝑎𝑠𝑒𝑠 ≠
𝑂𝑅𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 and 𝑂𝑅𝑐𝑎𝑠𝑒𝑠 ≠ 1. We say that G-E correlation is present in a source population if 
𝑂𝑅𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 ≠ 1 and this correlation is independent from the respective disease status of the 
individual. If the prevalence of the disease is small, i.e. the disease is rare in the population, 
ORcontrols in the presence of G×E and absence of population G-E converges to 1 (Schmidt and 
Schaid 1999). 
Generally, ORs of genetic main effect, environmental main effect, and G×E interaction can be 
estimated via logistic regression models. Assume we want to model the probability P(D=1|G,E) 
for a SNP and a single environment ( data as in Table 2.2). 
𝑙𝑜𝑔𝑖𝑡(P(D = 1|G, E)) = log (
P(D = 1|G, E)
P(D = 0|G, E)
) = 𝛼 + 𝛽𝐸 + 𝛽𝐺 + 𝛽𝐺×𝐸𝐺𝐸, (2.1) 
where βE=log(ORE), βG=log(ORG), and βG×E =log(ORG×E). 
The OR of the G-E correlation in cases and controls can also be modeled via logistic regression. 
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 𝑙𝑜𝑔𝑖𝑡(P(E = 1|G, D = 1)) = log (
P(E = 1|G, D = 1)
P(E = 0|G, D = 1)
) = 𝛼𝑐𝑎𝑠𝑒𝑠 + 𝛽𝑐𝑎𝑠𝑒𝑠𝐺 and
 (2.2) 
 𝑙𝑜𝑔𝑖𝑡(P(E = 1|G, D = 0)) = log (
P(E = 1|G, D = 0)
P(E = 0|G, D = 0)
) = 𝛼𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 + 𝛽𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠𝐺,
 (2.3) 
where βcases=log(ORcases) and βcontrols=log(ORcontrols). 
It is easy to see from the previous page that G×E interaction can be measured 
 𝛽𝐺×𝐸 = log(𝛹) = 𝑙𝑜𝑔 (
𝑂𝑅𝑐𝑎𝑠𝑒𝑠
𝑂𝑅𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠
) = 𝛽𝑐𝑎𝑠𝑒𝑠 − 𝛽𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠.   (2.4) 
Equation (2.4) is crucial to this dissertation. 
The βs can be estimated from the data by the maximum likelihood estimates (MLE) ?̂?, which 
would then approximately follow a normal distribution, by 
?̂?𝐺=(1,2) = 𝑙𝑜𝑔 (
𝑛1𝐺0𝑛000
𝑛0𝐺0𝑛100
)  ∼ 𝑁(𝛽𝐺 , 𝜎𝐺
2),  with 𝜎𝐺




?̂?𝐸           = 𝑙𝑜𝑔 (
𝑛101𝑛000
𝑛100𝑛001
) ∼ 𝑁(𝛽𝐸 , 𝜎𝐸
2),  with 𝜎𝐸




?̂?𝑐𝑎𝑠𝑒𝑠     = 𝑙𝑜𝑔 (
𝑛1𝐺1𝑛100
𝑛1𝐺0𝑛101
) ∼ 𝑁(𝛽𝑐𝑎𝑠𝑒𝑠, 𝜎𝑐𝑎𝑠𝑒𝑠
2 ), with 𝜎𝑐𝑎𝑠𝑒𝑠




?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 = 𝑙𝑜𝑔 (
𝑛0𝐺1𝑛000
𝑛0𝐺0𝑛001
) ∼ 𝑁(𝛽𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠, 𝜎𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠
2 ), with 𝜎𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠











) = ?̂?𝑐𝑎𝑠𝑒𝑠 − ?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 ∼ 𝑁(𝛽𝐺×𝐸, 𝜎𝐺×𝐸
2 ), 
with 𝜎𝐺×𝐸
2 = ∑ ∑ ∑
1
𝑛𝐷𝐺𝐸





Logistic regression is a very flexible approach in association studies and is therefore is widely 
used in genetic main effect, environmental main effect, and G×E and gene-gene interaction 
(G×G) studies. It allows for adjusted analysis by simple inclusion of additional covariables.  
For a binary disease outcome such as case-control status, most existing association tests, 
including interaction tests, are based on logistic regression models. To test for the presence of 
G×E interaction for a SNP, one needs to construct a test statistic testing whether the null 
hypothesis (H0) is followed for each SNP. 
H0: 𝛽𝐺×𝐸= 0, no G×E interaction at the SNP 
The corresponding ?̂?𝐺×𝐸 can be estimated from the data. 
 




The classic case-control test (CC) for G×E interaction tests H0 using the standard Wald-type 
test statistics, constructed for each SNP. This test statistic, TCC, is distributed in an 















Piegorsch and colleagues proposed the case-only test (CO) for gene-environment interaction, 
seeking to achieve greater power than the case-control test (Piegorsch, Weinberg et al. 1994). 
They used equation (2.4) as a basis for their estimator of G×E interaction and additionally 
introduced two critical constraints to construct a valid test. They assume that the disease of 
interest is rare in the population and that G-E correlation is absent, i.e. genotypes and 
environment are independent and thus ORcontrols=1 => βcontrols=0. These assumptions allow the 
construction of a test statistic, which is distributed as N(0,1) under H0, and is characterized by 








∼ 𝑁 (𝛽𝐺×𝐸 ,1) 
However, when the assumptions are violated, the case-only method leads to biased estimates 
and TCO has highly inflated type I error rate. Thus, testing for significance is no longer 
trustworthy. 
 
Mukherjee’s Shrinkage Estimator 
Mukherjee and Chatterjee proposed another method to test for G×E interaction, relying on 
empirical Bayes models (please refer to empirical Bayes in the subsequent sections). They 
named the G×E interaction estimator based on their approach an empirical Bayes type 
shrinkage estimator for G×E and introduced the corresponding test statistic (MUK-EB), 
(Mukherjee and Chatterjee 2008). The MUK-EB estimator combines the robust case-control 
and powerful case-only estimators into a single estimator as 
?̂?𝑀𝑈𝐾−𝐸𝐵 = (1 − 𝐵)?̂?𝑐𝑎𝑠𝑒𝑠 + 𝐵?̂?𝐺×𝐸 . 
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The weight B is chosen according to the evidence in the data on the G-E correlation. If G-E is 
present in the controls then B→1 and ?̂?𝑀𝑈𝐾−𝐸𝐵 converges to ?̂?𝐺×𝐸. When no evidence of G-E 
is present, then B→0 and ?̂?𝑀𝑈𝐾−𝐸𝐵 converges to ?̂?𝑐𝑎𝑠𝑒𝑠. 
To derive the shrinkage factor B, Mukherjee and Chatterjee demonstrated that the G-E 
correlation for each SNP can be modeled by the use of ?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠. They used a variance 
parameter τ2 representing the degree of uncertainty with respect to G-E correlation per SNP. 
?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠  | 𝛽𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠  ∼  𝑁(𝛽𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠, (𝜎𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠)
2)   
𝛽𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 | 𝜏
2    ∼ 𝑁(0, 𝜏2)    










?̂?𝐺×𝐸 .    
This estimator, even though derived from the Bayesian perspective, is neither Bayes nor 
empirical Bayes, but a pure function of the observed data. 


















∼ 𝑁 (𝛽𝐺×𝐸 ,1) 
The MUK-EB test was shown to be more powerful than the case-only test. At the same time 
the type I error for MUK-EB is substantially less inflated as for the case-only test, which makes 
the test applicable to significance testing in the presence of G-E correlation (Mukherjee and 
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Chatterjee 2008). However, the type I error of MUK-EB can still be inflated in the presence of 
a large number of G-E correlations in the source population (Mukherjee, Ahn et al. 2008). 
 
Murcray’s Two Step Approach 
Murcray and colleagues introduced a two-step procedure to test for G×E interaction (MUR). 
At the first step, they proposed to screen for the correlation between genotype and environment 
irrespective of the disease status by 
 𝑙𝑜𝑔𝑖𝑡(P(E = 1|G)) = 𝛼𝑎𝑙𝑙 + 𝛽𝑎𝑙𝑙𝐺 
Therefore, 𝑂𝑅𝑎𝑙𝑙 =
(𝑝100 +𝑝000 )(𝑝1𝐺1 +𝑝0𝐺1 )
(𝑝101 +𝑝001 )(𝑝1𝐺0 +𝑝0𝐺0 )
, for G=1 or 2 and data from Table 2.2. 
The maximum likelihood estimate (MLE) of βall, 













∼ 𝑁(𝛽𝑎𝑙𝑙, 1) 
Only SNPs passing the first step proceed to the second step, meaning only those SNPs with 
?̂?𝑎𝑙𝑙  significantly different from zero. At the second step of the MUR procedure, SNPs passed 
on from step one are tested for G×E interaction using the classic case-control test. Since steps 
one and two are independent, the overall procedure provides a valid test for interaction 
(Murcray, Lewinger et al. 2009). Furthermore, given that a substantially reduced number of 
SNPs is passed to the second level compared to the CC or CO test, the common Bonferroni 
multiple testing adjustments are performed based on that number of second level SNPs, leading 
to the power gain over the CC test. However, the power of the test depends on the case-control 
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ratio. An excess number of controls compared to cases leads to an overall loss in power for the 




3. Population Stratification in Studies of G×E Interaction 
A large number of naturally occurring populations are heterogeneous and stratified, meaning 
that a population is composed of discrete homogeneous subpopulations or continuous 
admixture is present. These subpopulations have possibly different ethnic backgrounds and 
therefore different genetic makeup as well as environmental exposures. For such admixed 
populations with uncovered substructure, the assumption of G-E independence is often violated 
as a result of confounding or effect modification. However, within a specific substratum, the 
assumption of independence may still hold. 
Quite a few statistical methods have been proposed to estimate G×E interaction in large-scale 
case-control studies, including those described in Chapter 2. However, not all of the proposed 
methods are robust to the presence of hidden substructure in the study sample, such as 
population stratification. As a consequence, their performance often leads to biased effect 
estimates. Unfortunately, population stratification (PS) is not easily identifiable and is hard to 
control for using classic approaches such as matching or stratified analysis. The extent of 
population stratification bias depends on certain characteristics of the study sample, 
specifically on the number of admixed ethnicities, differences in genotype and exposure 
frequencies, and differences in disease prevalence across the strata. 
In the following, we derive an equation to measure the theoretical population stratification bias 
of G×E interaction in a case-control design. We investigated the magnitude of the bias due to 
population stratification for G×E interaction in case-control studies and compared estimates of 
G×E interaction to the genetic main effect estimates and to the case-only estimates of 
interaction in terms of robustness to the presence of PS. An analytical study of various realistic 
situations was performed to measure population stratification bias using our derived equation. 
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We named this measure of bias the confounding interaction ratio for case-control estimator of 
G×E interaction (CIRCC). We used equations derived earlier to evaluate the bias of the genetic 
main effect by the so-called confounding rate ratio (CRR) (Lee and Wang 2008) and of G×E 
interaction in a case-only design by the confounding interaction ratio for the case-only 
estimator of G×E interaction (CIRCO) (Wang and Lee 2008). 
Furthermore, we compared four common methods for G×E interaction (Chapter 2) in terms of 
their robustness to the presence of population stratification in the study sample. We performed 
a simulation study for a set of different scenarios admixing similar or more divergent sub-
populations. The EHB-GECHI approach was compared to CC, CO MUK-EB (see Chapter 1). 
We also evaluated the ability of principal component analysis (PCA) (Price, Patterson et al. 
2006) as integrated in the EIGENSOFT statistical package to correct for population 
stratification bias in studies of G×E interaction. 
 
3.1. Measures of Population Stratification Bias 
 
3.1.1. Notation 
Assume, that a study population consists of j = 1 … J discrete subpopulations. Let E(E) and 
G(G) denote the presence (absence) of the exposure and of the susceptibility genotype for a 
person. We define pj to be the prevalence of the environment E, qj to be the frequency of the 
susceptible genotype G, and bj to be the background disease risk (a risk for non-carriers of the 
risk allele, unexposed to the environment in subpopulation j). Then, ej =
pj
1−pj
 denote the 
exposure prevalence odds and gj =
qj
1−qj
 denotes the genotype frequency odds. Let nj denote 
the total number of individuals in the jth subgroup. Note that in Section 3.1 we consider the 
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situation of collecting all individuals (cases and controls) from the entire population. This gives 
us the opportunity to estimate risk in the case-control or the case-only study settings instead of 
operating only with odds ratios. Please note that certain notation is redefined newly for each 
section of this dissertation and is valid only for that particular section. 
 
3.1.2. Confounding Rate Ratio for Case-Control Design and Confounding Interaction 
Ratio for the Case-Only Design 
Lee and Wang in (Lee and Wang 2008) derived an equation to quantify population stratification 
bias for genetic main effect estimation in a case-control study. They termed the newly 
introduced measure of population stratification bias the confounding rate ratio (CRR). Here we 
outline their derivation. Let RRG denote the relative risk of disease for individuals carrying the 
susceptibility genotype as compared to those who do not. Assume RRG is constant across the 
strata, meaning that in this case population stratification is a confounder only and is not an 



















The confounded relative risk RRG
c  is defined as the overall risk in the admixed population 
RRG




Define weights 𝑤𝑗 =
𝑛𝑗(1−𝑞𝑗)
∑ 𝑛𝑘(1−𝑞𝑘)𝑘

















       (3.1) 
To introduce a measure of population stratification bias in case-only studies of G×E interaction, 
we present once again the work of Wang and Lee described in (Wang and Lee 2008). Let RRGE 
denote the relative risk of disease for those subjects with (G,E) compared to (G, E) individuals. 
Similarly RRG denotes the relative risk of disease for individuals with (G, E) compared to (G, E) 
and RRE denotes the relative risk of disease for individuals with (G, E) compared to (G, E). Let 
RRGE, RRG, and RRE be constant across the strata of admixed population. Once again, PS is 
acting as confounder here and not like an effect modifier (Chapter 1). Assume that genotype 
and environment are independent within each stratum, for validity of the case-only G×E 
estimate. The G×E interaction effect on the multiplicative scale can be measured by RRG×E =
RRGE
RRGRRE
  (Chapter 2) and can be estimated by the case-only approach. If a study collects each 
and every case in the whole population, then the number of disease carriers would be nGE =
∑ njqjpjbj
J
j=1 RRGE, nG̅E = ∑ nj(1 − qj)pjbj
J
j=1 RRE, nGE̅ = ∑ njqj(1 − pj)bj
J
j=1 RRG, and 
nG̅E̅ = ∑ nj(1 − qj)(1 − pj)bj
J
j=1   
for (G, E), (G, E), (G, E), (G̅, E) subjects, respectively. 











Therefore, the confounding interaction ratio for the case-only estimator of G×E interaction 

























j=1 ,  φG = ∑ wjgj
J
j=1 , φE, φG 
denote the means, SD(φE) = √∑ wj(ej − φE)
2J
j=1   and SD(φG) = √∑ wj(gj − φG)
2J
j=1  the 
standard deviations, CVE  and CVG denote the coefficients of variation of the exposure 
prevalence odds and the genotype frequency odds, respectively, and rGE denotes the correlation 
coefficient between the exposure prevalence odds and genotype frequency odds. 
 
3.1.3. Derivation of Confounding Interaction Ratio for the Case-Control Design 
 To derive an equation for the confounded interaction ratio for a case-control study, CIRCC, we 
followed the method and used the notation as described above (Lee and Wang 2008, Wang and 
Lee 2008). In a case-control study, the G×E interaction effect on the multiplicative scale can 
be measured by RRG×E =
RRGE
RRGRRE
. Note that in this section we newly redefine DR, RR, CV, 
SD and all notations from the previous section accordingly for the case-control design. Assume 
that the study was able to collect all the affected subjects, from here on cases, and controls from 
the entire population. Thus, we are still deriving risks and not odds ratios. Let DRG denote 
disease rate for carriers of a susceptible genotype given absence of any environmental factor 





 is the confounded relative 

















In the same manner, let DRE denote the disease rate for an individual exposed to the 
























The confounded relative risk RRGE










































Thus, the ratio of the confounded effect to the true effect of G×E interaction CIRCC in a case-




























































∑ 𝑤𝑗𝑒𝑗𝑔𝑗 ∑ 𝑤𝑗𝑏𝑗𝑗𝑗
/ (
∑ 𝑤𝑗𝑔𝑗𝑏𝑗𝑗
∑ 𝑤𝑗𝑔𝑗 ∑ 𝑤𝑗𝑏𝑗𝑗𝑗
∑ 𝑤𝑗𝑒𝑗𝑏𝑗𝑗
























Define separate weights for cases wj1 and for controls wj0. 
wj0 =




(1 − pk)(1 − qk)
 
wj1 =






















j=1 , φ′s denote 
the means of genotype and exposure frequencies, subscript 1 refers to cases and 0 to controls. 
SDs are standard deviations defined as 
SD(φE) = √∑ wj(ej − φE)
2J














































       (3.3) 
where CVE and CVG are the coefficients of variation of the exposure prevalence odds and the 
genotype frequency odds; and rGE is the correlation coefficient between the exposure prevalence 
odds and genotype frequency odds occurrence. Note that the mathematical form of CIRCC 
derived here is similar to the CIRCO measures of population stratification bias for the case-only 
design (Wang and Lee 2008), see previous section. It can be seen from the equation that there 
would be no population stratification bias when the exposure prevalence odds and the genotype 
frequency odds are uncorrelated in cases and controls, when there is no variation in the 
exposure prevalence odds, or when there is no variation in the genotype frequency odds across 
subpopulations. For CIRCC, overestimation of RR (CIRCC > 1) occurs when genotype and 
exposure are negatively correlated. Underestimation (CIRCC < 1) occurs when exposure and 
genotype have positive correlation and the range of the background disease risks is 
considerably smaller than the range of both genotype and exposure frequencies. For CIRCO, 
overestimation (CIRCO > 1) of the parameter occurs when genotype and exposure are positively 
correlated, while underestimation (CIRCO < 1) occurs when exposure and genotype are 
negatively correlated (Wang and Lee 2008). 
 
3.1.4. Calculation Settings  
To investigate the potential size of the confounding interaction ratio in a case-control study, 
CIRCC, we calculated this measure over a range of realistic scenarios. Generally, we followed 
the procedures described by Wacholder et al. (Wacholder, Rothman et al. 2000), and Wang 
and Lee (Amos, Wu et al. 2008). Additionally, we investigated the bias for samples including 
j = 2, 3, 5 or 8 subpopulations. For each scenario we assumed that there are j = 2, 3, 5 or 8 
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strata each of equal size. We allowed for different genotype and exposure frequencies and 
different baseline disease risks across the strata. Genotype qj and exposure frequencies pj were 
set to one of the three intervals 0.01–0.3, 0.1-0.4 and 0.3–0.6. These intervals reflect the range 
of frequencies of different alleles for a large number of genes in European populations reported 
in (Cavalli-Sforza, Menozzi et al. 1994). The background risk of the disease bj was chosen 
from intervals 1.0–1.5 or 1.0–3.0, representing a realistic range of cancer rates among 
Europeans (Wacholder, Rothman et al. 2000). In each of the corresponding intervals, values of 
the genotype and exposure frequencies were set to be equally distant on the logit scale and 
values of the baseline disease risk were set to be equally distant on the logarithmic scale. 
Therefore, we obtained unique values of three parameters for each stratum. Such a choice of 
the parameters is unique for each interval. 
Next, we calculated the bias due to population stratification employing the following approach: 
We set eight values for the exposure and genotype frequencies as well as for baseline disease 
risk as described above from the corresponding intervals. Then for j=2 subpopulations we 
considered all possible combinations of the corresponding pairs of genotype and exposure 
frequencies and disease risks out of eight possible values for each parameter (all possible 
combinations of two values in each interval out of eight). For j=3 subpopulations; we 
considered all possible combinations of triples from eight values of genotype, exposure 
frequencies, and background disease risks. To investigate both possible situations when 
genotype and exposure are positively and negatively correlated, we fixed disease risks and 
randomly permuted values for genotype and exposure frequencies in triples. For j=5 
subpopulations, we repeated the procedure as described for j=3, but for combinations of five 
values of parameters. For j=8 subpopulations, we fixed the background disease risk and 
randomly permuted eight values for the genotype frequencies and eight values for the exposure 
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prevalence. Finally, we found the distribution of CIRCC, CIRCO, and CRR for each of the 18 
scenarios and obtained the minimum, maximum, and the quartiles of its distribution. 
 
3.1.5. Results 
Table 3.2 summarizes the results for CIRCC calculated for the admixture of two and eight 
subpopulations. The bias due to population stratification on average does not reach alarming 
values for the G×E interaction term in a case-control design, meaning it is always below 10%. 
However it can stretch up to 50% in the situations in which the ranges of genotype frequency, 
exposure prevalence and background disease risks are wide, such as for example in scenarios 
10 to 14. To evaluate the degree of population stratification bias in case-only studies, we 
calculated CIRCO for the same 18 scenarios. The results are summarized in Table 3.3. It is clear 
that the case-control estimator of G×E interaction is more robust to the presence of population 
stratification compared to the case-only estimator for all considered scenarios. On average, the 
degree of population stratification bias in a case-control study is tolerable. However, it can 
reach 50% or higher for the case-only estimator. Comparison of Table 3.2 and Table 3.3 
demonstrates that the bias due to population stratification of the case-control estimator depends 
on the range of the background disease risks across the strata. In contrast, this statement is false 
for the case-only estimator. Calculations of CIRCC for the admixture of 3 and 5 strata are 
presented in Table 3.4. 
Wacholder (Wacholder, Rothman et al. 2000) mentioned that the bias of the interaction term is 
generally bigger than the bias in genetic main effects. We investigated the situations in which 
the population stratification bias of G×E interaction effect estimates were greater, smaller, or 
comparable to genetic main effects. We calculated the bias in main effects for the same set of 
18 scenarios as in Table 3.2 using CRR as a measure of the population stratification bias. The 
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results for scenarios 1 to 18 are represented graphically in Figure 3.1 to Figure 3.5. This 
reveals that population stratification bias decreases for each scenario and for all three measures 
of bias (CRR, CIRCC, CIRCO) when the number of admixed subpopulations increases in the 
study sample from 2 to 8. The largest bias appears for the admixture of 2 subgroups. We can 
see that CIRCC is greater than CRR in scenarios 1 and 10, is smaller in scenarios 4, 7, 8, 13, 14, 
15, 16, 17, 18 and is comparable in scenarios 2, 3, 5, 6, 9, 12. Therefore, bias as measured by 
CIRCC is greater than that for CRR when the exposure prevalence range in terms of variation 
of the odds ratios of the largest and the smallest values are extremely disparate. CIRCC is 
generally smaller than CRR when genotype frequency range in terms of the variation of the 
odds ratios is considerably wider than the exposure prevalence odds ratios range. Finally, 
CIRCC is comparable in size to the CRR when the genotype frequency odds ratios range is 
similar to the exposure frequency odds ratios range across the strata. 
The grey-shaded areas in Figure 3.1 to Figure 3.5 represent theoretical bounds for CIRCC, 
CIRCO, and CRR, derived in (Amos, Wu et al. 2008, Lee and Wang 2008). We calculated 
theoretical bounds for CIRCC in the same way. Table 3.1 presents equations to calculate the 
corresponding lower (L) and upper (U) theoretical bound. We do not provide details on the 
boundary derivations, because they were derived in the same way as already published. In 
contrast to the bias in the case-only design (CIRCO), the magnitude of variation in background 
disease risk affects the degree of the population stratification bias for both CIRCC and the CRR. 
The bias is larger for a larger variation in the disease prevalence (scenarios 10 to 18). It is clear 
from the figures that the case-control design is significantly more robust to population 
stratification than the case-only design. 
The bias of G×E interaction effect due to population stratification is usually small. However, 
it can still reach extreme values in realistic situations even for the robust case-control design, 
for example, when two divergent subpopulations are admixed. 
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Table 3.1 Theoretical bounds for CRR, CIRCC and CIRCO 
bounds of CRR 𝑈 =
√𝑄 × 𝐵 × (√𝑄 × 𝐵 + 1)2









bounds of CIRCO 𝑈 =
√𝑄 × 𝑃 × (√𝑄 × 𝑃 + 1)2






U, theoretical upper bound; L, theoretical lower bound; Q=max(gj)/min(gj); P=max(ej)/min(ej); 
B=max(bj)/min(bj); j, subgroup indicator; gj, genotype frequency odds; ej, exposure frequency odds; bj, 
background disease risk; 
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Table 3.2 Confounding interaction ratio for case-control CIRCC, evaluated for 18 scenarios admixture of 2 and 8 subpopulations 
Scenario 
Parameter intervals CIRCC  2 from 8 ** 
CIRCC for 100 000 simulations of random 
permutation of 8 values*** 
bj pj qj min max min 25th  50th  75th  max 
1 1.0-1.5 0.01-0.3 0.01-0.3 0.80 1.28 0.86 0.97 1.00 1.03 1.16 
2 1.0-1.5 0.01-0.3 0.10-0.4 0.86 1.16 0.92 0.98 1.00 1.01 1.08 
3 1.0-1.5 0.01-0.3 0.30-0.6 0.90 1.11 0.94 0.99 1.00 1.01 1.06 
4 1.0-1.5 0.1-0.4 0.01-0.3 0.86 1.16 0.92 0.98 1.00 1.01 1.08 
5 1.0-1.5 0.1-0.4 0.1-0.4 0.91 1.07 0.96 0.99 1.00 1.01 1.04 
6 1.0-1.5 0.1-0.4 0.3-0.6 0.95 1.05 0.97 0.99 1.00 1.01 1.03 
7 1.0-1.5 0.3-0.6 0.01-0.3 0.90 1.11 0.94 0.99 1.00 1.01 1.06 
8 1.0-1.5 0.3-0.6 0.1-0.4 0.95 1.05 0.97 0.99 1.00 1.01 1.03 
9 1.0-1.5 0.3-0.6 0.3-0.6 0.98 1.01 0.98 1.00 1.00 1.00 1.02 
10 1.0-3.0 0.01-0.3 0.01-0.3 0.59 1.97 0.61 0.93 1.00 1.10 1.47 
11 1.0-3.0 0.01-0.3 0.1-0.4 0.68 1.46 0.79 0.95 1.00 1.05 1.24 
12 1.0-3.0 0.01-0.3 0.3-0.6 0.74 1.34 0.85 0.96 1.00 1.04 1.17 
13 1.0-3.0 0.1-0.4 0.01-0.3 0.68 1.46 0.78 0.96 1.00 1.05 1.23 
14 1.0-3.0 0.1-0.4 0.1-0.4 0.77 1.15 0.89 0.98 1.00 1.03 1.12 
15 1.0-3.0 0.1-0.4 0.3-0.6 0.84 1.17 0.92 0.98 1.00 1.02 1.09 
16 1.0-3.0 0.3-0.6 0.01-0.3 0.74 1.34 0.85 0.97 1.00 1.04 1.17 
17 1.0-3.0 0.3-0.6 0.1-0.4 0.84 1.17 0.92 0.98 1.00 1.02 1.08 
18 1.0-3.0 0.3-0.6 0.3-0.6 0.91 1.08 0.94 0.99 1.00 1.01 1.06 
 
bj, disease risk ratio, qj, genotype frequency; pj, exposure frequency; both G and E ranges are spaced to be equidistant on the logarithmic scale; * study cohort consists of 2 discrete, 
admixed populations; ** study cohort consists of 8 discrete, admixed populations; min, minimum of CIRCC; max, maximum of CIRCC; 25
th, 50th, 75th, percentile of the CIRCC; 
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Table 3.3 Confounding interaction ratio for case-only CIRCO, evaluated for 18 scenarios admixture of 2 and 8 subpopulations 
Scenario 
 
Parameters CIRCO 2 from 8 * 
CIRCO for 100 000 simulations of random 
permutation of 8 values** 
bj pj qj min max min 25th  50th  75th  max 
1 1.1-1.5 0.01-0.3 0.01-0.3 0.09 3.5 0.29 .69 0.95 1.31 2.59 
2 1.1-1.5 0.01-0.3 0.1-0.4 0.3 2.57 0.55 0.83 0.98 1.18 1.77 
3 1.1-1.5 0.01-0.3 0.3-0.6 0.45 2.16 0.67 0.89 0.99 1.13 1.53 
4 1.1-1.5 0.1-0.4 0.01-0.3 0.3 2.57 0.53 0.83 0.98 1.18 1.76 
5 1.1-1.5 0.1-0.4 0.1-0.4 0.5 1.96 0.73 0.92 1.00 1.09 1.39 
6 1.1-1.5 0.1-0.4 0.3-0.6 0.6 1.67 0.80 0.94 1.00 1.07 1.28 
7 1.1-1.5 0.3-0.6 0.01-0.3 0.45 2.16 0.66 0.89 0.99 1.13 1.54 
8 1.1-1.5 0.3-0.6 0.1-0.4 0.60 1.67 0.79 0.94 1.00 1.07 1.27 
9 1.1-1.5 0.3-0.6 0.3-0.6 0.70 1.44 0.85 0.96 1.00 1.04 1.19 
10 1.1-3.0 0.01-0.3 0.01-0.3 0.09 3.49 0.27 0.69 0.96 1.34 2.93 
11 1.1-3.0 0.01-0.3 0.1-0.4 0.28 3.19 0.51 0.83 0.99 1.18 1.90 
12 1.1-3.0 0.01-0.3 0.3-0.6 0.41 2.41 0.63 0.88 0.99 1.14 1.63 
13 1.1-3.0 0.1-0.4 0.01-0.3 0.28 3.19 0.50 0.84 0.98 1.19 1.91 
14 1.1-3.0 0.1-0.4 0.1-0.4 0.52 2.04 0.71 0.91 0.99 1.09 1.47 
15 1.1-3.0 0.1-0.4 0.3-0.6 0.62 1.68 0.77 0.94 1.00 1.07 1.33 
16 1.1-3.0 0.3-0.6 0.01-0.3 0.41 2.20 0.62 0.88 0.99 1.13 1.62 
17 1.1-3.0 0.3-0.6 0.1-0.4 0.62 1.62 0.78 0.94 1.00 1.07 1.32 
18 1.1-3.0 0.3-0.6 0.3-0.6 0.70 1.36 0.83 0.96 1.00 1.05 1.22 
 
bj, disease risk ratio, qj, genotype frequency; pj, exposure frequency; both G and E ranges are spaced to be equidistant on the logarithmic scale; * study cohort consists of 2 
discrete, admixed populations; ** study cohort consists of 8 discrete, admixed populations; min, minimum of CIRCO; max, maximum of CIRCO; 25




Table 3.4 Confounding interaction ratio for case-control CIRCC, evaluated for 18 scenarios, admixture of 3 and 5 subpopulations 
Scenario 
Parameters 
CIRCC for 100 000 simulations of 
random permutation for all possible 
combinations of 3 values out of 8* 
CIRCC for 100 000 simulations of random 
permutation for all possible combinations of 
5 values out of 8** 
bj pj qj min  25th 50th 75th max  min  25th 50th 75th max  
1 1.0-1.5 0.01-0.3 0.01-0.3 0.8 0.98 1.00 1.03 1.17 0.85 0.97 0.99 1.02 1.17 
2 1.0-1.5 0.01-0.3 0.1-0.4 0.89 0.99 1.00 1.02 1.11 0.91 0.98 0.99 1.01 1.08 
3 1.0-1.5 0.01-0.3 0.3-0.6 0.91 0.99 1.00 1.01 1.08 0.94 0.99 1.00 1.01 1.05 
4 1.0-1.5 0.1-0.4 0.01-0.3 0.89 0.99 1.00 1.02 1.11 0.93 0.99 1.00 1.01 1.09 
5 1.0-1.5 0.1-0.4 0.1-0.4 0.92 0.99 1.00 1.01 1.07 0.95 0.99 1.00 1.01 1.05 
6 1.0-1.5 0.1-0.4 0.3-0.6 0.94 0.99 1.00 1.01 1.05 0.97 0.99 1.00 1.00 1.04 
7 1.0-1.5 0.3-0.6 0.01-0.3 0.91 0.99 1.00 1.01 1.08 0.94 0.99 1.00 1.01 1.06 
8 1.0-1.5 0.3-0.6 0.1-0.4 0.94 0.99 1.00 1.01 1.05 0.96 0.99 1.00 1.01 1.04 
9 1.0-1.5 0.3-0.6 0.3-0.6 0.96 1.00 1.00 1.00 1.04 0.97 1.00 1.00 1.00 1.03 
10 1.0-3.0 0.01-0.3 0.01-0.3 0.57 0.95 1.01 1.09 1.59 0.63 0.91 0.97 1.06 1.68 
11 1.0-3.0 0.01-0.3 0.1-0.4 0.72 0.97 1.00 1.04 1.35 0.75 0.94 0.98 1.03 1.28 
12 1.0-3.0 0.01-0.3 0.3-0.6 0.79 0.98 1.00 1.03 1.22 0.81 0.96 0.98 1.02 1.23 
13 1.0-3.0 0.1-0.4 0.01-0.3 0.72 0.97 1.00 1.04 1.35 0.77 0.96 1.00 1.04 1.30 
14 1.0-3.0 0.1-0.4 0.1-0.4 0.82 0.98 1.00 1.02 1.2 0.85 0.97 1.00 1.02 1.17 
15 1.0-3.0 0.1-0.4 0.3-0.6 0.86 0.99 1.00 1.01 1.14 0.89 0.98 1.00 1.02 1.13 
16 1.0-3.0 0.3-0.6 0.01-0.3 0.79 0.98 1.00 1.03 1.22 0.83 0.97 1.00 1.03 1.24 
17 1.0-3.0 0.3-0.6 0.1-0.4 0.86 0.99 1.00 1.01 1.14 0.90 0.98 1.00 1.02 1.10 
18 1.0-3.0 0.3-0.6 0.3-0.6 0.89 0.99 1.00 1.01 1.10 0.91 0.99 1.00 1.01 1.08 
 
bj, risk ratio, pj,  genotype frequency; qj, exposure frequency; both G and E ranges are spaced to be equidistant on the logarithmic scale; * study cohort consists of 3 discrete, 
admixed populations; ** study cohort consists of 5 discrete, admixed populations; min, minimum CIRCC; max, maximum CIRCC; 25




Figure 3.1 Scenarios 1-4, degree of population stratification for G×E interaction and genetic 
main effects 
 
On the x-axis is the number of admixed subpopulations and on the y-axis are the minimum and maximum values 
of CRR, CIRCC, and CIRCO over 1000 replicates. In shades of grey are theoretical bounds of CRR, CIRCC, and 
CIRCO are depicted. Light grey corresponds to CIRCO theoretical bounds for the scenario, medium grey CIRCC, 





Figure 3.2 Scenarios 5-8, degree of population stratification for G×E interaction and genetic 
main effects  
 
On the x-axis is the number of admixed subpopulations and on the y-axis are the minimum and maximum values 
of CRR, CIRCC, and CIRCO over 1000 replicates. In shades of grey are theoretical bounds of CRR, CIRCC, and 
CIRCO are depicted. Light grey corresponds to CIRCO theoretical bounds for the scenario, medium grey CIRCC, 





Figure 3.3 Scenarios 9-12, degree of population stratification for G×E interaction and genetic 
main effects  
 
On the x-axis is the number of admixed subpopulations and on the y-axis are the minimum and maximum values 
of CRR, CIRCC, and CIRCO over 1000 replicates. In shades of grey are theoretical bounds of CRR, CIRCC, and 
CIRCO are depicted. Light grey corresponds to CIRCO theoretical bounds for the scenario, medium grey CIRCC, 





Figure 3.4 Scenarios 13-16, degree of population stratification for G×E interaction and genetic 
main effects  
 
On the x-axis is the number of admixed subpopulations and on the y-axis are the minimum and maximum values 
of CRR, CIRCC, and CIRCO over 1000 replicates. In shades of grey are theoretical bounds of CRR, CIRCC, and 
CIRCO are depicted. Light grey corresponds to CIRCO theoretical bounds for the scenario, medium grey CIRCC, 





Figure 3.5 Scenarios 17-18, degree of population stratification for G×E interaction and genetic 
main effects  
 
On the x-axis is the number of admixed subpopulations and on the y-axis are the minimum and maximum values 
of CRR, CIRCC, and CIRCO over 1000 replicates. In shades of grey are theoretical bounds of CRR, CIRCC, and 
CIRCO are depicted. Light grey corresponds to CIRCO theoretical bounds for the scenario, medium grey CIRCC, 
and dark grey CRR. The number at the corner denote the scenario, the order is the same as in Tables 3.2-3.4 
 
 
3.2. Degree of the Population Stratification Bias for G×E Interaction 
Methods 
In the previous section we have seen that the biggest bias occurs when there are only two 
subgroups admixed. Therefore we decided to investigate the magnitude of the bias only for j = 
2 strata in the population comparing four common methods for G×E interaction in GWAS. We 
included into our study CC, CO, MUK-EB and EHB-GECHI (see Chapters 1 and 2).  
Since an analytical solution to evaluate the degree of population stratification bias for other 
G×E interaction methods than case-control or case-only design is not readily available we 
undertook the following approach.  For each method estimates were obtained by fitting the 




and an “unadjusted” model, which omits information about individual’s membership in two 
subgroups. These two models are outlined in following Section 3.2.1. 
Furthermore, PCA, integrated in the EIGENSOFT software (Patterson, Price et al. 2006), was 
performed on each simulated data set to estimate the principal components. After simulation 
of an admixed sample, we included the first two principal components in the logistic regression 
models as covariates. As explained in Chapter 2 the first two principal components explain the 
most variation in the sample. Since we have only two admixed subpopulation it is enough to 
use only first two principal components. The G×E interaction effect estimates were recalculated 
for each method after principal components adjustment and the bias due to population 
stratification was thus re-evaluated. 
 
3.2.1. Methods 
Let G=1 (G=0) denote carriers (non-carriers) of the susceptibility genotype and E=1 (E=0) for 
exposed (non-exposed) individuals. We let D be a binary phenotype, such that D=1, cases and 
D=0, controls. We assumed that the study sample consists of two (j=1, 2) strata represented by 
S1 and S2, and Sj is an indicator variable, such that Sj=1 if the individual is in the jth subgroup 
and zero otherwise. We did not consider any issues concerning variance or precision of 
estimates, assuming that for large samples E(𝛽?̂?) = βl, l = CC, CO, MUK-EB, EHB-GECHI. 
 For the case-control study, an association between G×E interaction and the outcome D can be 
modeled in the following form using logistic regression 
“Adjusted” model for CC: logit(P(D= 1| G, E)) = α1_CC+α2_CCS2+βGG+βEE+βCCG×E, 
where regression coefficient βG is a measure of genetic main effect, βE is a measure of the 




generality let α1_CC specify the log odds of the disease (i.e. logit function of the baseline disease 
risk) in the “low”-risk ethnicity S1 and 0 < α2, where α2 specifies the log odds ratio of the 
disease risk comparing ethnicity S2 versus S1. Therefore to evaluate the observed bias we can 
omit the term from the model that is responsible to reflect the ethnic status of the individual 
and define “unadjusted” model for the CC study as follows 
“Unadjusted” model for CC:  logit(P(D = 1| G, E)) = αCC*+β*GG+β*EE+β*CCG×E, 
where * denotes the regression in the unadjusted model. 
Observed population stratification bias of the parameter estimate is defined as the difference 
between the corresponding parameters for the “Unadjusted” model and the “Adjusted” model. 
Therefore population stratification bias of the G×E interaction for the case-control design is 
equal to 
biasCC = β*CC - βCC. 
In a similar manner for case-only study, the “Adjusted” and “Unadjusted” models are given by 
“Adjusted” model for CO:  logit(P(E = 1| G, D = 1)) = α1_cases+α2_casesS2+βcasesG, 
 “Unadjusted” model for CO:  logit(P(E = 1| G, D = 1)) = αcases*+β*casesG. 
Therefore, bias for the case-only design is equal to 
biasCO=β*cases -βcases. 
Models for the subgroup of controls are only needed for other G×E methods. 
The “Adjusted” and “Unadjusted” models for control are given by 
“Adjusted” model for controls: logit(P(E=1|G,D=0))=α1_controls+α2_controlsS2+βcontrolsG, 




Mukherjee’s Empirical Bayes type shrinkage estimator of the G×E interaction is given by  
“Adjusted” and “Unadjusted” G×E parameter estimates of Mukherjee’s Empirical Bayes 



























∗  are variance estimates from “Adjusted” and “Unadjusted” case-control model 
respectively. For MUK-EB the bias is defined as 
biasMUK-EB=β*MUK-EB-βMUK-EB. 
The EHB-GECHI G×E effect estimates are calculated using the following equation 
βEHB-GECHI = βcases – posterior(βcontrols), 
therefore bias is given by 
biasEHB-GECHI = β*EHB-GECHI - βEHB-GECHI. 
Theoretical background for EHB-GECHI approach is given (Sohns 2012, Sohns, Viktorova et 
al. 2013) and summarized in Chapter 4 of this dissertation. 
 
3.2.2. Simulation Study Set-up 
We simulated case-control samples consisting of 1000 cases and 1000 controls sampled from 
an admixed population with different proportions of each of two subpopulations. Three 
different admixture sampling ratios were implemented 0.2, 0.4 and 0.5 reflecting an extreme 




sampling ratio 0.2, for example, means that 20% cases and 80% controls were sampled from 
“low”-risk ethnicity and 80% cases, 20% controls from “high”-risk subgroup. The usage of the 
two others ratios 0.4 or 0.5 is the same. We replicated each scenario 1000 times. 
In each simulated sample we created binary genotype data at 5000 independent, random SNPs. 
We simulated three different types of SNPs. A single SNP with G×E interaction effect, and 
1000 SNPs, with substantially varying frequency across two admixed subpopulations, denoted 
as differentiated SNPs. We called the rest of the SNPs dummy SNPs as they had no effect on 
the disease. A single binary environmental factor E was simulated, having no main effect on 
the disease. In each stratum susceptibility genotype frequencies at a marker locus for dummy 
SNPs were generated independently from a beta distribution following the Balding-Nichols 
model as in (Devlin and Roeder 1999). In this Balding-Nichols model two parameters are 
employed,  p(1 − Fst) Fst⁄  and (1 − p)(1 − Fst) Fst⁄ , where Fst =0.01 and p is the ancestry 
population allele frequency from the uniform [0.1, 0.9] distribution. Fst is Wright’s fixation 
index, a measure of genetic divergence among subgroups (Holsinger and Weir 2009), Fst =0.01 
is a typical value for European populations. For the interacting SNP the frequency in the “low”-
risk subpopulation was fixed at 0.1 and we vary this value in the risk subpopulation from 0.4 
to 0.8 respectively. For the differentiated SNPs with no association to the disease, we assumed 
a large variation in frequencies by setting Fst values to be equal to 0.06. For the simulation of 
the interacting SNP we assumed a multiplicative trait model and fixed the relative risk at a 
value of 2 for the casual genotype. Exposure frequencies and baseline disease risk were fixed 
for all scenarios. In the “low-risk” ethnicity we set the prevalence of the environment to be 
equal to 0.1 and the background disease risk to be 0.02. In the high risk ethnicity corresponding 
values were set to 0.3, 0.5 and 0.1 or 0.05 respectively. For our study we considered a cohort 
with two underlying discrete subpopulations that could be present in cases and controls in 




confounding for the 0.5 admixture sampling ratio. Table 3.5 summarizes simulated scenarios. 
We replicated each scenario 1000 times and obtained the distribution of the population 
stratification bias and mean squared error defined as MSE = bias2 + variance and their average 
values for G×E methods before and after principal components adjustment. 
Table 3.5 Summary of the simulated scenarios 
Scenario 
Parameters 
ratio p01 p02 pe1 pe2 pg1 pg2 
1 0.5 0.02 0.1 0.1 0.3 0.1 0.4 
2 0.5 0.02 0.1 0.1 0.3 0.1 0.8 
3 0.4 0.02 0.1 0.1 0.3 0.1 0.4 
4 0.4 0.02 0.1 0.1 0.3 0.1 0.8 
5 0.4 0.02 0.05 0.1 0.5 0.1 0.4 
6 0.2 0.02 0.1 0.1 0.3 0.1 0.8 
7 0.2 0.02 0.1 0.1 0.3 0.1 0.4 
8 0.2 0.02 0.05 0.1 0.5 0.1 0.8 
 
ratio, proportion of cases sampling from “low-risk” ethnicity; p01, baseline disease risk in “low-risk” ethnicity; 
p02, baseline disease risk in “at-risk” ethnicity; pe1, prevalence of environmental exposure in “low-risk” ethnicity; 
pe2, prevalence of environmental exposure in “at-risk” ethnicity; pg1, susceptible genotype frequency in “low-
risk” ethnicity; pg2, susceptible genotype frequency in “high-risk” ethnicity; 
 
 
3.2.3. Simulation Study Results 
Table 3.6 and Table 3.7 summarize results of the simulation study. The classic case-control 
estimator of G×E interaction, the recently introduced EHB-GECHI estimator and MUK-EB 
demonstrate smaller bias in all of the scenarios compared to the case-only estimator. One 
should note that for the matched case-control design (0.5) including two admixed 
subpopulations the case-control estimator tends to give better results in terms of smaller 
population stratification bias than the other considered estimators. For the moderate admixture 
or matched case-control design population stratification bias of the case-control estimator is 
negligible, however this is not the case for the case-only estimator. The explanation can be 
found by considering the main idea behind those methods. The original case-control estimator 
compares odds in cases and controls. In contrast to this the case-only estimator based only on 
the odds in cases. Therefore the case-control estimator tends to overcome the lack of 




into account other SNPs and analyzing each SNP separately. The EHB-GECHI method takes 
into consideration all other SNPs and therefore may suffer from difficulties in a single SNP 
estimate when there is some hidden substructure in other SNPs, like G-E correlations or 
presence of differentiating SNPs for which frequencies vary significantly across 
subpopulations. EIGENSTRAT is population stratification correction method, which is based 
on the principal components analysis and eigenvalues analysis. These are integrated in the 
software called EIGENSOFT (Patterson, Price et al. 2006). PCA was performed to derive 
principal components to account for population stratification. We included the first two 
principal components as covariates in the “unadjusted” model to account for PS. Population 
stratification bias was reevaluated for each G×E interaction approach after principal 
components adjustment and appeared to be practically zero for all methods. As only two sub-
populations were admixed it is sufficient to only include the first two principal components as 




Table 3.6 Bias of G×E interaction estimators, calculated as observed difference of the 
estimates in two logistic regression models for G×E interaction methods 
Scenario bias CC bias CO bias MUK-EB bias EHB-GECHI 
1 0.124 0.418 0.100 0.183 
2 0.351 0.234 0.260 0.249 
3 0.361 0.636 0.181 0.192 
4 0.101 0.905 0.247 0.267 
5 0.009 0.489 0.083 0.176 
6 0.015 0.969 0.300 0.332 
7 0.179 0.659 0.157 0.178 
8 0.518 0.383 0.418 0.301 
 
Table 3.7 Mean Squared Error of G×E interaction estimators  
Scenario MSE CC MSE CO MSE MUK-EB MSE EHB-GECHI 
1 0.071 0.201 0.073 0.087 
2 0.208 0.076 0.148 0.134 
3 0.210 0.441 0.117 0.106 
4 0.066 0.861 0.148 0.159 
5 0.053 0.269 0.067 0.089 
6 0.055 0.986 0.184 0.208 
7 0.078 0.460 0.082 0.082 
8 0.337 0.166 0.246 0.159 
 
Scenarios employed in analysis (Table 3.5 for specification); CC, Case-Control estimator; CO, Case-Only 
estimator; MUR, MUK-EB, Mukherjee’s Empirical Bayes type shrinkage estimator; EHB-GECHI, empirical 





4. Extensions for the Empirical Hierarchical Bayes Approach to 
G×E Interaction EHB-GECHI 
The general concept of the empirical hierarchical Bayes (EHB) modeling approach is described 
in the current Chapter, since the EHB analysis is the focus of this dissertation. Recently, Sohns 
proposed an empirical hierarchical Bayes approach to G×E interaction designated as EHB-
GECHI (Sohns 2012, Sohns, Viktorova et al. 2013). The EHB-GECHI was developed as a 
compromise between the often underpowered case-control test and the case-only test, which 
has highly inflated type I error in the presence of G-E correlation. The proposed method is 
based on a two-level hierarchical model to estimate G-E correlation and employs the chi 
distribution on the first level and a mixture distribution with point mass at zero on the second 
level. The EHB-GECHI method is based on the Lewinger et al. (Lewinger, Conti et al. 2007) 
hierarchical Bayes prioritization approach, which was originally proposed for the genetic main 
effect. Sohns expanded this approach to studies of G×E interactions, as well as to using the 
available pathway information. The method first obtains estimated posterior G-E correlation 
effects, which are calculated for each marker by borrowing information across all SNPs over 
the sample of controls. These posterior effects are subtracted from the corresponding case-only 
G×E interaction estimates. A detailed description of the EHB-GECHI method is available in the 
dissertation of M. Sohns (Sohns 2012) as well as in our joint paper (Sohns, Viktorova et al. 
2013). Here we only present the summarized derivation of the EHB-GECHI approach. The thesis 
by Sohns also includes the description and results of the extensive simulation study comparing 
EHB-GECHI with the methods mentioned above for G×E interaction in terms of rank power. 
Rank power is defined as the percentage of simulated replicates for which the true G×E 
interacting SNP is within the top ranking positions, according to the absolute value of the 




than the introduced rival methods (CC, CO, TWO, MUR, MUK-EB), while accounting for 
population-based G-E correlation. The original EHB-GECHI was introduced for binary trait, 
exposure, and genotype without covariates. We extend the EHB-GECHI approach in several 
ways. 
We demonstrate how the method can be applied to handle multilevel or continuous exposure 
and genotype variables in contrast to the original binary setting. This is an important extension 
because in many cases exposure information is collected as a continuous variable. Such 
recoding may lead to information loss. In addition, use of the continuous probabilities of 
genotypes, obtained through available imputation techniques, is taken into consideration more 
often. 
We considered the performance of EHB-GECHI under the assumption of the additive risk model 
in contrast to the dominant or recessive model discussed previously. It is well known that the 
additive risk model is preferred for most genetic scenarios, when the etiology of the disease is 
not known, and most probably is not recessive. It is therefore important that the approach be 
able to handle various risk models. 
We show that the EHB-GECHI approach can be applied adjusting for important covariates 
separately in cases and in controls. The separate adjustment is required by the construction of 
the EHB-GECHI approach.  We prove that separate adjustment is allowed when independence 
of the covariate distribution from the G×E interaction odds ratio is a reasonable assumption. 
We proposed using log-linear models in place of logistic regression models, when such an 
assumption is not valid. Originally, EHB-GECHI did not consider covariate adjustment. 
Certainly, adjustment for sex, age, ethnical background, and so on is usually performed during 




adjustment for important covariates. This chapter focuses on presenting the proposed 
extensions to the EHB-GECHI approach and the derivation of solutions. 
 
4.1. Empirical Hierarchical Bayesian Models 
Statistical science may be viewed as two main competing colleges of thought: the frequentist 
or classic approach to statistical inference and the Bayesian approach. In the following sections, 
we shall introduce the basics of empirical hierarchical Bayes data analysis. The major units of 
a Bayesian analysis are the likelihood function, which represents information on the parameters 
of the data, and the prior distribution, which quantifies what is known about the parameters 
before observing the data. To form the posterior distribution, the prior distribution and the 
likelihood are combined. The posterior distribution reflects the total knowledge on the 
parameters after observing the data. Simple summaries, such as mean or median, of the 
posterior distribution are used to express quantities of interest and eventually to draw 
conclusions. Most of the information given in the following sections was adopted from (Morris 
1983, Robert 1994, Lee 1997, Sohns 2012). 
 
4.1.1. The Bayes Model 
The initial step to perform Bayes inferences is to specify a probability model for the data. 
Assume that we want to specify a sampling model of n data points X=(X1,…,Xn) depending on 
the vector of unknown parameters θ=( θ1,…,θn) and that data points are independent, 
conditional on θ. This can be expressed in a functional term using the probability density 
function f(X|θ), where 






represents the probability of observing the data point X conditional on the values of parameters 
θ. In frequentist statistics, f(X|θ) is termed the likelihood function and is considered as a 
function of θ for fixed data points X. Parameter estimates in the frequentist inferences are 
derived by maximizing the likelihood and are termed maximum likelihood estimates (Robert 
1994, Dehling and Haupt 2004). Bayesians also are interested in the estimation of θ. However, 
they prefer to obtain the parameter estimates that are most likely given the fixed data. In other 
words, in the Bayes inference framework we are interested in the conditional probability of θ 








where π(θ) is the prior distribution function of θ, f(X|θ) is the likelihood function, h(X) is the 
marginal distribution function of X and π(θ|X) is the posterior distribution function of the 
parameters. In many situations, it is computationally challenging to obtain h(X) and therefore 
the posterior distribution often has no closed form. Thus 𝜋(𝜃|𝑋)  ∝ 𝑓(𝑋|𝜃)𝜋(𝜃) is widely used 
(Robert 1994, Gelman, Carlin et al. 1995). 
 
4.1.2. Empirical Hierarchical Bayes Models 
In the Bayes analysis framework, defining the prior distribution always involves large 
uncertainty and sometimes subjectivism and is therefore often subject to criticism (Lee 1997). 
However, it is possible to model this uncertainty in a Bayesian manner by the decomposing the 
prior information into separate distributional levels. This is what is referred to as hierarchical 
Bayes (HB) modeling (Robert 1994). According to the HB approach, the prior π(θ) is separated 
into conditional distributions ∫ 𝜋1(𝜃|𝜂1)𝜋2(𝜂1|𝜂2) … 𝜋𝐽(𝜂𝐽−1|𝜂𝐽) and a marginal distribution 




 𝜋(𝜃) = ∫ 𝜋1(𝜃|𝜂1)𝜋2(𝜂1|𝜂2) … 𝜋𝐽(𝜂𝐽−1|𝜂𝐽)𝜋𝐽+1(𝜂𝐽)𝑑𝜂1𝑑𝜂2 … 𝑑𝜂𝐽. 
The hyperparameter ηj is termed the level j hyperparameter to distinguish it from the parameter 
of interest θ. Therefore, given the data as in the previous section, we have the following 
hierarchical model. 
θi  ∼π(θi|η), with i=1…n, i.d. independently distributed 
η∼π(η) 
For such a two-level hierarchical model, the first stage represents the model hyperparameter θ 
relationship with level hyperparameter η. The second stage reflects our prior belief about η 
(Lee 1997). 
The hierarchical model can be combined with empirical Bayes models, resulting in empirical 
hierarchical Bayes models (EHB). The empirical Bayes models form a special class of Bayes 
models, which differ from the fully Bayesian approach in the construction of the prior 
distribution. The prior distribution in empirical Bayes methods is usually given a frequency 
interpretation, in contrast to that of the true Bayes methods (Lee 1997). In the empirical Bayes 
context, hyperparameter estimation is performed in a similar approach to that of the frequentist, 
i.e. through the maximization of the marginal distribution function, h(X|η) with respect to η. In 
this way, marginal maximum likelihood estimates (MMLE) of the parameters are obtained 
(Berger 1985, Heron, O'Dushlaine et al. 2011). 
Consider a general EHB model: 
Level 1  𝑋𝑖|𝜃𝑖   ∼    𝑓(𝑋𝑖|𝜃𝑖) , with i=1…n, i.d. 
Level 2 𝜃𝑖|𝜂     ∼ 𝜋(𝜃𝑖|𝜂) , iid independent identically distributed 
Level 3   η         ∼  π(η). 








and the marginal distribution function of the data is given by 
ℎ(𝑋|𝜂) = ∫ 𝑓(𝑋𝑖|𝜃𝑖)𝜋(𝜃𝑖|𝜂)𝑑𝜃𝑖. 
Thus, the marginal likelihood function of the data is obtained by marginalizing the likelihood 
over the parameters of interest 
𝐿 = ∏ ℎ(𝑋𝑖|𝜂)
𝑛
𝑖=1 = ∏ ∫ 𝑓(𝑋𝑖|𝜃𝑖)𝜋(𝜃𝑖|𝜂)𝑑𝜃𝑖
𝑛
𝑖=1 . 
When the marginal distribution has a relatively simple form, it is possible to obtain an exact 
solution of the MMLE performing standard iterative maximum likelihood methods, such as, 
for example, the expectation-maximization algorithm (EM), (Lee 1997). 
EB analysis assumes that the prior distribution is known by using MLE estimates, ?̂? and 
modeling 𝜃𝑖|?̂? ∼  𝜋(𝜃𝑖|?̂?), 𝑖𝑖𝑑.  Based on this assumption the posterior of θi can be calculated 
by, 




Therefore the posterior depends on all data, summarized in ?̂?. 
 
4.2. The Empirical Hierarchical Bayes Approach to G×E Interaction 
(EHB-GECHI) 
Let D=1 denote that an individual has the disease (case), D=0 otherwise (control). Let G=1 
denote carriers of the minor allele, G=0 non-carriers, i.e. a dominant model for SNP. A binary 




Estimates of G-E correlation within cases and controls can be obtained from the following 
logistic regression models 
logit (P(E = 1| G, D = 1)) = 𝛼𝑚
𝑐𝑎𝑠𝑒𝑠 + 𝛽𝑚
𝑐𝑎𝑠𝑒𝑠G    (4.1) 
logit (P(E = 1| G, D = 0)) =𝛼𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 + 𝛽𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠G    (4.2) 
Under the assumption of a rare disease and population-based G-E independence, βcontrols=0. 
Then (4.1) corresponds to the valid model for the case-only test for G×E interaction (as 
illustrated in Chapter 2) and (4.2) provides estimates of the G-E correlation effects within 
controls. However, when such assumption is not true, 𝛽𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠coefficients should be properly 
estimated and consequently subtracted from 𝛽𝑚
𝑐𝑎𝑠𝑒𝑠 coefficients in order to obtain an unbiased 
estimate of the G×E interaction effect. For example, with the classic case-control approach, 
one can estimate the G-E correlation within controls for each SNP using equation 4.2. These 
estimates are then subtracted from the coefficients within the cases (4.1). 
In the context of GWAS, let M be the total number of genetic markers or SNPs m, m=1 … M, 
and 𝛽𝑚
𝑐𝑎𝑠𝑒𝑠, 𝛽𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 be the corresponding regression coefficients for G-E correlation among 
cases or controls, respectively (obtained by equations (4.1) and (4.2) for each SNP m) with 
corresponding standard deviations 𝜎𝑚
𝑐𝑎𝑠𝑒𝑠, 𝜎𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠. The remainder of Section 4.2 is based on 
(Sohns 2012, Sohns, Viktorova et al. 2013). The test statistics are 𝑇𝑚
𝑐𝑎𝑠𝑒𝑠 = ?̂?𝑚
𝑐𝑎𝑠𝑒𝑠 𝜎𝑚




𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠⁄ , both normally distributed. A hierarchical Bayes framework is 
applied to model the ?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠estimated effect and to calculate ?̂?𝑚
𝑐𝑎𝑠𝑒𝑠 − 𝑠𝑔𝑛𝑚?̂?𝑚, with  ?̂?𝑚  
being a posteriori estimators of |𝛽𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠|, and sgnm denoting the sign of ?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠. The 
corresponding hierarchical model is given by  
Level 1 |?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠|  | 𝜆𝑚   ∼   𝜎𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠𝜒1(𝜆𝑚)     (4.3) 
Level 2 𝜆𝑚 | 𝜃, 𝜎, 𝑝   ∼    𝑝𝜎𝜒1(𝜃) + (1 − 𝑝)𝛿(0)     (4.4) 
where λm are noncentrality parameters of the 𝜒 distribution with one degree of freedom 




is assumed to have a 𝜒1 distribution with noncentrality parameter θ as a measure of correlation 
and a scaling parameter σ > 0. Given λm=0, δ(0) denotes a point mass at zero. 
Next, the probability density function, the prior probability, marginal distribution, and posterior 
expected values can be derived. What results is the following form for the posterior expectation 
of the non-centrality parameter 
 ?̂?𝑚 = 𝐸[𝜆𝑚| |?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠| 𝜃, 𝜎, ?̂?], 
based on the MLE estimates of the hyperparameters Θ̂ = (𝜃, 𝜎, ?̂?). The EHB-GECHI rank 















  (4.5) 
Notice that the case and the control part of the differences (?̂?𝑚
𝑐𝑎𝑠𝑒𝑠 − 𝑠𝑔𝑛𝑚 ?̂?𝑚) are independent 
of each other. It is known that 𝑉𝑎𝑟(?̂? 𝑚
𝑐𝑎𝑠𝑒𝑠) = (𝜎 𝑚
𝑐𝑎𝑠𝑒𝑠)2 is estimated by (𝜎 𝑚
𝑐𝑎𝑠𝑒𝑠)2. Therefore 
one only needs to obtain the variance for the control part, which is 𝑉𝑎𝑟[𝜆𝑚|?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠].  To 
estimate this variance Sohns proposed using an approximation by (Kass and Steffey 1989). To 
derive the rank statistic 𝑇𝑚
𝐸𝐻𝐵−𝐺𝐸 the following steps are undertaken: 
a. Obtain the marginal likelihood of the hierarchical model 𝐿 = ∏ ℎ(|?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠| |𝜃, 𝜎, 𝑝)𝑚 . 
The density functions for the hierarchical model and the hyperparameters Θ = (θ, σ, p) are 
𝑓(|?̂?𝑚










  𝑔(𝜆𝑚|𝜃, 𝜎, 𝑝) = 𝑝 (𝜑 (
𝜆𝑚−𝜃
𝜎
) + 𝜑 (
𝜆𝑚+𝜃
𝜎
)) /𝜎 + (1 − 𝑝)𝛿(0) 






𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠| |𝜃, 𝜎, 𝑝) = ∫ 𝑓(|?̂?𝑚




























b. Obtain the MLE Θ̂ = (𝜃, 𝜎, ?̂?) from the marginal log likelihood maximizing with respect 
to Θ. (θ̂, σ̂, p̂) are common hyperparameters estimates. 
c. Obtain the posterior expectation of λm as ?̂?𝑚 = 𝐸[𝜆𝑚| |?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠| 𝜃, 𝜎, ?̂?] based on (θ̂, σ̂, p̂). 
d. Obtain the inverse negative Hessian of the marginal log-likelihood evaluated at the MLE,  










f. Obtain the first order approximation to the posterior variance using an approximation by 
Kass and Steffey (1989). 
𝑉𝑎𝑟[𝜆𝑚||?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠|] = 𝐸 [𝑉𝑎𝑟[𝜆𝑚| |?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠|, Θ]] + 𝑉𝑎𝑟 [𝐸[𝜆𝑚| |?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠|, Θ]]
≈ 𝑉𝑎𝑟[𝜆𝑚| |?̂?𝑚















𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠|, Θ̂] = 𝐸[𝜆𝑚
2 | 𝜆𝑚 > 0, |?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠|, Θ̂]𝑃[𝜆𝑚 > 0| | ?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠|, Θ̂]
+ 𝐸[𝜆𝑚
2 | 𝜆𝑚 = 0, |?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠|, Θ̂]𝑃[𝜆𝑚 = 0| |?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠|, Θ̂]
 





2 |𝜆𝑚 = 0, ?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠, Θ̂] = 0 
g. Insert the posterior expectation and the posterior variance into the final test statistic 
𝑇𝑚






  (Sohns 2012, Sohns, Viktorova et al. 2013) 
Detailed equations for the posterior variance derivation can be found in (Sohns 2012). 
 
4.3. General Exposure Variable and Genotype Variable 
The EHB-GECHI method requires estimation of G-E correlations separately within cases and 
controls. This can be achieved employing equations (4.1) and (4.2). Therefore, the question 
arises as to if EHB-GECHI can be extended to work with continuous or multi-level exposures 
and categorical genotypes. This is certainly the case. In the regression models (4.1) and (4.2), 
the exposure variable can be represented by multiple levels or by a continuous variable in a 
general linear models framework with a link function appropriate to the format of the E data. 
For example, in the case of normally distributed E the following model can be applied to the 
data, conditional on the disease. 
E(E|G,D) = αG×E + βG×EG.       (4.6) 
According to equation (4.6), the relationship between genotype and environment is modeled as 
a simple linear regression. This approach to data modeling (formula (4.6)) was evaluated by 
Clarke and Morris (Clarke and Morris 2010). If E and G are coded as categorical or are 
categorical by nature, then proportional, multinomial, or ordinal regression techniques can be 
performed to model the G-E relationship (Kraft, Yen et al. 2007). 
As an alternative, we propose modeling P(G|E, D) instead of the original P(E|G, D) (note that 
we follow the approach of Piegorsch et al. to construct the necessary proof (Piegorsch and 




can estimate G-E correlation effects separately in cases and controls. We treat the binary 
genotype variable as an outcome and estimate the main effects for the exposure categories. 
To demonstrate the equality of the data modeling approaches, first consider the ratio 
𝑃(𝐺 =  0|𝐸 =  1, 𝐷 = 0)𝑃(𝐺 =  1|𝐸 =  0, 𝐷 = 0)
𝑃(𝐺 =  1|𝐸 =  1, 𝐷 = 0)𝑃(𝐺 =  0|𝐸 =  0, 𝐷 = 0)
 




 as discussed in Chapter 2, where ORGE is the odds ratio relating risk at the 
G=1, E=1 combination to the G=0, E=0 ‘baseline’ genotype-exposure combination, ORG is the 
odds ratio relating risk at the G=1, E=0 to the G=0, E=0 ‘baseline’ combination and ORE is the 
odds ratio relating risk at the G=0, E=1 gene-exposure combination to the ‘baseline’ 
combination. Consider the following data model 
logit (P(D = 1| G, E)) = αCC + βGG + βEE + βCCG×E   (4.7) 










𝑃(𝐺 = 1|𝐸 = 1, 𝐷 = 1)𝑃(𝐺 = 0|𝐸 = 0, 𝐷 = 1)𝑃(𝐺 = 0|𝐸 = 1, 𝐷 = 0)𝑃(𝐺 = 1|𝐸 = 0, 𝐷 = 0)
𝑃(𝐺 = 1|𝐸 = 1, 𝐷 = 0)𝑃(𝐺 = 0|𝐸 = 0, 𝐷 = 0)𝑃(𝐺 = 0|𝐸 = 1, 𝐷 = 1)𝑃(𝐺 = 1|𝐸 = 0, 𝐷 = 1)
 
   
=
𝑃(𝐺 = 1|𝐸 = 1, 𝐷 = 1)𝑃(𝐺 = 0|𝐸 = 0, 𝐷 = 1)
𝑃(𝐺 = 0|𝐸 = 1, 𝐷 = 1)𝑃(𝐺 = 1|𝐸 = 0, 𝐷 = 1)
𝑃(𝐺 = 0|𝐸 = 1, 𝐷 = 0)𝑃(𝐺 = 1|𝐸 = 0, 𝐷 = 0)
𝑃(𝐺 = 1|𝐸 = 1, 𝐷 = 0)𝑃(𝐺 = 0|𝐸 = 0, 𝐷 = 0)
  









P(G = 1|E = 1, D = 1)P(G = 0|E = 0, D = 1)
P(G = 0|E = 1, D = 1)P(G = 1|E = 0, D = 1)
)
− log (
P(G = 1|E = 1, D = 0)P(G = 0|E = 0, D = 0)
P(G = 0|E = 1, D = 0)P(G = 1|E = 0, D = 0)
)
= log(𝑂𝑅𝑐𝑎𝑠𝑒𝑠) − log(𝑂𝑅𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠) =  𝛽𝑐𝑎𝑠𝑒𝑠 − 𝛽𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 
Therefore, it is possible to model P(G|E,D) instead of P(E|G,D), the interpretation of the beta 
coefficients from the logistic regression models (4.1) and (4.2) is the same. These calculations 
are easily extended for a categorical or a continuous E variable. The proportional odds 
regression analysis techniques to model P(G ≤ k|E, D) or multinomial for a genetic response 
model to design P(G=k|E,D), k = 0, 1, 2 can be performed in situations when the genotype 
variable is coded as 0, 1, and 2. We proved the equality of modeling the probability of the 
exposure, conditional on the genotype or otherwise, within the logistic regression framework. 
This provides us with a simple way to extend the EHB-GECHI approach to application with a 
continuous or categorical exposure variable. 
 
4.4. Additive Risk Model 
We discussed characteristics of case-control studies and possibilities for different types of 
genotype and exposure coding within the regression analysis framework. However, we have 
not discussed the possibility of assuming a particular mode of inheritance so far. Logistic 
regression has an advantage over the chi-squared test (which is not discussed in this 
dissertation), in that it is easier to test different genetic models (co-dominant, log-additive, 
dominant, recessive) or account for the covariates. The assumption of a specific mode of 




commonly used for the inheritance mode: the additive model refers to an “additive” risk on the 
log-scale, where each allele carries an equal risk;  the dominant model, where the relative risk 
associated with one at-risk allele is the same as the risk for carriers of two allele copies; and  
the recessive model, where the only individuals at risk are those carrying two copies of the risk 
allele (Zeggini and Morris 2010). The co-dominant model formulation is the one, assuming no 
particular mode of inheritance, in which the relative risk of a disease associated with the 
heterozygous genotype and with the homozygous genotype do not relate to one another from a 
statistical point of view (Sasieni 1997). It is easy to implement these various models in a logistic 
regression framework. To do so, the genotypes at each locus, for example AA/AT/TT, where 
T is the risk allele, are coded as categorical for a genotypic association test, 0/1/2 for an additive 
risk test, and 0/1/1 or 0/0/1 for the dominant or recessive test. 
In real data settings, it is clear that we do not know the true mode of inheritance for the disease 
and can therefore only assume a genetic risk model for the analyses. Previously, it was shown 
that the additive risk model has an advantage over the other models. It is a more powerful 
model to test for when the true inheritance mode is additive or close to additive. Furthermore, 
it has comparable power to the dominant model when the true mode of inheritance is dominant 
or similar to dominant (Lettre, Lange et al. 2007). However the disadvantage of the additive 
risk model implementation within the logistic regression analysis framework is that analytical 
estimates of the corresponding beta coefficients (logs of the odds ratios) are not available 
(Eiichiro 2004), but iterative estimates are available. Therefore we cannot prove analytically 
that the relationship βCC = βcases-βcontrols holds under the assumption of the additive risk model. 
It is clear that both estimators ?̂?𝐶𝐶 and ?̂?𝑐𝑎𝑠𝑒𝑠 − ?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 are testing the same null hypothesis 
of no G×E interaction effect. However, model fit to the simulated data demonstrates that the 
equality does not hold exactly any longer. Therefore, to derive the properties of the two 




asymptotic theory to generalize our conclusions for limited-sample estimates. Simulation 
results based on a limited sample are presented in this chapter. 
 
4.5. Simulation Study Set-up 
A simulation study was conducted to evaluate sample properties of ?̂?𝐶𝐶 and ?̂?𝑐𝑎𝑠𝑒𝑠 − ?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠. 
For a total of 1500 cases and 1500 controls, the genotypes of 5000 SNPs were generated for 
each replicate. Power, type I error, and MSE of both ?̂?𝐶𝐶 and ?̂?𝑐𝑎𝑠𝑒𝑠 − ?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 were assessed 
based on 100 replicates. The phenotype variable D and the exposure variable E were generated 
as binary variables, where 1 stands for cases or exposed and 0 for controls or non-exposed, 
respectively. The genotype G at the locus was coded as 0/1/2 according to the minor allele 
count and was generated to satisfy Hardy-Weinberg equilibrium. As one of the 5000 SNPs, a 
single SNP with G×E interaction effect was created, according to the model 
logit (P(D = 1| G, E)) = pd + β G×E G×E, 
with disease prevalence pd = 0.05 and exposure frequency pe = 0.1, 0.3, odds ratio of the 
interaction effect exp(β G×E) = ORG×E = 1.5, 2, 2.5 and the interacting SNP MAF pa = 0.1, 0.3. 
All the other SNPs were sampled with a MAF from a beta distribution B(1,3) truncated to [0.01, 
0.5]. The genotypes of these SNPs were generated independently of the disease or exposure 
(dummy SNPs). Dummy SNP genotypes were generated to evaluate the type I error of both 
estimators after multiple testing Bonferroni correction. 
We fit three regression models to the data, equation (4.8), (4.9), (4.10), to estimate βCC, βcases 
and βcontrols for each of the 5000 SNPs and each of the 100 replicates. 
logit (P(D = 1| G, E)) = αCC + βGG + βEE + βCCG×E   (4.8) 




logit (P(E = 1| G, D = 0)) = αcontrols + βcontrolsG    (4.10) 
We compared the characteristics of  ?̂?𝐶𝐶 and ?̂?𝑐𝑎𝑠𝑒𝑠 − ?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 estimators visualizing the 
difference and evaluating their corresponding type I error, power, and MSE for the simulated 
scenarios. The goal of the simulation study was to compare ?̂?𝐶𝐶 and ?̂?𝑐𝑎𝑠𝑒𝑠 − ?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 based 
on the listed characteristics. It is therefore sufficient that we simulate a single G×E interacting 
SNP to assess the power and dummy SNPs to assess the type I error. 
 
4.6. Simulation Results  
To demonstrate that the equality does not hold exactly, we plotted ?̂?𝐶𝐶 versus ?̂?𝑐𝑎𝑠𝑒𝑠 −
?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠. Figure 4.1 demonstrates exemplarily differences in corresponding estimators with 
pe = 0.3, pa = 0.3, ORGxE = 1.5, 2, 2.5. We obtained similar results for other combinations of 
the parameter values (plots not shown). As shown on Figure 4.1 and Figure 4.2, ?̂?𝐶𝐶 and 
?̂?𝑐𝑎𝑠𝑒𝑠 − ?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 are close to each other, however they are not exactly the same. Asymptotic 
theory suggests that for an infinitely large sample size, both estimators will converge to the 
simulated true values, in our example 0.405, 0.693, or 0.916, respectively, and are therefore 
asymptotically equivalent. Deviations from equality decrease with decreasing size of the 
estimated effect. For example, ORG×E = 1.5 (a) compared to ORG×E = 2.5 (c) in Figure 4.1. 
Deviations slightly increase with decreasing frequency of E (Figure 4.2c) and slightly decrease 
with decreasing frequency of G (Figure 4.2b), both compared to Figure 4.2a. 
As MSE, type I error, power, and rank power are typical characteristics used to compare 
estimators, we considered them for both estimators. Table 4.1 presents a comparison of MSE, 
type I error, power, and rank power for the following settings pe = 0.1 or 0.3, pa = 0.1 or 0.3 
and exp(0.693) = ORG×E = 2 versus exp(0.405) = ORG×E = 1.5. Clearly in terms of these major 




hypothesis, we can conclude that ?̂?𝐶𝐶 and ?̂?𝑐𝑎𝑠𝑒𝑠 − ?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 are practically equivalent 
estimators of the G×E interaction effect even for samples that are moderate in size (1500 cases 




a) pe = 0.3, pa = 0.3, exp(0.405) = ORGxE = 1.5 
b) pe = 0.3, pa = 0.3, exp(0.693) = ORGxE = 2 








In bold are simulated true log(ORG×E). Points 
located on the diagonal line represent the 
equality of two estimators ?̂?𝐶𝐶 and ?̂?𝑐𝑎𝑠𝑒𝑠 − ?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠, deviations represent violations of the 
exact equality.




Figure 4.2 Comparison of βcases-βcontrols vs. βcc as estimators of G×E interaction for different 
exposure frequency and allele frequency 
 
 
a) pe = 0.3, pa = 0.3, exp(0.693) = ORGxE = 2 
b) pe = 0.3, pa = 0.1, exp(0.693) = ORGxE = 2 







In bold are simulated true log(ORG×E). Points located on the diagonal line represent the 





We conclude that the EHB-GECHI approach can be applied under the assumption of the “log-
additive” mode of disease inheritance, as both estimators of G×E interaction are asymptotically 
equivalent and perform similarly when applied to moderately sized studies. 
Table 4.1 Properties of two estimators for ORG×E  
Estimator  βG×E βcases-βcontrols βG×E βcases-βcontrols 
Scenario 
ORG×E = 1.5 ORG×E = 2 
pe = 0.3 & pa = 0.3 
MSE 0.03 0.03 0.03 0.03 
power 0.17 0.17 0.91 0.92 
type I error 0.05 0.06 0.05 0.05 
rank power top 1 0.38 0.38 0.95 0.95 
rank power top 25 0.76 0.76 1.00 0.99 
Scenario pe = 0.3 & pa = 0.1 
MSE 0.06 0.06 0.06 0.06 
power 0.04 0.04 0.36 0.34 
type I error 0.04 0.05 0.04 0.04 
rank power top 1 0.06 0.06 0.45 0.44 
rank power top 25 0.35 0.35 0.86 0.83 
Scenario pe = 0.1 & pa = 0.3 
MSE 0.07 0.07 0.06 0.06 
power 0.02 0.02 0.36 0.38 
type I error 0.03 0.04 0.01 0.01 
rank power top 1 0.07 0.07 0.67 0.67 
rank power top 25 0.32 0.31 0.92 0.92 
 
 
4.7. Covariate Adjustment 
It is well recognized that in genetic association studies, including G×E interaction studies, great 
care should be taken to account for covariates to avoid bias. As defined in Chapter 2, a 
covariable is a variable in the analysis that relates to both the genotype of interest and to the 
phenotype (disease status), but is not an intermediate factor of the cause of disease (Rothman, 
Greenland et al. 1980). This is of key importance in case-control studies, as uncontrolled 
differences between disease carriers and healthy individuals in the study sample may lead to 
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spurious associations or mask true association signals (Zeggini and Morris 2010). In genetic 
association studies, it is generally recommended to adjust for age and sex of the individuals if 
the study design does not include matching for, these variables (Zeggini and Morris 2010). 
Other important covariables are those accounting for the ancestry of the individuals, such as 
principal components. As was discussed in detail in Chapter 3, failure to control for population 
stratification leads to bias in estimates. 
EHB-GECHI was originally proposed without discussing covariate adjustment. Since EHB-
GECHI requires estimates of the G-E correlation obtained within cases and controls, a proof is 
needed to illustrate that separate adjustment for covariates within cases and controls in a 
logistic regression framework would lead to the same estimates as an adjustment on the whole 
case-control sample. 
Let Z denote any covariate, and G, E, D all binary. To perform association analysis adjusted 
for the covariate Z one can fit the following three logistic regression models to the data. 
logit (P(D = 1| G, E)) = αCC_Z + βG_ZG + βE_ZE + βCC_ZG×E + βZ_CCZT (4.11) 
logit (P(E = 1| G, D = 1)) = αcases_Z + βcases_ZG + βZ_casesZT   (4.12) 
logit (P(E = 1| G, D = 0)) = αcontrols_Z + βcontrols_ZG + βZ_controlsZT  (4.13) 
In the equations above βCC _Z = log(ORG×E|Z), where ORG×E|Z is the population G×E interaction 
odds ratio adjusted for Z, likewise corresponding coefficients from (4.12) and (4.13) have the 
same interpretation. 
To prove that the population interaction odds ratio, ORG×E|Z, can indeed be written as the ratio 
of the population odds ratios in cases and controls respectively, or that the relationship βCC _Z 
= βcases_Z-βcontrols_Z holds, assume that ORG×E is independent of the covariate Z (in the case of a 
categorical Z, we assume that the G×E interaction effect is the same across the strata of Z). This 
assumption is commonly made in analyses that adjust for covariates Z as G×E×Z terms are 
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rarely included in the regression model. In finite samples, the estimated interaction odds ratio 
will not generally be identical to the ratio of estimated odds ratios, but the result holds 
asymptotically. This follows from the consistency (provided the model is not misspecified) of 
the estimated odds ratios in cases and controls and the equality holding at the population level.  
Denote f0(G,E,Z)=f(G,E,Z|D=0) and f1(G,E,Z)=f(G,E,Z|D=1) as the conditional probability of 
(G, E, Z) given D=0 or D=1. Then 









so OddsG=1,E=1|Z = P(D=1|G=1 E=1, Z=z)/(1- P(D=1|G=1 E=1, Z=z))  
OddsG=0,E=0|Z = P(D=1|G=0 E=0, Z=z)/(1- P(D=1|G=0 E=0, Z=z)) 
OddsG|E=0,Z = P(D=1|G=1 E=0, Z=z)/(1- P(D=1|G=1 E=0, Z=z)) 
OddsE|G=0,Z = P(D=1|G=0 E=1, Z=z)/(1- P(D=1|G=0 E=1, Z=z)) 
Then, the case-control estimate of an adjusted G×E interaction odds ratio 
ORG×E|Z=(Odds G=1,E=1|ZOdds G=0,E=0|Z)/(OddsG|E=0,ZOddsE|G=0,Z) 
reduces to e(γ+δ3Ζ) . 
Now consider the estimator based on the comparison of adjusted G-E correlations in cases and 
controls, which EHB-GECHI proposes. Proceeding as above, starting with the probability of 







ORG-E_cases reduces to e(γ+1+4Ζ+δ3Ζ) and ORG-E_controls reduces to 𝑒(1+4Ζ) , so 
ORG×E|Z= ORG-E_cases|Z/ORG-E_controls|Z=𝑒(𝛾+𝛿3𝛧) , 
that is, the equivalent to that for the case-control estimator. 
Both are equal to the G×E interaction parameter, exp(), provided only that 3 = 0, i.e., that 
there is no 4-way interaction in the log-linear model (3-way interaction of G×E×Z in logistic 
regression framework), or equivalently that Z does not modify the magnitude of the G×E 
interaction. There is no need to assume Z to be independent of G, E, or Z or any of its lower-
order interactions for this result to hold. 
Another possible solution to the covariates problem relies on the simultaneous estimation of 
G-E correlation in cases and controls adjusted for the covariate Z in a single model. This can 
be performed with log-linear modeling. It was demonstrated by Umbach and Weinberg and 
later by Eiichiro (Umbach and Weinberg 1997, Eiichiro 2004) that the estimated coefficients 
of G-E correlation obtained employing a log-linear model are exactly equivalent to those 
calculated based on the logistic model. Therefore, one can fit the following single log-linear 
model to the data to obtain βCC_Z and βcontrols_Z and consequently βcases_Z as βCC_Z 
+βcontrols_Z=βcases_Z. We used notations as in (Umbach and Weinberg 1997).  
Let nijk denote the number of subjects having D = i, G = j, and E = k and N is the total number 
of individuals. For the sake of simplicity, assume that i, j, and k all binary. Replacing any 





Table 4.2 Data representation for log-linear model 
 E=1 E=0 Total 
 G=1 G=0 G=1 G=0  
D=1 n111 n101 n110 n100 n1.. 
D=0 n011 n001 n010 n000 n0.. 
Total n.11 n.01 n.10 n.00 N 
 
Log-linear models assume a multiplicative relationship between categorical variables, that is, 
the expected value of any cell counts nijk can be modeled as a product of the overall number of 
observations (N) and the main effect of each variable and their respective interaction. 
log(nijk)=α0+βG_controlsG+βE_controlsE+βcontrolsG×E+αD+βGG×D+βEE×D+βCCG×E×D   (4.14) 
Equation (4.15) links the logistic model given in (4.8) to the log-linear model in (4.14) 
(Bishop, Fienberg et al. 2007)) 
log(n1jk)-log(n0jk)=logit(P(D=1|G,E,Z))=α+βGG+βEE+βCCG×E          (4.15) 
Log-linear models allow us to model cell counts for eight cells in the table above explicitly and 
simultaneously. Clearly from (4.14), adjustment for the categorical covariate Z can be handled 
in the log-linear models framework to obtain estimates βCC_Z and βcontrols_Z simultaneously 
adjusted for Z. For additional discussion on covariates adjustment in log-linear data analysis 
please refer to (Umbach and Weinberg 1997). Based on our proof for the logistic regression 
framework and discussion on log-linear models, we conclude that the analysis of the data 




5. Modified Empirical Hierarchical Bayes Approach for G×E 
Interaction 
In Chapter 4, we introduced the EHB-GECHI approach for G×E interaction. It combines 
estimates of G×E interaction from the case-only test and posterior estimates of population-
based G-E correlations made among controls to construct a powerful rank statistic. As 
discussed in Chapter 4, this statistic can only be applied to perform ranking and is not 
recommended for significance testing, since the test has inflated rate of type I error. 
In the current chapter, we introduce an improved, computationally faster, and more stable 
alternative approach we have developed, which obtains the posterior estimates of G-E 
correlation in controls basing on a normal-normal hierarchical model. The normal-normal 
model is a classic example of the empirical Bayes inferences framework (Chapter 4). This 
model allows us to reduce the variance of G-E control-based estimates. Thus, we gain power 
over the case-control statistic while keeping a tighter control on type I error than a pure case-
only test. We name this new approach the empirical hierarchical Bayes approach for G×E 
interaction (EHB-GENN). With EHB-GENN, only a single hyperparameter τ2, the common 
variance of G-E effects, has to be estimated in contrast to three hyperparameters in the previous 
EHB-GECHI method (Sohns, Viktorova et al. 2013), (Chapter 4). This leads to greater 
estimation stability and simplicity. Thanks to the improved type I error rate control, EHB-GENN 
can be utilized for significance testing and not just for ranking of G×E interactions, a notable 
and important improvement compared to EHB-GECHI. 
We conducted an extensive simulation study to evaluate our approach. We compared EHB-
GENN with EHB-GECHI and Mukherjee’s empirical Bayes approaches in terms of the achieved 
power and inflation of type I error, since these two methods were altogether favorable to other 
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tests (CC, CO, MUR) in most situations (Sohns, Viktorova et al. 2013). We compared rank 
power of EHB-GENN against all other G×E methods, EHB-GECHI, CC, CO, MUK-EB, and 
MUR. 
As already mentioned in Chapter 1, joint discovery of G×E interactions and genetic main 
effects may aid the detection of genetic variants potentially missed by the initial GWASs 
focusing on the marginal marker-trait association or pure interaction analysis (Kraft, Yen et al. 
2007, Dai, Logsdon et al. 2012, Vanderweele, Ko et al. 2013). Thus, methods capable of 
considering genetic main and G×E interaction effects simultaneously are important. 
In 2007, Kraft and colleagues presented a joint likelihood ratio test of SNP main and G×E 
interaction for case-control data (Kraft, Yen et al. 2007). In 2011, Dai and colleagues exploited 
Kraft’s approach and proposed three joint tests different from Kraft et al. in two respects (Dai, 
Logsdon et al. 2012). They proposed using a marginal genetic association component instead 
of the main effect estimate in a model for G×E interaction. Secondly, they demonstrated that 
not only the CC, but also the CO or the MUK-EB estimators can be used to test the G×E 
interaction component (Dai, Logsdon et al. 2012). Dai’s joint tests are more flexible than and 
at least as powerful as Kraft’s likelihood test. Therefore, we outline three joint 2-degree-of-
freedom tests (CCJ, COJ, MUK-EBJ), proposed by Dai (Dai, Logsdon et al. 2012). Similarly to 
Dai, we construct the joint EHB-GENNJ test, proposing combining both estimators of the genetic 
marginal effect and the EHB-GENN G×E interaction in a single statistic. Both EHB-GENN and 
joint EHB-GENNJ do not assume G-E independence, which makes them favorable in the 
genome-wide testing context.  
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5.1. The Normal-Normal Model 
(Morris 1983) 
Assume that p parameters need to be estimated θ=(θ1,…,θp) and that we have p independent 
unbiased estimates X=(X1,…,Xp), E(Xi)= θi, i=1…p. Assuming Xi’s are independently normal, 
we can write 
Level 1 𝑋𝑖|𝜃𝑖    ∼  𝑁(𝜃𝑖, 𝑉), 
 Level 2  𝜃𝑖|𝜇, 𝐴  ∼  𝑁(𝜇, 𝐴 ), 
with V=var(Xi), A=var(θi) (equal variances case), i=1…p, and η=(μ, A) are level 
hyperparameters. The estimates Xi are usually a statistic of the original data, for example 
sample means. Assume that V, common variance is known and do not need to be estimated in 
a Bayesian manner. We concentrate on the estimation of hyperparameters θ.  
For this model, the marginal distribution of Xi is given by 
𝑋𝑖|𝜇, 𝐴  ∼  𝑁(𝜇, 𝑉 + 𝐴), 
and estimates of η can be obtained by maximizing the log of the marginal likelihood, given as 










Maximization yields the MMLE ?̂? =
1
𝑛
∑ 𝑋𝑖 . Plugging in this estimate, the posterior 
distribution 𝜋(𝜃𝑖|𝑋𝑖, ?̂?, 𝐴) is obtained as 





The posterior estimate of θi is given as 
 
86 
𝜃𝑖 = 𝐵?̂? + (1 − 𝐵)𝑋𝑖. 
In the case of A being an unknown hyperparameter, it can also be estimated from the data. The 




2 and the known V, then 
?̂? = max (0, 𝑠2 − 𝑉). 
Any desirable number of hierarchical levels can be implemented within EHB models. 
 
5.2. Construction of the EHB-GENN Statistics 
As discussed earlier, G×E interaction is challenging to detect, particularly on the genome-wide 
scale, mainly due to the lack of power of common interaction tests. Addressing this issue, the 
CO test can be performed to increase power, however a large inflation in type I error associated 
with the test in the presence of G-E correlation must be taken into consideration. It is essential 
to account for population-level G-E correlation in studies of G×E interaction when using case-
only-related methods. The method we propose aims to estimate this correlation efficiently 
based on the information in controls as a sample from the general population, such that an 
increase in power over CC is achieved, while keeping type I error inflation low. 
Consider a case-control study with a total of N individuals, N1=ccr×N0 cases and N0 controls, 
where ccr stands for case-control ratio. Let m denote a SNP, m = 1…M, where M is the total 
number of SNPs in a GWAS analysis. Let G denote a genotype and Gm denote a genotype at a 
specific SNP m. Let E denote the exposure variable and D the disease outcome variable. Let us 
also assume that all three variables D, G, and E are binary. 
We assume that G-E effects in controls, i.e. parameters 𝛽𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠, m=1…M, can be estimated, 
yielding independent and unbiased estimates ?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠. Standard logistic regression models 
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(5.1) and (5.2) below can be applied per SNP to derive the needed effect estimates of G-E 
within cases and within controls (?̂?𝑚
𝑐𝑎𝑠𝑒𝑠 and ?̂?𝑚




logit(P(E=1|G, D=1))=αcases+βcasesGm     (5.1) 
logit(P(E=1|G, D=0))=αcontrols+βcontrolsGm     (5.2) 
Remember that the G×E interaction estimate on the multiplicative scale can be represented as 
the difference of βcases-βcontrols per SNP, (Chapter 2). We propose estimating βcases-
posterior(βcontrols) for each SNP to reduce the variance of the control-based G-E correlation. 
Adopting empirical hierarchical Bayes inference theory (Chapter 4), we propose the 
hierarchical Bayes model (5.3)-(5.4) to estimate the posterior mean of G-E correlation in 
controls and its variance. 
Level 1  ?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠  | 𝛽𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠   ∼  𝑁(𝛽𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠, (𝜎𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠)2)  (5.3)  
Level 2  𝛽𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 | 𝜏2    ∼    𝑁(0, 𝜏2)     (5.4)  
If ?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 are maximum likelihood estimates (MLE) of the true parameters, obtained from 
equation (5.2), then, referring to the asymptotic theory, we can assume that they are normally 
distributed and can construct a valid two-stage model (5.3)-(5.4). 
Here 𝜎𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 is the standard error of ?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠. Each 𝜎𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 can be substituted by the 
corresponding MLE. The prior mean of G-E effects in controls (𝛽𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠) is centered at zero, 
since we expect no association for the vast majority of SNPs and the prior variance is τ2. The 
hyperparameter τ2 is estimated borrowing information across all SNPs from the marginal 
distribution of ?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠, given in (5.5) by maximizing the log of the marginal likelihood (L), 
given by (5.6) with respect to τ2 
?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠  | 𝜏2  ∼  𝑁(0, (𝜎𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠)2 + 𝜏2)      (5.5) 
 
88 
  (5.6) 
where fm(?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠  | 𝜏2) is the marginal density function. From (5.3) and (5.4), we derive the 
posterior distribution of the unknown parameters 𝛽𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠, m = 1 … M, see (5.7) below. 
𝛽𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠  | ?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠, 𝜏2  ∼  𝑁((𝛽𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠)∗, (𝜎𝑚
2 𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠)∗)   (5.7) 
(𝛽𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠)∗ = posterior(𝛽𝑚







𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠)2 + 𝜏2) and 
?̂?m = (𝜎𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠)2/((𝜎𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠)2 + ?̂?2)  
Here, Bm is the SNP specific shrinkage factor, 0 ≤  𝐵m ≤ 1. The amount of shrinkage depends 
on τ2, with virtually no shrinkage in ?̂?𝑚
𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 when Bm≈0 (τ2→∞) and complete shrinkage to 
zero when Bm=1(τ2 =0). 
The corresponding variance of posterior(𝛽𝑚









































































covariate adjustment separately within cases and within controls as well as effect estimation 
based on a multilevel or continuous genotype or exposure variable is discussed in Chapter 4. 
All extensions we derived for EHB-GECHI are applicable to the EHB-GENN approach. 
 
5.3. Simulation Study Set-up 
We simulated genotypes (G) at 10,000 SNPs (m), one environmental factor (E) and disease 
outcome (D) for a total of 3000 individuals, with three different case-control ratios (ccr), 1:1 
(1500 : 1500), 1:2 (1000 : 2000) and 2:1 (2000 : 1000) to represent balanced and unbalanced 
study designs. Linkage disequilibrium (LD) between SNPs was not modeled. Presence of the 
correlation structure between SNPs should not affect the validity of our approach but only its 
efficiency. All three variables D, G, and E were generated as binary, where 1 codes for cases, 
carriers, and exposed and 0 stands for controls, non-carriers, and unexposed. Table 5.1 
summarizes the simulation scenarios generated. The simulation setup remains the same as in 
(Sohns 2012) for a valid comparison across the G×E interaction methods. 
A single SNP with G×E interaction effect was generated based on the following disease model  
logit(P(D=1|Gm, E))=pd +βG×EGm×E 
with baseline disease risk pd   = 0.01 or 0.05, exposure frequency pe=0.1, 0.3, or 0.5, genotype 
carrier frequency pg = 0.1, 0.3, or 0.5 and odds ratio associated with G×E interaction exp 
(βG×E)=ORG×E=1.2, 1.5, 2, 2.5, 3. Note that E and G are not modeled as main effects. However, 
the frequencies influence the number of individuals in each G×E stratum. Among the total 
number of SNPs, we designed a number of signals, NG-E =0, 1000, 2500, or 5000, with 
population-based G-E correlation. The strength of these correlations was classified in three 
groups, low, medium, and high, based on the sampling distribution of the corresponding 
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coefficients N(0, log(1.5)/2), N(0.7,0.1), and exp(N(0,log(1.5)/2)), respectively. Figure 5.1 
demonstrates the distribution of these three groups of G-E correlation effects in controls. For 
the remaining SNPs, without any G×E interaction or G-E correlation effect, the frequency of 
the at-risk genotype carriers was sampled from a beta distribution B(1, 3) truncated to [0.01, 
0.5]. Analysis was conducted for each of 1000 replicated datasets. 
Figure 5.1 Distribution of G-E correlation effects in controls 
ORG-E(low)~N(0,log(1.5)/2), ORG-E(medium)~N(0.7,0.1), and ORG-E(high)~exp(N(0,log(1.5)/2)) 
 
Table 5.1 Simulation study settings, 3240 scenarios 
Scenario  Frequency Number OR 
Prevalence of D pd = 0.01, 0.05   
E pe = 0.1, 0.3, 0.5 1 ORE=1 
G×E interaction SNP pg = 0.1, 0.3, 0.5 1 ORG×E=1.2, 1.5, 2, 2.5, 3 
G-E correlated SNPs 0.01 - 0.5 0, 1000, 2500, 5000 ORG-E=(low, medium, high) 
 
 
5.4. Simulation Study Results 
We evaluated the performance of EHB-GENN with regard to type I error, power, and rank power 
and compared those to EHB-GECHI and MUK-EB. As expected, the power of EHB-GENN 
increases with increasing G×E effect size, increasing pg, pe frequencies, and decreasing pd. The 
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power of EHB-GENN depends on ccr, generally favoring a balanced design (Figure 5.2). This 
behavior persists independently of the number of G-E correlations. Figure 5.2 illustrates 
different ccrs, different G-Es, and effect sizes for ORG×E=2.5 and pg=0.3, pe=0.3, pd=0.05 
(upper row) or ORG×E=2.5, pg=0.5, pe=0.5, pd=0.05 (lower row). As can be seen from Figure 
5.2, having twice as many controls as cases is the most unfavorable situation. Figure 5.2 also 
indicates an increase in power with increasing genotype frequency and exposure. The power 
depends on the number of SNPs with G-E. The EHB-GENN test achieves higher power in the 
presence of low-effect G-E correlation when compared to medium or high effects. The decline 
in power depending on the number of G-E correlations is not dramatic and even less so in high 
effect scenarios.  
Subsequently, we compared the type I error rate and the power of EHB-GENN with EHB-GECHI 
and MUK-EB. To account for the possible inflation of the family-wise type I error rate due to 
the multiple testing of 10,000 SNPs we used Bonferroni correction, by setting up the 
significance level for the p-value of each test to 5×10-5. For clarification note that, under the 
null hypothesis the percentage among 1000 replications is given, where any one of 10,000 
SNPs is significant. Evaluation shows that relative loss in absolute power of the EHB-GENN 
method compared to the EHB-GECHI or the MUK-EB approaches are smaller on average than 
inflation of the type I error of the later methods in comparison to EHB-GENN. This conclusion 
is depicted in Tables 5.2 and 5.3. Table 5.2 portrays type I error and power of EHB-GENN, 
EHB-GECHI, and MUK-EB for 1500 cases and 1500 controls, ORG×E=2.5, pd=0.05, with 
pg=0.3, pe=0.3 on the left and pg=0.5, pe=0.5 on the right in the absence of or presence of a 
large number of G-E correlations with either medium or high effect. Table 5.3 portrays the 
results for pd=0.01, all other conditions remaining the same as in Table 5.2. If the G-E 
independence assumption is valid (OR_G-E = 1 in Tables 5.2, 5.3), all three approaches 
maintain type I error at a nominal 5% level or lower (see ORG×E =1, in italics). Tables 5.2 and 
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5.3 also reflect that under the assumption of G-E independence (OR_G-E=1), the type I error 
rate of EHB-GENN is less conservative than that of EHB-GECHI or MUK-EB. This leads to a 
power gain for our new approach in such settings. We therefore conclude that EHB-GENN is 
more powerful than EHB-GECHI and MUK-EB, under the assumption of G-E independence 
(Table 5.2 and Table 5.3, upper blocks). In the presence of a large number of G-Es of medium 
to high effect size, EHB-GENN always holds type I error less than or equal to 10%, except for 
situations with an infrequent environmental factor, i.e. in our simulation pe=0.1, when type I 
error can rise to 20%. In this case, the responsible sub-stratum is not large enough to estimate 
the variance of the correlation signals properly. Clearly, EHB-GENN has much lower type I 
error compared to EHB-GECHI and MUK-EB in the presence of G-E correlations of medium to 
high effect size. Controlling type I error is a critical issue when performing significance testing 
in contrast to a ranking of test statistics for follow-up. Hence, the ability of EHB-GENN to 
maintain it at a reasonable 10% or lower level compared to over 50% for EHB-GECHI or around 
20% for MUK-EB (Table 5.2 and Table 5.3) is a clear advantage of the EHB-GENN approach. 
Table 5.2 and Table 5.3 also present results on the power of the three approaches. In general, 
EHB-GENN appears to have lower power compared to the competitors; this should be seen as 
a compromise with the type I error control. The EHB-GENN approach always has greater or 
equal power compared to the classic CC test (data not shown). To evaluate the relative loss of 
power combined with a decrease in type I error towards an acceptable level for EHB-GENN 
versus the other two considered methods, we plotted the differences in type I error of EHB-
GECHI (Figure 5.3, upper row) or MUK-EB (Figure 5.3, lower row), respectively, minus type 
I error of EHB-GENN on the y-axis and the corresponding differences in power on the x-axis. 
Please note the difference in the scales between the upper (EHB-GENN versus EHB-GECHI) and 
lower (EHB-GENN versus MUK-EB) rows of Figure 5.3. Each of the points on the graphs 
represents one simulated scenario. Points above the diagonal reflect the situation in which the 
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increase in type I error level is greater than the power gain of the rival method compared to 
EHB-GENN. In most situations, we observe a much larger type I error level increase compared 
to the corresponding power increase of the competitors. In many situations, both EHB-GECHI 
and MUK-EB do not even gain in power at all at the expense of a large inflation in type I error. 
To summarize the results on power and type I error, EHB-GENN is an improvement on the 
earlier EHB-GECHI approach, because it maintains type I error rate reasonably well in the 
presence of G-E correlations, whereas the loss in power is not very critical. The EHB-GENN 
test is more powerful than the case-control test. In contrast to MUK-EB, it does not assume G-
E independence in the general population. Moreover, EHB-GENN is computationally much 
faster than EHB-GECHI and more stable in terms of parameter estimation. 
We also evaluated the rank power of our approach. EHB-GENN always has equal or greater 
rank power than the CC or CO methods in the presence of G-E correlations. The rank power 
gain of EHB-GENN compared to CO is extreme, reaching almost 100% in the presence of a 
large number of G-E correlations with high effect size, because the CO test has almost no 
power in these scenarios. EHB-GENN nearly always has greater rank power than MUR except 
in some situations of low G-E correlations, when for a rare exposure variable EHB-GENN lacks 
in power. On average over the 1000 replicates, EHB-GENN has about 5% lower rank power 
than EHB-GECHI for the top 100 ranks. The rank power of EHB-GENN was often lower than 
that for MUK-EB but not dramatically so. Nevertheless, in scenarios with low G-E correlation 
signals and some scenarios with high effect signals, the rank power of EHB-GENN was larger 
than that of MUK-EB. Rank power of EHB-GENN vs. CC, MUR, CO, MUK-EB, and EHB-
GECHI is demonstrated in Figures 5.4-5.6 for different ccr (1:1, 1:2, 2:1). 
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Figure 5.2 Power of EHB-GENN to detect a SNP with GxE interaction for ccr = 1:1, 1:2, 2:1 and different numbers of G-E correlations (# of G-E 
correlation) with different effect sizes OR_G-E low, medium and high, ORG×E  = 2.5, pg = 0.3, pe = 0.3, pd = 0.05 (upper row) and ORG×E  = 2.5, pg 




Table 5.2 Type I error (in italic) and Power of EHB-GENN, EHB-GECHI, MUK-EB, pd=0.05 
ccr =1:1 pd  = 0.05, pe  = 0.3, pg  = 0.3 pd  = 0.05, pe  = 0.5, pg  = 0.5 
OR_G-E N_G-E ORG×E EHB-GENN EHB-GECHI MUK-EB EHB-GENN EHB-GECHI MUK-EB 
1 0 
1 0.05 0.03 0.01 0.04 0.03 0.02 
1.2 0.00 0.00 0.00 0.00 0.00 0.00 
1.5 0.01 0.01 0.01 0.20 0.19 0.09 
2 0.22 0.23 0.11 0.97 0.94 0.80 
2.5 0.74 0.72 0.42 1.00 1.00 0.99 
3 0.96 0.95 0.73 1.00 1.00 1.00 
medium 
2500 
1 0.10 0.92 0.18 0.06 0.82 0.06 
1.2 0.00 0.00 0.00 0.00 0.00 0.00 
1.5 0.02 0.09 0.05 0.05 0.18 0.09 
2 0.38 0.83 0.62 0.63 0.93 0.80 
2.5 0.87 0.98 0.95 0.97 0.99 0.98 
3 0.99 0.99 1.00 1.00 0.99 1.00 
5000 
1 0.08 0.93 0.33 0.05 0.82 0.11 
1.2 0.00 0.00 0.00 0.00 0.00 0.00 
1.5 0.02 0.09 0.05 0.04 0.17 0.09 
2 0.34 0.81 0.62 0.60 0.92 0.80 
2.5 0.84 0.96 0.95 0.97 0.99 0.98 
3 0.99 0.98 0.99 1.00 1.00 1.00 
high 
2500 
1 0.05 0.54 0.08 0.05 0.32 0.30 
1.2 0.00 0.00 0.00 0.00 0.00 0.00 
1.5 0.01 0.08 0.04 0.04 0.18 0.10 
2 0.38 0.84 0.62 0.58 0.95 0.83 
2.5 0.85 0.99 0.95 0.97 0.99 0.99 
3 0.99 1.00 1.00 1.00 1.00 1.00 
5000 
1 0.04 0.52 0.15 0.05 0.30 0.04 
1.2 0.00 0.00 0.00 0.00 0.00 0.00 
1.5 0.01 0.08 0.04 0.04 0.18 0.10 
2 0.36 0.83 0.62 0.56 0.95 0.82 
2.5 0.84 0.99 0.95 0.97 0.99 0.99 
3 0.98 1.00 1.00 1.00 1.00 1.00 
 
Abbreviations: ccr, case-control ratio; pd, baseline disease risk; pe, exposure frequency; pg, genotype 
carrier frequency; OR_G-E, odds ratio associated with G-E correlation; N_G-E, number of SNPs with 
population based G-E correlation (strength of G-E correlations); ORG×E, odds ratio associated with G×E 
interaction; EHB-GENN, parametric empirical hierarchical Bayes approach for G×E interaction, based 
on normal-normal model; EHB-GECHI, empirical hierarchical Bayes approach to G×E interaction, based 
on chi-distribution; MUK-EB, empirical Bayes shrinkage estimator; 
Notes: ORG×E =1corresponds to the null hypothesis; 
 N_G-E=0 corresponds to absence of G-E correlation; 
 Significance level per test is set to 5×10-5, as 10,000 SNPs were simulated;  
 
96 
Table 5.3 Type I error (in italic) and Power of EHB-GENN, EHB-GECHI, MUK-EB pd=0.01 
ccr =1:1 pd  = 0.01, pe  = 0.3, pg  = 0.3 pd  = 0.01, pe  = 0.5, pg  = 0.5 
OR_G-E N_G-E OR_G×E EHB-GENN EHB-GECHI MUK-EB EHB-GENN EHB-GECHI MUK-EB 
1 0 
1 0.05 0.03 0.05 0.04 0.04 0.02 
1.2 0.00 0.00 0.00 0.00 0.00 0.00 
1.5 0.13 0.14 0.06 0.23 0.21 0.12 
2 0.92 0.90 0.67 0.97 0.97 0.83 
2.5 1.00 1.00 0.93 1.00 1.00 1.00 
3 1.00 1.00 0.99 1.00 1.00 1.00 
medium 
2500 
1 0.09 0.92 0.20 0.07 0.76 0.07 
1.2 0.00 0.00 0.00 0.00 0.00 0.00 
1.5 0.09 0.11 0.05 0.13 0.22 0.13 
2 0.84 0.90 0.68 0.90 0.96 0.83 
2.5 1.00 0.99 0.95 1.00 0.99 1.00 
3 1.00 0.99 0.99 1.00 1.00 1.00 
5000 
 
1 0.09 0.93 0.35 0.08 0.82 0.07 
1.2 0.00 0.00 0.00 0.00 0.00 0.00 
1.5 0.06 0.10 0.05 0.08 0.22 0.13 
2 0.70 0.87 0.68 0.83 0.96 0.83 
2.5 0.99 0.97 0.95 0.99 0.99 0.98 
3 1.00 0.99 0.99 1.00 1.00 1.00 
high 
2500 
1 0.08 0.53 0.08 0.07 0.34 0.04 
1.2 0.00 0.00 0.00 0.00 0.00 0.00 
1.5 0.01 0.13 0.07 0.04 0.22 0.12 
2 0.42 0.90 0.70 0.60 0.97 0.83 
2.5 0.87 0.99 0.93 0.96 1.00 0.98 
3 1.00 1.00 0.99 1.00 1.00 1.00 
5000 
 
1 0.06 0.49 0.13 0.05 0.27 0.05 
1.2 0.00 0.00 0.00 0.00 0.00 0.00 
1.5 0.01 0.14 0.07 0.04 0.21 0.12 
2 0.36 0.90 0.70 0.57 0.96 0.83 
2.5 0.84 0.99 0.93 0.96 1.00 0.98 
3 0.99 0.99 0.99 1.00 1.00 1.00 
 
Abbreviations: ccr, case-control ratio; pd, baseline disease risk; pe, exposure frequency; pg, genotype 
carrier frequency; OR_G-E, odds ratio associated with G-E correlation; N_G-E, number of SNPs with 
population based G-E correlation (strength of G-E correlations); ORG×E, odds ratio associated with G×E 
interaction; EHB-GENN, parametric empirical hierarchical Bayes approach for G×E interaction, based 
on normal-normal model; EHB-GECHI, empirical hierarchical Bayes approach to G×E interaction, based 
on chi-distribution; MUK-EB, empirical Bayes shrinkage estimator; 
Notes: ORG×E =1corresponds to the null hypothesis; 
 N_G-E=0 corresponds to absence of G-E correlation; 
 Significance level per test is set to 5×10-5, as 10,000 SNPs were simulated;  
 
97 
Figure 5.3 Evaluation of relative changes in power and type I error. The difference in power (on x-axis) and the difference in type I error (on y-




Figure 5.4 Rank power comparison to detect a G×E interaction in the top 100 SNPs between EHB-GENN and competing methods (CC, MUR, CO, 
MUK-EB, EHB-GECHI) for parameter combinations (ORGxE = 1.2, 1.5, 2, 2.5, 3; pg = 0.1, 0.3, 0.5; pe = 0.1, 0.3, 0.5, and pd = 0.05) given 1500 
cases and 1500 control, and 1000 replicates. 
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Figure 5.5 Rank power comparison to detect a G×E interaction in the top 100 SNPs between EHB-GENN and competing methods (CC, MUR, CO, 
MUK-EB, EHB-GECHI) for parameter combinations (ORGxE = 1.2, 1.5, 2, 2.5, 3; pg = 0.1, 0.3, 0.5; pe = 0.1, 0.3, 0.5, and pd = 0.05) given 1000 
cases and 2000 control, and 1000 replicates. 
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Figure 5.6 Rank power comparison to detect a G×E interaction in the top 100 SNPs between EHB-GENN and competing methods (CC, MUR, CO, 
MUK-EB, EHB-GECHI) for parameter combinations (ORGxE = 1.2, 1.5, 2, 2.5, 3; pg = 0.1, 0.3, 0.5; pe = 0.1, 0.3, 0.5, and pd = 0.05) given 2000 





Figure 5.4-Figure 5.6, plots a) demonstrate that EHB-GENN has much greater rank power in 
almost all simulation scenarios compared to the case-control test. Comparing EHB-GENN 
versus MUR (Figure 5.4-Figure 5.6, plots b)), we conclude that in presence of a larger number 
of G-E correlations with high effect size. EHB-GENN reaches remarkably increased rank power. 
The rank power of MUR is higher compared to EHB-GENN when there are only G-E 
correlations with low effect size. From Figure 5.4-Figure 5.6, plots c) it can be seen that EHB-
GENN outperforms the case-only test too. A clear triangular structure above the x-axis suggests 
that EHB-GENN has considerably larger rank power than CO in presence of medium to high G-
E correlation signals. Irrespective of other parameters, the CO test has very low rank power in 
these situations. The EHB-GENN approach performed better, achieving greater rank power than 
MUK-EB (Figure 5.4-Figure 5.6, plots d)) in presence of G-E correlations with low effect 
size. Generally, EHB-GENN has lower rank power, thank MUK-EB; however, the loss in rank 
power is not dramatic. EHB-GECHI has a higher rank power than EHB-GENN (Figure 5.4-
Figure 5.6, plots e)) for almost all simulated scenarios. The average loss in rank power for all 
situations over 1000 replicates is ≤ 5% for EHB-GENN. It is important to notice that the rank 
power of MUK-EB and EHB-GECHI compared to EHB-GENN should be discussed in the context 
of the type I error inflation for each of the methods. 
Generally, EHB-GENN can be applied for significance testing in GWAS to search for G×E 
signals without assuming gene-environment independence. It maintains adequate power and in 
this respect nearly always performs better, in terms of reaching higher rank power than CC or 
MUR tests, those methods requiring no assumption of genotype-environment independence. 
Based on the results from the simulation study, we recommend performing EHB-GENN to test 
for interaction when a large number of G-Es with moderate to high effect size is expected to 
occur in the study sample and preferably with a frequent exposure variable, so that the strata 




5.5. Joint Tests for Genetic Marginal Effect and G×E Interaction Effects 
Originally, a joint likelihood ratio test for the genetic main effect combined with the G×E 
interaction effect was introduced by Kraft and colleagues (Kraft, Yen et al. 2007). They 
compared power and sample size requirement of this joint test to all: the marginal case-control 
test, case-control and case-only tests for G×E interaction. It was revealed that even though for 
many penetrance models the joint test is not the most powerful, it is nearly optimal across all 
genetic risk models considered (Kraft, Yen et al. 2007). Dai and colleagues presented a novel 
approach to joint testing (Dai, Logsdon et al. 2012). They proposed identifying the involvement 
of a genetic factor in terms of its marginal association with the trait and/or involvement in gene-
environment interaction. This allows them to use CC, CO and MUK-EB estimators to estimate 
the G×E interaction component (Dai, Logsdon et al. 2012). Dai’s joint tests are more flexible 
than and at least as powerful as the likelihood test by Kraft et al. We present below three joint 
2 degrees of freedom tests (CCJ, COJ, MUK-EBJ), proposed by Dai (Dai, Logsdon et al. 2012). 
In accordance with Dai’s proposal, let us consider the four logistic regression models presented 
in equations (5.9) – (5.12). Let D denote the binary disease outcome, E denote the exposure 
variable, and G denote genotype. Let Z be a vector of potential covariates. 
logit(P(D=1|G))=α0+αGGm+𝛼𝑍
𝑇ZT      (5.9) 
logit(P(D=1|G, E))=β0+βGGm+βEE+βCCGm×E+βZZT   (5.10) 
logit(P(E=1|G, D=1)) = λ0 + βcasesGm+λZZT     (5.11) 
logit(P(E=1|G, D=0))=γ0+βcontrolsGm+γZZT     (5.12) 
Equation (5.9) models the association between trait D and SNP effect Gm, therefore αG = 0 
tests for the presence of the genetic marginal effect of SNP m. The hypothesis βCC = 0 in 




G and E main effects. In order to combine two regression estimators 𝛼𝐺  ̂ and 𝛽𝐶𝐶  ̂  of two 
different models (5.9) and (5.10) into a single test statistic, these estimators should be 
asymptotically independent. As suggested in Dai et al. (2011), the independence follows, since 
for any two nested generalized linear models with a canonical link function, the parameter 
estimates of a smaller model are asymptotically independent of the estimates in a larger model 
(Dai, Logsdon et al. 2012). Because of the independence, Dai’s tests statistics have a simple 
form of the sums of two squared Z scores. Under the two null hypotheses H01: αG=0 and H02: 
βCC=0, or βCO=0, or βMUK-EB=0, all three test statistics follow a χ2 distribution with 2 degrees 
of freedom. 
The corollary to the theorem concludes the statement of asymptotic independence: We present 
the corollary as in (Dai, Kooperberg et al. 2012). 
Corollary (Dai, Kooperberg et al. 2012): Let Y be an outcome variable in a generalized linear model 
with a canonical link function g, and let X be the genetic variable, E the environmental variable 
and Z the additional covariates. Consider two nested generalized linear models 
𝑔{𝐸(𝑌|𝐸)} =  𝛽0 + 𝛽1𝑋 + 𝛽2𝑍. 
𝑔{𝐸(𝑌|𝑋, 𝐸)} =  𝛾0 + 𝛾1𝑋 + 𝛾2𝐸 + 𝛾3𝑋 × 𝐸 + 𝛾4𝑍. 
Then the maximum likelihood estimators, 𝛽1̂ and 𝛾3̂are asymptotically independent.  
In the logistic regression models framework, a simulation study performed by Dai and 
colleagues demonstrated almost zero empirical correlation when the sample size was at least a 
few hundred individuals (Dai, Kooperberg et al. 2012). 
Based on the corollary above, one can conclude that 𝛼G and ?̂?CC estimated on the basis of 




distributed as 2 df chi square (𝜒2𝑑𝑓
2 ) for joint testing of genetic marginal and G×E interaction 











        (5.13) 
The following joint test statistics for CO and MUK-EB can be obtained in the same way (Dai, 






















      (5.15) 
The estimators ?̂?𝑀𝑈𝐾−𝐸𝐵  and 𝑉𝑎?̂?(?̂?𝑀𝑈𝐾−𝐸𝐵) correspond to Mukherjee’s et al. empirical Bayes 
shrinkage estimator for G×E interaction that can be derived based on models (5.10), (5.11), 
and (5.12) as shown in (Mukherjee and Chatterjee 2008) and summarized in Chapter 2. 
 
5.6. Joint EHB-GENNJ Test 
Based on the same reasoning as above, we constructed a joint test for the EHB-GENN approach. 
We showed in Chapter 2 that βCC=βcases βcontrols (5.10-5.12). As proven in Chapter 4, the latter 
relationship also holds after separate covariate adjustment within cases and controls, when the 
covariate distribution is independent of the G×E interaction. Thus βCC is a linear combination 
of βcases and βcontrols. Independence of 𝛼G and ?̂?cases is stated in (Dai, Logsdon et al. 2012) and 
follows from the examination of covariance of respective estimating functions for the two 





Since ?̂?𝐸𝐻𝐵−𝐺𝐸𝑁𝑁 =  ?̂?𝑐𝑎𝑠𝑒𝑠 − 𝑝𝑜𝑠𝑡𝑒𝑟𝑖𝑜𝑟(?̂?𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠), independence of 𝛼G and ?̂?𝐸𝐻𝐵−𝐺𝐸𝑁𝑁follows 
immediately. We propose the joint test statistic EHB-GENNJ for simultaneous testing of genetic 











     (5.16) 
where 𝑉𝑎𝑟(̂?̂?𝐸𝐻𝐵−𝐺𝐸𝑁𝑁 ) =  (√(?̂?𝑚




, (see Section 5.2). 
In contrast to the CO test that was employed in Dai’s 2 df test construction (Section 5.5), our 
EHB-GENN approach does not require the assumption of G-E independence (Section 5.2). Thus, 
this also holds for the EHB-GENNJ approach by the construction. 









. All four tests have the same contributor for estimating the 
genetic marginal effect and differ only in the G×E interaction component; we therefore expect 
to see the same behavior as seen in the simulation study described in Section 5.4 in terms of 
the comparative performance of these tests. For the general comparison between main effect 
association tests and joint tests, we refer to the simulation studies previously conducted and 
published (Kraft, Yen et al. 2007, Dai, Logsdon et al. 2012, Vanderweele, Ko et al. 2013). 
Dai’s joint tests were evaluated in terms of type I error, power, and robustness to G-E 
correlations (Dai, Logsdon et al. 2012, Vanderweele, Ko et al. 2013). These previous studies 
suggest that in the presence of main genetic effects only the classic case-control main effect 
test is more powerful than joint tests; however, the power loss of the joint test is only moderate 
to small. In the situation in which both a genetic main effect and a G×E interaction effect are 






6. Applications to Lung Cancer Data from the ILCCO/TRICL 
Consortium  
Lung cancer remains to be the leading cause of the cancer mortality in the world (Jemal, Bray 
et al. 2011). Every year, nearly 1.35 million newly diagnosed cases occur worldwide (Herbst, 
Heymach et al. 2008). A substantial proportion of individuals newly diagnosed with lung 
cancer dies within two years of diagnosis (Ferlay, Autier et al. 2007). Tobacco smoking is the 
major risk factor in lung cancer, accounting for nearly 85% of cases in men and 50% in women 
worldwide (Jemal, Bray et al. 2011). However, a fairly large proportion of patients develop the 
disease without any history of smoking (Bryant and Cerfolio 2007, Sun, Schiller et al. 2007, 
Couraud, Zalcman et al. 2012). Furthermore, there are many reports suggesting that a positive 
family history of lung cancer is an important risk factor, especially in the young (Coté, Liu et 
al. 2012, Krebsregister and (GEKID) 2013). It is widely accepted that lung cancer is a complex 
disease, attributed to the complex interaction of genetic and environmental factors (Osann 
1991, Catelinois, Rogel et al. 2006, Chiu, Cheng et al. 2006, Kabir, Bennett et al. 2007, 
O'Reilly, McLaughlin et al. 2007, Brüske-Hohlfeld 2009). 
Despite many studies devoted to identifying genetic factors that modify lung cancer risk, the 
majority of genetic markers and genes responsible for the development of lung cancer remain 
undiscovered. In recent years, quite a number of GWASs and meta-analyses were conducted. 
These have identified some risk variants for lung cancer. SNPs on chromosome 5p15 (Landi, 
Chatterjee et al. 2009, Truong, Hung et al. 2010, Brenner, Boffetta et al. 2012, Fehringer, Liu 
et al. 2012, Timofeeva, Hung et al. 2012, Li, Yin et al. 2013, Myneni, Chang et al. 2013), 6q23-
25 (Bailey-Wilson, Amos et al. 2004, Hung, McKay et al. 2008, Amos, Pinney et al. 2010), 




Boffetta et al. 2012, Fehringer, Liu et al. 2012, Timofeeva, Hung et al. 2012) were discovered 
to be in association with lung cancer overall or with a specific histological subtype, such as 
adenocarcinoma, non-small-cell and small-cell lung cancer (NSCLC, SCLC) in European and 
Asian populations, some of them in African Americans. Several GWASs on smoking behavior 
have identified loci associated with the number of cigarettes per day as well as other measures 
of tobacco addiction/consumption (Lee, Jeon et al. 2005, Bierut, Madden et al. 2007, 
Thorgeirsson, Geller et al. 2008, Heller, Zielinski et al. 2010, Liu, Tozzi et al. 2010, 
Thorgeirsson, Gudbjartsson et al. 2010). 
We had access to four lung cancer case-control GWASs from the International Lung Cancer 
Consortium/Transdisciplinary Research in Cancer of the Lung (ILCCO/TRICL) consortia. The 
GWASs are described below. In our investigation into genetic variants influencing the risk of 
lung cancer, we performed five statistical tests on each of the four GWASs, assuming a 
dominant mode of inheritance for all analyses. We applied EHB-GENN to investigate G×E 
interaction. We also applied joint CCJ, COJ, and MUK-EBJ proposed by Dai and colleagues 
(Dai, Logsdon et al. 2012), all described in Chapter 5, to test simultaneously for the genetic 
marginal and gene-environment interaction effects. Moreover and in a similar way to those, we 
combined both estimators of the genetic main effect (G) and G×E interaction, later obtained by 
EHB-GENN, into a single joint test statistic EHB-GENNJ (see Chapter 5) and applied it to the 
respective GWAS datasets. Several authors have suggested that G×E interaction might help 
detect genetic variants potentially missed by standard tests for association of main effects 
(Kraft, Yen et al. 2007, Dai, Logsdon et al. 2012, Vanderweele, Ko et al. 2013). Specifically, 
some SNPs may exercise a small to moderate genetic main as well as a G×E interaction effect. 
Therefore, joint tests for the marginal association combined with the test for G×E interaction 




2007, Dai, Logsdon et al. 2012). Thus, joint testing can help identify such signals in lung 
cancer. 
 
6.1. ILCCO/TRICL GWAS Study Description  
We analyzed four GWASs from the ILCCO/TRICL consortia. The German Lung Cancer 
GWAS (GLC) (Holle, Happich et al. 2005, Wichmann, Gieger et al. 2005, Sauter, Rosenberger 
et al. 2008), the Central Europe Lung Cancer GWAS (Central Europe IARC, CE-IARC) 
(Amos, Wu et al. 2008, Hung, McKay et al. 2008), the Toronto Lung Cancer GWAS (Samuel 
Lunenfeld Research Institute, SLRI) (Hung, McKay et al. 2008), and the Texas Lung Cancer 
GWAS (MD Anderson Cancer Center, MDACC) (Amos, Wu et al. 2008, Hung, Christiani et 
al. 2008, Wang, Broderick et al. 2008) were included in the analysis. 
The German Lung Cancer Study (GLC, Bickeböller, Heinrich, Risch) is a population-based, 
case-control study comprising of 514 cases and 488 controls. It is a genome-wide study that 
includes cases diagnosed with lung cancer before the age of 51 and controls matched to them 
by sex and age. All subjects in the GLC Study were genotyped on the HumanHap 550K 
genome-wide SNP chip (Landi, Chatterjee et al. 2009). The GLC GWAS consists of three 
independent studies conducted in Germany, namely the Heidelberg Lung Cancer Study 
numbering 201 cases, the LUCY Study numbering 305 cases and the KORA Study with 488 
controls (Sauter, Rosenberger et al. 2008). 
The Heidelberg Lung Cancer Study is an ongoing hospital-based case-control genome-wide 
study initiated and conducted by the German Cancer Research Center (DKFZ, PD Risch). 
Initially started in 1997, more than 2,000 lung cancer cases were recruited in collaboration with 




on occupational exposure, tobacco smoking, and educational status, as well as family history 
of lung cancer for a subgroup of participants is available (Sauter, Rosenberger et al. 2008). 
Lung Cancer in the Young (LUCY) is a multicenter study with 31 participating hospitals in 
Germany, organized and conducted by the Helmholtz Zentrum Munich in collaboration with 
the University Medical Center, Göttingen. Patients with histologically or cytologically 
confirmed primary lung cancer were recruited. The data comprise information on family 
history, smoking exposure, occupational exposure, and blood samples (Sauter, Rosenberger et 
al. 2008). Recruitment ended in 2011, with a total of 847 lung cancer cases and 5,524 family 
members being recruited. 
Cooperative Health Research in the Augsburg Region (KORA) is a population-based, genome-
wide study in the area of Augsburg in southern Germany, conducted by the Helmholtz Zentrum 
Munich. In total, 18,000 participants were recruited between 1984 and 2001. The data include 
information on multiple phenotypes, medical and laboratory data, as well as blood samples to 
uncover genetic information (Sauter, Rosenberger et al. 2008). KORA is a representative 
sample of Caucasians in Germany (Steffens, Lamina et al. 2006). 
The Central Europe Lung Cancer Study of the IARC (CE-IARC, Brennan) is a hospital-
based case-control genome-wide study conducted in 15 centers in 6 central and eastern 
European countries (Czech Republic, Hungary, Poland, Romania, Russia, Slovakia) and in 
Liverpool (United Kingdom) between 1998 and 2002. The study collected lifestyle risk factors, 
occupational, medical, and family history information on a total of 2633 newly diagnosed lung 
cancer cases and 2884 controls frequency matched by age, sex, geographical area, and period 
of recruitment (Scelo, Constantinescu et al. 2004). All study individuals were genotyped on 
Illumina HumanHap 300K platforms (Hung, McKay et al. 2008). 
The Toronto Lung Cancer Study (SLRI, Hung), is a hospital-based, genome-wide, case-




Research Institute in the greater Toronto area between 1997 and 2002. The study contained 
genetic, lifestyle risk factors, occupational, medical, and family history information on 332 
lung cancer patients and 505 controls of European origin (Hung, McKay et al. 2008).  
Table 6.1 demonstrates major characteristics of the GWASs and individuals, as well as 
information on the respective genotyping platform. 
Table 6.1 Characteristics of the four lung cancer GWASs, QC is quality control 
 GLC CE-IARC SLRI MDACC 
Data collection area Germany 
Central Europe: Czech 
Republic, Hungary, 
Poland, Romania, Russia, 
Slovakia 
greater Toronto area, 
Canada 
Houston, Texas, USA 
Origin of control Population-based Hospital-based Hospital-based Hospital-based 
Frequency matching factors Ages, sex, location Age, sex, location Age, sex, ethnic origin 
Age, sex, ethnic origin, 
smoking habits 
Genotyping HumanHap 550K HumanHap 300K HumanHap 300K HumanHap 300K 
Cases/Controls genotyped 514/488 1989/2625 332/505 1154/1137 
Cases/Controls after QC 467/468 1901/2503 331/499 1150/1134 
# SNPs after QC 529,730 312,452 310,045 314,072 
  cases controls cases controls cases controls cases controls 
Gender (Male/Female) 286/181 237/231 1493/408 1821/682 159/172 190/309 655/495 644/490 
Age (years) 
< 45 169 112 
246 415 41 233 176 120 
45-49 239 283 
50-54 50 73 272 378 32 62 109 107 
55-59 - - 329 394 28 46 158 210 
60-64 - - 386 435 46 32 186 278 
65-69 - - 353 430 62 35 202 236 
70-74 - - 286 368 69 41 184 134 
≥ 75 - - 29 83 52 49 135 49 
Missing 9 0 - - 1 1 - - 
Smoking status 
Never 35 214 144 884 91 215 - - 
Former 45 121 373 656 95 143 601 655 
Current 377 133 1380 954 90 90 549 479 
Any 10 - 4 7 55 46 - - 
Missing - - - 2 - 5 - - 
Smoking quantity (for smokers in pack/years) 
Moderate (≤ 20 pack/years) 83 152 248 619 38 122 160 230 
Heavy      (> 20 pack/years) 328 101 1504 988 145 106 990 904 





6.2. GWAS Data Quality Control  
Quality control (QC) of the data in the genome-wide context is essential. We performed 
standard, systematic quality control on all four ILCCO/TRICL datasets prior to the association 
and interaction analyses and after QC carried out by the data providers. QC was mainly 
conducted in PLINK (Purcell, Neale et al. 2007) and EIGENSOFT (Price, Zaitlen et al. 2010). 
Comparable quality criteria were applied for each of the four GWAS. 
QC was performed on the subject level as well as on the SNP level (see Table 6.2). Standard 
filters on the subject level included checks for genotype call rate, cryptic relatedness as 
measured by identity by state (IBS) between pairs of subjects (if the IBS is too high, subjects 
might be closely related and should be excluded from further analysis), ancestral origin that 
can be determined for example by principal component (PC) (study populations should be as 
homogeneous as possible and subjects with a different ethnic background should be excluded 
from analysis), excessive number of heterozygous individuals (if the heterozygosity for a 
subject is too high, the DNA is suspected of being contaminated, low heterozygosity suggests 
that hybridization might have failed). Standard filters on the SNP level include checks for SNP 
call rate, minor allele frequency (MAF) (many genotype-calling algorithms tend to perform 
poorly for SNPs with low MAF, and the power of a study is low in detecting associations for 
SNPs with a low MAF, usually lower than 0.01), Hardy-Weinberg equilibrium (HWE) (SNPs 
are excluded if significantly more or fewer individuals are heterozygous at a SNP than 
expected, HWE is performed on unrelated control subjects with relatively homogeneous 
ancestry). 
For the GLC study, principal component analyses on a subset of around 100,000 independent 
markers was performed to access the population structure and identify ethnic outliers. As an 
outcome, we obtained 20 principal components (PC) with corresponding p-values < 0.05. 




and restrict the sample only to individuals of Caucasian origin, we performed an iterative 
procedure integrated in EIGENSOFT to remove outliers automatically. A similar procedure 
was performed for the SLRI study. For the CE-IARC study, STRUCTURE software was used 
to identify population outliers as individuals with an ancestry probability rate of being 
Caucasians < 80%. The MD Anderson Cancer Center (MDACC) used a procedure in PLINK 
(absolute value of the nearest neighbor > 4) to identify outliers. Table 6.2 summarizes the 
quality control criteria that we used to preprocess our data. 
Table 6.2 Filters for standard quality control of ILCCO/TRICL GWASs 
Level  Filter Standard value for filter 
Subject 
Call rate ≥ 90% 
Cryptic relatedness proportion of IBD < 0.20 
Sex mismatch female F < 0.2 and male F > 0.8 
Heterozygosity mean F +/- 6 SD F, over all samples 
Ethnic origin Caucasian ancestry PLINK nearest neighbor Z score| < 4 
  
SNP 
Call rate ≥ 95% 
MAF ≥ 1% 
HWE p-values HWE in controls ≥ 10-7 
 
F, estimate for homozygosity, Wright’s inbreeding coefficient; SD, standard deviation; Recommended 
values to assign the sex are <0.2 for females and >0.8 for males; 
 
6.3. Covariates 
All four GWASs collected covariate information on individuals, such as sex, age, smoking 
status, smoking amount, and ethnicity (See Table 6.1). 
An individual’s sex was coded as 1 for female and 0 for male. Age was originally presented in 
years, later being coded as a categorical variable grouping age into blocks of five years, after 
an initial group encompassing everyone under the age of 45 years (Table 6.1). As described in 
Section 6.1, the GLC Study only contains subjects younger than 51 years. As a result, the GLC 




Tobacco smoking as the major risk factor in lung cancer development was considered as the 
major environmental risk factor possibly interacting with the genetic factors of the individuals 
to influence occurrence of the disease. In all studies, smoking information was collected as 
pack-years per individual, defined as the number of cigarette packs smoked by the subject in 
one day multiplied by the duration of smoking in years (Amos, Wu et al. 2008). Hence pack-
years combines the amount smoked and the duration. Figure 6.1 demonstrates the distribution 
of pack-years in the four studies within cases and controls. Clearly, cases tend to have 
consumed more pack-years than controls. For our analysis, the smoking status of each subject 
was coded in two different ways: NE describes ever=1 and never=0 smokers and MH denotes 
heavy=1 and moderate=0 smokers. We defined never smokers as those individuals having 
consumed no more than 100 cigarettes over their life span and ever smokers as those having 
consumed more. Generally, there were few never smokers in the GWASs. The MDACC study 
considered only ever smokers. For the MH coding, we defined moderate smokers as those with 
a consumption ≤ 20 pack-years and heavy smokers with a consumption > 20 pack-years. Never 
smokers were excluded from the consideration in this model to ensure comparison across the 
GWASs, as the MDACC study did not include never smokers. 
To account for possible population stratification, PCs should be included as covariates in the 
analysis. For the GLC study, the first four significant PCs, for CE-IARC the first six significant 
PCs, representing the six countries of the data collection, for MDACC the first two PCs and 





Figure 6.1 Distribution of pack-years in each GWAS within cases and within controls 
 
 
6.4. Data Analysis Strategies 
To discover signals that may influence the risk of lung cancer we performed five statistical 
tests, the new EHB-GENN approach and four joint tests as described in Chapter 5, on the 
GWASs described in Section 6.2. 
After the quality control procedures and prior to the interaction analysis, we estimated G-E 
correlation effects within cases and within controls and their corresponding standard errors by 
the appropriate PLINK functions (Purcell, Neale et al. 2007). We also estimated the genetic 
main effects. We assumed a dominant mode of inheritance for all analyses, which were 
performed for both environment models never vs. ever and moderate vs. heavy (Section 6.4). 
For the joint testing, we included sex, age, and principal components as covariates and 
additionally controlled for smoking as main effect. 
To ensure that the application of EHB-GENN on the lung cancer GWASs is appropriate, we first 




GWASs. The frequency of smokers ranges from 54% to 65% with the frequency of heavy 
smokers ranging from 40% to 63%. Taking into account the sample sizes of the GWASs, we 
concluded that the exposed sub-strata are big enough to estimate the necessary parameters. We 
then looked at the distribution of the G-E correlation signals in controls for each study. There 
was evidence for the presence of a relatively large number of G-E correlation signals with 
medium and sometimes high effect size in all studies. This suggests that the application of 
EHB-GENN on these data is appropriate and can be advantageous. Figure 6.2 and Figure 6.3 
present histograms of the beta coefficients estimating G-E correlation effects in controls for all 
GWASs studies. We displayed the beta coefficients estimating G-E correlation in controls 
giving the ordered absolute values for the largest 100,000 coefficients. For the GLC study with 
HumanHap 550K, 529,730 SNPs passed quality control thresholds, here approximately 19% 
of the data are shown. For the CE-IARC, MDACC, and SLRI studies with HumanHap 300K, 
approximately 30% of the data are demonstrated. We split the data into two to three histograms 
for visualization purposes, owing to a large difference in the scales of G-E correlation effects.  
First, we applied the EHB-GENN approach to test for G×E interaction as described in Chapter 
5. To construct the EHB-GENN test statistics posterior estimates of G-E correlation effects were 
derived based on their prior estimates obtained with PLINK. Then the ZEHB-GENN statistic was 
constructed per SNP to test for significance. Results of this analysis are presented in Section 
6.7.  
Subsequently, we applied the 2 df tests proposed by Dai (Dai, Logsdon et al. 2012) and our 
EHB-GENNJ to test simultaneously for the genetic main and gene-environment interaction 
effects as described in Chapter 5. Results of the joint test are presented in Section 6.8. Table 




Figure 6.2 Frequency histograms of the beta coefficients estimating G-E correlation effects in 
controls for each GWAS for never vs. ever smokers. Shown are the 100,000 largest coefficients 
in absolute value. 
 





Figure 6.3 Frequency histograms of the beta coefficients estimating G-E correlation effects in 
controls for each GWAS for moderate vs. heavy smokers. Shown are the 100,000 largest 
coefficients in absolute value. 
 




Table 6.3 Summary of methods applied to ILLCO/TRICL GWASs. 
Method Test Statistics 
EHB-GENN 𝑍𝐸𝐻𝐵 −𝐺𝐸𝑁𝑁 =
?̂?𝑐𝑎𝑠𝑒𝑠 − (𝛽𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 )∗












































Abbreviations: EHB-GENN, parametric empirical hierarchical Bayes approach for G×E interaction; EHB-GENN
J/ 
CCJ/ COJ/ MUK-EBJ, joint method for genetic main (G) and G×E interaction effect based on original G×E test 
indicated; CC, classical case-control interaction estimator; CO, case-only interaction estimator; MUK-EB, 
empirical Bayes shrinkage estimator; 
 
6.5. Review and Replication of Results of Genetic Main Effect Analysis 
We reviewed the literature, investigating SNPs’ genetic main effect on the risk of developing 
lung cancer. Here, we first summarize some previously found results, i.e. significant 
association signals for lung cancer in Caucasian, Asian, and African American populations. 
We performed an extensive search of the PubMed database for articles concerning GWAS 
involving lung cancer. 
A number of genome regions were identified. SNPs on chromosome 15q25.1 (Amos, Wu et al. 
2008, Hung, McKay et al. 2008, Thorgeirsson, Geller et al. 2008), on chromosome 5p13.3 
(McKay, Hung et al. 2008, Wang, Broderick et al. 2008, Landi, Chatterjee et al. 2009), on 
chromosome 6p21.33 (Wang, Broderick et al. 2008), on 12p13.3 (Shi, Chatterjee et al. 2012), 




association with lung cancer consists of two SNPs on chromosome 15q24-25, namely 
rs1051730 mapped to the CHRNA3 gene and rs8034191, mapped to the AGPHD1 gene. 
Originally this signal was reported by three independent research groups in different datasets 
on the same day. Our search identified 40 potentially relevant articles for this association. 
Amos and colleagues (Amos, Wu et al. 2008) reported the association of these two variants 
and lung cancer based on the case-control sample of 1,154 current and former (ever) smoking 
cases of European ancestry and 1,137 frequency-matched, ever-smoking controls from 
Houston, Texas. They also replicated the findings on an additional cohort of 711 cases and 632 
controls from Texas and 2,013 cases and 3,062 controls from the UK. They reported an odds 
ratio of 1.32 and p-value (p < 10-17) of the combined analysis for both SNPs (Amos, Wu et al. 
2008). Many other studies replicated this signal in case-control and meta-analyses with p-
values significant for association in Caucasians (Hung, McKay et al. 2008, Thorgeirsson, 
Geller et al. 2008, Broderick, Wang et al. 2009, Lips, Gaborieau et al. 2010, Truong, Hung et 
al. 2010, Fehringer, Liu et al. 2012, Timofeeva, Hung et al. 2012). The same two SNPs were 
also identified as influencing the risk of lung cancer in Asians (Truong, Hung et al. 2010, Gu, 
Dong et al. 2012) and African Americans (Amos, Pinney et al. 2010). Additionally, a single 
SNP, rs16969968 on chromosome 15q mapped to the CHRNA5 gene, was identified as being 
associated with lung cancer risk in Europeans (Lips, Gaborieau et al. 2010) and African 
Americans (Walsh, Amos et al. 2012). 
Another interesting signal for the association with lung cancer was formed by SNPs on 
chromosome 5p15, namely rs2736100, which belongs to the TERT gene and rs402710, located 
on the CLPTM1L gene. These two SNPs were replicated in many large meta-analytic GWASs, 
including over 10,000 individuals and as many as 21 different GWASs to confirm signals 
(Wang, Broderick et al. 2008, Truong, Hung et al. 2010, Timofeeva, Hung et al. 2012). For 




5.00×10-8) and the association of rs402710 (OR = 0.87, p = 1.70×10-7) with the risk of lung 
cancer based on a meta-analysis of 14,900 cases and 29,485 controls of Caucasian origin 
(Timofeeva, Hung et al. 2012). A candidate SNP meta-analysis study for the variant rs2736100 
confirmed the association of this marker with lung cancer risk. The SNP rs2736100 was 
associated with the risk of lung cancer in a dominant model (OR = 1.14, 95% CI: 1.01-1.28; p 
= 0.03) based on 14,492 subjects (Wang, Zhang et al. 2013). A few meta-analyses reported the 
association of rs2736100 with the risk of adenocarcinoma (OR = 1.23, p = 3.02×10-7) e.g. 
(Landi, Chatterjee et al. 2009). These signals were also confirmed in the Chinese (Hsiung, Lan 
et al. 2010, Li, Yin et al. 2013). 
The third interesting signal comprises markers on chromosome 6p21. Hung and colleagues 
(Hung, McKay et al. 2008) reported that a signal of ten SNPs clustered in a segment of 
approximately one mega-base on chromosome 6p with rs432479 was the strongest in their data 
(Hung, McKay et al. 2008). However Hung et al. (Hung, McKay et al. 2008) mentioned that 
this association is not confirmed and needs to be studied further and replicated. In the same 
year, Wang et al. (Wang, Broderick et al. 2008) published a study describing the association of 
another SNP, rs3117582, mapped to BAT3-MSH5, with p = 4.97 × 10−10 in the same 
chromosomal region, based on their pooled analyses of 5,095 cases, and 5,200 controls.   
Many other SNPs across the genome have been reported to influence the risk of lung cancer 
generally or to be associated with the specific histology, such as NSCLC, SCLC, or 
adenocarcinoma risk. However, not all of these findings have been replicated in other studies 
or populations; therefore we only briefly mention some of them. For example, Timofeeva et al. 
mentioned that SNPs on 12p13 demonstrate an association with lung cancer. Furthermore, it 
was shown in the same study that the 9p21.3 variation is a determinant of squamous cell lung 




rs2036534, rs667282, rs12910984, and rs6495309 were reported to be in association with lung 
cancer risk in the Chinese, but this was not confirmed in Caucasians (Wu, Hu et al. 2009). 
Since not all of the published studies controlled for smoking in their analyses, which is 
important from our point of view, we obtained the main effect analysis results for each of four 
GWASs from the research groups of CE-IARC, GLC (our group), SLRI, and MDACC, 
controlled for sex, age, PC, and main effect of smoking. None of the SNPs passed the genome-
wide significant level after including smoking as covariate in any GWAS. 
In the CE-IARC Study, two SNPs on chromosome 15q25 rs8034191 and rs1051730 had p-
values < 10-5. These two SNPs were reported to be in association with lung cancer in the CE-
IARC GWAS by Hung and colleagues (Hung, McKay et al. 2008). They reported 
corresponding SNP p-values, 8.8×10-10 (rs8034191) and 5.4×10-9 (rs1051730) in the model not 
adjusted for smoking. Another two markers had p-values lower than 10-5, rs10516367 
(KCNIP4 gene) and rs1407503 (GALNT12 gene). 
For the GLC Study, there were some SNPs with corresponding p-values ≤ 10-5 spread along 
the genome, however no clear signal for the presence of a genetic main effect for any of the 
SNPs. Among those, three SNPs belonged to genes, namely rs2866908 (DKK2), rs2916508 
(CTNNA2), rs9643575 (TRIM55). 
For the SLRI Study, six markers had p-values ≤ 10-5, however only two among them were 
mapped to genes. These two SNPs are rs12112953 (ADCY1), rs266508 (RGSL1). 
In the MDACC Study, no SNPs in coding regions or the close neighborhoods of genes with p-





6.6. Results for G×E Interaction Analysis 
Generally, we do not discuss or present the results of G×E interaction analysis on those SNPs 
located outside of known genes or further than ±500Kb from protein coding regions. For such 
signals it is hard to argue for any association with the specific trait. We therefore omitted them 
from the discussion. For all the studies and both exposure models (NE and MH) in the analysis 
applying EHB-GENN to test for G×E interaction, we only describe SNPs with p-values of 
interaction p ≤ 10-4 here. 
In the CE-IARC study, we did not identify any SNPs with genome-wide significant interaction 
effect for either exposure models, NE or MH. In the NE model, there was only one SNP located 
in the coding region mapped to the C1orf21 gene on chromosome 1 with p=7.02×10-6. Other 
SNPs investigated for this study and NE coding with p-values ≤ 10-4 were located in non-coding 
regions and therefore are not discussed. For the MH coding, two SNPs located on chromosome 
14, rs2302591 and rs175891, mapping to the TTLL5 gene, form an interesting signal. This 
tumor suppressor candidate gene encodes a member of the tubulin tyrosine ligase-like protein 
family. This protein may function as a co-regulator of glucocorticoid-receptor-mediated gene 
induction and repression. This protein may also function as an alpha tubulin polyglutamylase 
(Uhlen, Oksvold et al. 2010). Another signal here consists of three SNPs on chromosome 16, 
rs200528 (p = 3.05×10-5), rs3803716 (p = 2.94×10-5), and rs2112783 (p = 2.79×10-5) that 
belong to the TNRC6A gene. 
In the GLC study with NE exposure coding, two SNPs, rs13244987 and rs13438768, reached 
genome-wide significance with p-values of 3.33×10-8 and 9.12×10-8, respectively. Both 
markers belong to the human protein coding locus LOC645249, known to be expressed 
differently in tumor and normal cell tissues. Marker rs7308621 on chromosome 12 in the RERG 
gene is worth mentioning, as this gene participates in tumor formation. Another interesting 




namely rs7982922 (p = 7.53×10-7), rs10492572 (p = 8.20×10-6), and rs10492573 (p = 
5.63×10-6). For the GLC, MH coding, two SNPs in the ARHGEF38 gene with p-values < 10-5 
appeared. Another signal for this analysis references three SNPs on chromosome 9 located in 
the TRPM3 gene. These SNPs are rs1421156 with p = 1.72×10-6, rs656875 with p = 1.30×10-
6, and rs672801 with p = 4.43×10-6. 
In the SLRI study and NE exposure model there are two signals of interest. The first signal 
consists of three SNPs (rs1337862, rs1337863, rs945949) with p-values of the order of 10-4 on 
chromosome 6, mapping to the NKAIN2 gene. It is known that the chromosomal translocation 
involving this gene is a cause of lymphoma. The second suggestion comprises five SNPs 
(rs12956176, rs4486983, rs9646509, rs1880113, rs1403762) with p-values of the order of 10-
5 on chromosome 18 in the KLHL14 gene. For the MH coding, a single SNP is an interesting 
signal; rs6872156 with p = 8.31×10-6 on chromosome 5 in the DUSP1 gene. The role of this 
gene is increasingly recognized in tumor biology (Moncho-Amor, Ibanez de Caceres et al. 
2011). Furthermore, two SNPs in ADAMTSL1 and two SNPs in the closure of the WWOX gene 
were identified. 
In the MDACC Study, MH analysis, there was only one SNP; rs9323666 (p = 3.79×10-5) 
located on chromosome 14 in the NRXN3 gene. The rest of the SNPs with relatively small p-
values in this analysis were spread along the genome and were not located in any genes or their 
surroundings. Table 6.4 summarizes our findings and gives further description of gene 
characteristics. Figure 6.3 portrays Manhattan plots for GWASs for the G×E interaction 





Table 6.4 SNPs discovered by EHB-GENN in G×E Interaction Analysis of the ILCCO/TRICL 
GWASs 
GWAS E SNP p ZEHB-GENN CHR Mapping
* characteristics** 
CE-IARC NE rs2779286 7.02×10-6 1 C1orf21 Human protein coding gene  
MH 
rs1455701 4.31×10-5 1 
+/- 500kb  
of the  
ERRFI1 
Rare mutations in MIG-6 have 
been identified in human lung 
cancer(Zhang 2008). 
rs7620618 2.12×10-6 3 ±GOLGA4 
Human protein coding gene, 
postulated to play a role in Rab6-
regulated membrane-tethering in 
the Golgi apparatus (Meyer, 
Brieger et al. 2009). 
rs4563628 2.42×10-4 5 
+/- 500kb  
of the TAG 













This protein may function as a 
coregulator of glucocorticoid 
receptor mediated gene induction 
and repression (Uhlen, Oksvold et 
al. 2010). 
Tumor-suppressor candidate 
(Liang, Wang et al. 2005). 
rs1126289 4.31×10-5 16 PRKCB 
Protein kinase C (PKC) family 
members are known to be 
involved in diverse cellular 
signaling pathways. PKC family 
members also serve as major 
receptors for phorbol esters, a 
class of tumor promoters (Uhlen, 








Expression TNRC6A delocalizes 
other GW-body proteins and 
impairs RNAi and mRNA-induced 




















LOC645249 is a human protein 
coding gene, expressing 
differently between tumor and 
normal samples. The expression 
profile of the gene has been 
previously studied in human non-
small-cell lung cancer (Takahashi, 
Forrest et al. 2009). 
rs7308621 4.31×10-4 12 RERG 
RERG, a member of the RAS family 
of GTPases, inhibits cell 
proliferation and tumor formation 












Plasma membrane electron 
transport pathways are involved in 
functions such as cellular defense, 
intracellular redox homeostasis, 
and control of cell growth and 




rs4939642 4.65×10-5 18 MAPK4 
Mitogen-activated protein (MAP) 
kinase 4 is a member of the 
mitogen-activated protein kinase 
family (Uhlen, Oksvold et al. 2010). 
MAP kinase pathways constitute 
one of the hallmarks of many 









Pancreatic islets, lung 
macrophages, breast and 
myocytes as well as basal cells in 
prostate, squamous and 
respiratory epithelium and 
showed strong staining (Uhlen, 
Oksvold et al. 2010). 







The product of TRPM3 belongs to 
the family of transient receptor 
potential (TRP) channels. TRP 
channels are cation-selective and 
are important for cellular calcium 
signaling and homeostasis (Uhlen, 
























The protein encoded by this gene 
is a transmembrane protein that 
interacts with the beta subunit of 
Na, K-ATPase (ATP1B1). A 
chromosomal translocation 













protein coding, interacts with 
Torsin A 
MH rs6872156 8.31×10-6 5 DUSP1 
Candidate cancer biomarker. 
DUSP1/MKP1 is a dual-specific 
phosphatase that regulates 
MAPKs activity, with an 
increasingly recognized role in 
tumor biology (Moncho-Amor, 









ADAMTSL1 encodes a secreted 
protein and member of the 
ADAMTS family. This protein may 
have important functions in the 
extracellular matrix” (Uhlen, 






+/- 500kb  
of the 
WWOX 
WW domain-containing proteins 
play an important role in the 
regulation of a wide variety of 
cellular functions such as protein 
degradation, transcription, and 
RNA splicing (Uhlen, Oksvold et al. 
2010). 
MDACC 
MH rs9323666 3.79×10-5 14 NRXN3 
Neurexins are a family of proteins 
that function in the vertebrate 
nervous system as cell adhesion 
molecules and receptors (Uhlen, 
Oksvold et al. 2010). 
Polymorphic site of NRXN3 gene 
was significantly associated with 
risk of breast cancer (Kusinska, 
Górniak et al. 2012). NRXN3 
polymorphisms are associated 
with alcohol dependence 
(Hishimoto, Liu et al. 2007). 
 
Abbreviations: genome-wide association study, GWAS; single nucleotide polymorphism, SNP; a parametric 
empirical hierarchical Bayes approach for G×E interaction, EHB-GENN; E = environmental coding (NE = never 
vs. ever, MH = moderate vs. heavy); p, p-value; 
*Listed are only SNPs located within ±500kb of coding regions and with p-values < 10-4  




Figure 6.4 Manhattan plots of p-values for EHB-GENN. Depicted are p-values for each SNP 
 
 




6.7. Results of Joint Tests for Genetic Main and G×E Interaction Effects  
We performed four joint tests, namely EHB-GENNJ, as well as CCJ, COJ, MUK-EBJ, on our 
GWAS data, to search for the association signals possibly missed by classic main effect or pure 
interaction genome-wide association tests. For all the studies and both exposure models, NE 
and MH, we only address SNPs with p-values of interaction effect ≤ 10-5 located within ±500kb 
of coding regions. 
In the CE-IARC Study with NE coding, two SNPs on chromosome 15q24-25 rs1051730 and 
rs8034191 mapped to the nicotine acetylcholine acceptor subunit CHRNA3 and AGPHD1 
genes had genome-wide significant p-values applying 𝑇𝐸𝐻𝐵−𝐺𝐸𝑁𝑁
𝐽
 (p = 6.0×10-10, p = 2.4×10-
9). These two markers were previously reported as being in association with lung cancer, 
identified by the classic main genetic effect test (Amos, Wu et al. 2008, Hung, McKay et al. 
2008, Amos, Gorlov et al. 2010, Fehringer, Liu et al. 2012, Timofeeva, Hung et al. 2012) and 
discussed in Section 6.4. For the same GWAS with MH coding, the same two SNPs rs1051730, 
and rs8034191 had greater p-values; however, they remained significant on the genome-wide 
level (p = 5.8×10-9, p = 6.7×10-8). Another signal of two SNPs, rs13106574 (p = 8.5×10-6), 
rs13149938 (p = 1.8×10-6) on chromosome 4 that both belong to the gene SLC10A6 was 
discovered in this analysis. The SLC10A6 locus is an important human sodium-dependent 




 identified a SNP on chromosome 5p15 that mapped to the TERT gene: rs2736100 
with corresponding p-value of 8.5×10-6. The telomerase reverse transcriptase (TERT) gene is a 
candidate lung cancer biomarker. Recently, a number of studies reported TERT variant 
rs2736100 in association with lung cancer impacting differently on lung cancer histology in 




Boffetta et al. 2012, Timofeeva, Hung et al. 2012). SNPs of the TERT gene including 
rs2736100 were also found to be associated with the risk of lung cancer in the Chinese 
population (Li, Yin et al. 2013, Myneni, Chang et al. 2013). This variant is discussed in Section 
6.5. However, it is important to mention that it was previously only identified in a large scale 
meta-analysis study and that no single study prior to this has reported this signal. We also 
identified signals on chromosomes 16 and 14 with 𝑇𝐸𝐻𝐵−𝐺𝐸𝑁𝑁
𝐽
 described in Table 6.5 for CE-
IARC, MH. 
In the GLC study with never vs. ever coding, five SNPs with p-values lower than 10-5 on 
chromosome 13 that belong to different genes including ENOX1 were identified by joint 
𝑇𝐸𝐻𝐵−𝐺𝐸𝑁𝑁
𝐽
 analysis (rs1014744, rs10492572, rs10492573, rs10507886, and rs7982922), see 
Table 6.4. The ENOX1 protein is the constitutive ENOX family protein with an essential role 
in the enlargement phase of cell growth (Jiang, Gorenstein et al. 2008). It belongs to the same 
protein family and is very similar to the ENOX2 gene that expresses on the cell surface of 
malignancies and is detectable in the serum of patients with cancer (Cho, Chueh et al. 2002, 
Hostetler, Weston et al. 2009). Three regions on chromosome 13 including 13q14, where 
ENOX1 is mapped, were reported to influence non-small-cell lung cancer (NSCLC) 
development (Tamura, Zhang et al. 1997). Another signal in the same analysis (GLC, NE) 
comprises four SNPs on chromosome 7 rs13244987 (p = 5.1×10-8), rs13438768 (p = 4.2×10-
8), rs847916 (P = 7.9×10-6), rs847918 (P = 6.3×10-8). With the MH model, we found the 
signals on chromosome 9 as described in Table 6.5 and some additional individual association 
signals spread along the genome. 
In SLRI NE, we identified the following SNPs with 𝑇𝐸𝐻𝐵−𝐺𝐸𝑁𝑁
𝐽
. Two SNPs rs10517026 (p = 
1.98×10-6) and rs10517026 (p = 1.61×10-6) on chromosome 4 mapped to the protein coding 




a p-value ≤ 10-6 with 𝑇𝐸𝐻𝐵−𝐺𝐸𝑁𝑁
𝐽
 and ≤ 10-7 with 𝑇𝐶𝐶
𝐽
. For the SLRI Study and the MH model, 
the 𝑇𝐸𝐻𝐵−𝐺𝐸𝑁𝑁
𝐽
 test did not identify any SNPs with p-values ≤ 10-5. The 𝑇𝐶𝐶
𝐽
test revealed five 
SNPs with p-values ≤ 10-5 that belong to genes. Data are in Table 6.5. 
In MDACC, MH analysis, SNPs in the SLC24A3 gene (rs1555852, rs2876537, rs4239730) on 
chromosome 20 form possible association signal 𝑇𝐶𝐶
𝐽
  (p = 4.6×10-6, p = 3.3×10-6, p = 2.9×10-
6). The SLC24A3 product is known as prostate cancer-associated protein 6. 
The most prominent findings of simultaneous testing with each coding (NE, MH), each joint 
test statistic (EHB-GENNJ, CCJ, COJ, MUK-EBJ) and for each GWAS (CE-IARC, GLC, SLRI, 
MDACC) are summarized in Table 6.5. In Table 6.5, only SNPs with corresponding p-values 
≤ 10-5 for at least one of the joint tests and those located within the known genes or maximum 
±500Kb away from the gene were included. Manhattan plots in Figure 6.5 visualize the results 
for each GWAS. Generally EHB-GENNJ has similar power and as the consequence similar p-
values as COJ and MUK-EBJ and smaller p-values compared to CCJ. However when SNP has 
protective effect against the outcome (negative estimated coefficient of the association with the 
trait) then CCJ has greater power and as consequence lower p-values for such signals. An 
example of the later statement are SNPs rs2736100 (TERT, CE-IARC GWAS, MH) and 
rs9347645 (PARK2, SLRI GWAS, MH) in Table 6.5. Even though the simulation study in 
Chapter 5 reflected slight power loss of the EHB-GENN compared to both COJ and MUK-EBJ 
in real data we observed only minor increase in p-values for the important signals. For example, 
SNP rs1051730 (CHRNA3, CE-IARC GWAS, NE) has p-value 5.97×10-10 testing with EHB-





Table 6.5 Markers indicated by joint tests in ILCCO/TRICL data with p-values ≤ 10-5 for at least one of the joint tests 








NE rs2779286** 1 G C1orf21 9,00×10-06 1,30×10-03 8,72×10-06 1,64×10-04 
 rs38012 7 G GLCCI1 8,09×10-06 1,72×10-04 7,94×10-06 5,38×10-05 
 rs3784179 14 C AKAP6 2,79×10-05 3,67×10-06 2,86×10-05 4,02×10-05 
 rs1051730* 15 A CHRNA3 5,97×10-10 1,67×10-09 5,93×10-10 6,42×10-10 
 rs8034191* 15 C AGPHD1 2,37×10-09 5,34×10-09 2,36×10-09 2,63×10-09 
 rs9302935 17 G LOC400618 1,27×10-03 1,93×10-06 1,29×10-03 3,09×10-05 
 rs1006957 17 T UBB 8,25×10-06 1,35×10-05 8,27×10-06 8,21×10-06 
MH rs6685121 1 G LOC100505872 3,71×10-06 5,29×10-06 3,86×10-06 4,45×10-06 
 rs7620618** 3 T ±GOLGA4 8,10×10-07 1,99×10-03 8,26×10-07 2,47×10-05 
 rs13149938 4 G SLC10A6 1,80×10-06 4,09×10-06 1,79×10-06 1,81×10-06 
 rs13106574 4 C SLC10A6 8,54×10-06 1,44×10-05 8,46×10-06 8,77×10-06 
 rs2736100 5 C TERT 4,70×10-04 8,50×10-06 4,95×10-04 1,34×10-04 
 rs4563628** 5 C ±TAG 5,76×10-04 7,52×10-06 5,87×10-04 6,79×10-04 
 rs4324798 6 A LOC401242 9,35×10-06 3,00×10-05 9,51×10-06 1,30×10-05 
 rs1076204 11 C ABCC8 3,30×10-05 9,33×10-06 3,48×10-05 1,46×10-05 
 rs2302591** 14 T TTLL5 2,90×10-06 5,37×10-03 2,88×10-06 4,04×10-06 
 rs175891** 14 G TTLL5 9,29×10-06 9,45×10-03 8,93×10-06 1,47×10-03 
 rs1051730* 15 A CHRNA3 5,76×10-09 3,42×10-09 5,77×10-09 5,76×10-09 
 rs8034191* 15 C AGPHD1 6,72×10-09 6,33×10-09 6,72×10-09 6,72×10-09 
 rs200528 16 A TNRC6A 9,29×10-06 3,37×10-03 8,74×10-06 5,29×10-04 
 rs2112783 16 A TNRC6A 9,70×10-06 3,87×10-03 9,13×10-06 5,86×10-04 
 rs9937754 16 T LOC1009 5,47×10-06 8,66×10-05 5,96×10-06 2,25×10-05 
 rs12944442 17 A ANKFN1 7,57×10-06 9,88×10-06 7,47×10-06 9,51×10-06 
  rs2866908 4 T DKK2 6,26×10-06 1,42×10-05 6,26×10-06 6,86×10-06   *    , -06 , -05 , -06 , -06 
GLC 
NE rs6891265 5 C ±SLC27A6 6,81×10-06 2,89×10-05 6,82×10-06 9,77×10-06 
 rs13244987** 7 A LOC645249 5,09×10-08 2,37×10-05 5,04×10-08 5,09×10-08 
 rs13438768** 7 C ±LOC645249 4,19×10-08 1,32×10-04 4,23×10-08 4,19×10-08 
 rs847916* 7 G ±SCIN 7,91×10-06 1,05×10-05 7,90×10-06 9,87×10-06 
 rs847918 7 T ±SCIN 6,34×10-06 1,93×10-05 6,33×10-06 6,89×10-06 
 rs10849065 12 T B4GALNT3 6,78×10-06 7,79×10-04 6,79×10-06 3,42×10-04 
 rs7982922** 13 A ENOX1 3,01×10-07 1,20×10-06 3,00×10-07 5,46×10-07 




 rs10492573** 13 G ENOX1 2,27×10-06 1,32×10-05 2,29×10-06 2,31×10-06 
 rs10507886 13 T ±POU4F1 8,34×10-06 1,45×10-04 8,28×10-06 1,79×10-05 
 rs1014744 13 T ±ATXN8OS 8,85×10-06 9,09×10-05 8,81×10-06 4,75×10-05 
 rs9911873 17 G LUC7L3 3,46×10-04 8,89×10-06 3,47×10-04 5,14×10-05 
 rs847916 7 G ±SCIN 7,67×10-06 7,66×10-06 7,67×10-06 7,62×10-06 2866908* 4 T DKK2 4 98 -05 3 84 -06 4 98 -05 1 10 -05 
MH rs9643575* 8 C TRIM55 1,69×10-06 6,69×10-06 1,68×10-06 1,69×10-06 
 rs4876151 8 C ±MYOM2 6,12×10-06 5,66×10-05 6,13×10-06 6,13×10-06 
 rs656875** 9 C TRPM3 7,56×10-06 7,08×10-04 7,54×10-06 8,55×10-06 
 rs1421156** 9 G TRPM3 9,52×10-06 6,09×10-04 9,57×10-06 1,33×10-05 
SLRI 
NE rs10517026* 4 G LOC100507930 1,98×10-06 4,23×10-07 1,98×10-06 2,40×10-06 
rs10517031* 4 G LOC100507930 1,61×10-06 3,39×10-07 1,61×10-06 1,86×10-06 
rs12956176** 18 A KLHL14 5,40×10-05 2,25×10-06 5,43×10-05 4,43×10-05 
MH rs10517026 4 G LOC100507930 7,01×10-05 6,66×10-06 7,01×10-05 7,13×10-05 
rs10517031* 4 G LOC100507930 3,48×10-05 3,28×10-06 3,48×10-05 3,65×10-05 
  rs9347645 6 C PARK2 2,81×10-03 3,81×10-06 2,82×10-03 1,47×10-03 
  rs482449 11 T ±MIR100HG 1,26×10-01 9,45×10-07 1,26×10-01 7,43×10-04 
 rs11631489 15 G AGBL1 1,10×10-01 3,29×10-06 1,10×10-01 5,15×10-03 
MDACC 
MH rs2538909 7 A ±ZNF804B 2,52×10-07 6,92×10-07 2,53×10-07 7,82×10-07 
 rs552247 7 G ±MEOX2 9,90×10-06 7,79×10-06 9,93×10-06 1,19×10-05 
 rs12276659 11 G PARVA 9,53×10-06 3,07×10-03 9,55×10-06 9,54×10-06 
  rs4239730 20 A SLC24A3 4,59×10-05 2,90×10-06 4.63×10-05 2.49×10-05 
  rs2876537 20 C SLC24A3 1.91×10-04 3.30×10-06 1.93×10-04 2.63×10-05 
  rs1555852 20 A SLC24A3 8.61×10-05 4.57×10-06 8.69×10-05 3.66×10-05 
 
Abbreviations: GWAS, genome-wide association study; SNP, single nucleotide polymorphism; CHR, chromosome number; MA, minor allele; EHB-GENN, a parametric empirical 
hierarchical Bayes approach for G×E interaction; ILCCO, International Lung and Cancer Consortium/ TRICL, Transdisciplinary Research in Cancer of the Lung; ±, denote that SNP 
locates ±500Kb of the gene; CC, classical case-control interaction estimator; CO, case-only interaction estimator; MUK-EB, empirical Bayes shrinkage estimator; TJ, joint test statistics; 
p, p-value associated with the joint test 
  E = environmental coding (NE = never vs. ever, MH = moderate vs. heavy; Gene = SNP to gene or nearest gene annotation; * denotes SNPs with p-value ≤ 10-5 testing for classical 





Figure 6.5 Manhattan plots of p-values for SNPs joint effect based on the EHB-GENN test for G×E interaction component 
 
 






One objective of research in human genetics is to understand how genetic and environmental 
factors interact to cause different diseases. In statistical terms, G×E interaction is present when 
the effect of the genotype on disease risk depends on the level of exposure to an environmental 
factor, or vice versa (Clayton and McKeigue 2001). In this dissertation, three major concerns 
to studies of G×E interaction were addressed: the extent of bias due to the uncovered population 
stratification; the presence of G-E correlation; and the lower power of common tests to identify 
an interaction. 
In Chapter 3, we focused on the evaluation of bias due to population stratification in studies of 
G×E interaction. We derived an equation to evaluate the population stratification bias for the 
case-control estimator of the interaction odds ratio. We demonstrated analytically that 
population stratification bias can reach an intolerable level for case-control studies of G×E 
interaction. We compared bias in estimates of G×E interaction effects in case-control and case-
only studies with bias in genetic main effect estimates. We concluded that the case-control 
design is significantly more robust to population stratification than the case-only design. On 
average, the degree of bias for the G×E interaction effect estimate in case-control studies is 
similar to that in genetic main effect studies and constitutes about 2%-3%. Exceptions are some 
extreme situations that cannot easily be avoided, an example of which is the admixture of two 
subpopulations in a study sample. In this situation, the bias can reach on average 10%-15%. 
Researchers should be aware that bias can theoretically rise up to 30%-40% in case-control 
studies of interactions and to over 50% in case-only studies. 
We compared common methods to detect G×E interaction in terms of their robustness to 




approach, Mukherjee’s empirical Bayes method, Murcray’s two step approach, and the 
empirical hierarchical Bayes method to G×E interaction, based on the chi distribution. We 
demonstrated that principal component analysis adjustment reduced population stratification 
bias to almost zero and is thus also appropriate to correct for this bias in G×E interaction 
studies. 
EHB-GECHI was previously demonstrated as an attractive method for GWAS of G×E 
interactions (Sohns, Viktorova et al. 2013). Therefore, further extensions of the EHB-GECHI 
approach were presented in Chapter 4. Extending the original work of Melanie Sohns (Sohns 
2012), we demonstrated that the method can handle multilevel and continuous genotype and 
exposure variables. We also showed that it is applicable under the assumption of the log-
additive genetic model on the multiplicative scale and can deal with covariate adjustment. 
These extensions are essential, as they allow more flexibility in the use of the original EHB-
GECHI approach. In many situations, information on the exposure is collected as a categorical 
or continuous variable. Therefore, the ability of the approach to work with the original data 
without their reduction to a binary variable is important and may help in obtaining a more 
precise estimation. 
Generally, the ability of the particular statistical approach to handle various genetic models 
such as additive, dominant, and recessive, makes it more attractive, since a properly chosen 
model adds power to the interaction test. By means of the simulation study and reliance on 
asymptotic theory, we revealed that EHB-GECHI is valid under the assumption of the log-
additive risk inheritance model. The validity of the approach for dominant and recessive 
models is illustrated in the dissertation of Sohns (Sohns 2012). The additive risk model is 
commonly used to model the risk inheritance mode in epidemiologic study, since it takes into 
account natural genotype coding, according to the minor allele count. Furthermore, it performs 




The adjustment for major covariates such as sex, age, and principal components for ethnicity 
(as discussed in Chapter 3) is often needed in genetic association and interaction studies. 
Therefore, proof of the validity of the EHB-GECHI approach under the adjusted analysis is 
clearly important. We showed that if independence of the interaction OR and the covariate is  
given, then separate adjustment within cases and controls leads to the same estimates as those 
resulting from adjustment in the whole case-control sample. This proof validates EHB-GECHI 
after separate adjustment within cases and controls, as required by the approach. We proposed 
using log-linear models when the independence assumption is not valid, in order to obtain 
adjusted estimates for cases and controls simultaneously. However, a limitation of the log-
linear regression framework is its ability to model only categorical variables but not continuous 
ones. 
In Chapter 5, we developed an alternative, computationally much faster approach (it requires 
three times less computer time (CPU)) compared to the EHB-GECHI, approach. Another 
prominent advantage of our novel EHB-GENN method is that the analytically closed form of 
the posterior distribution for the test statistics of this approach is available. EHB-GENN is based 
on a two-stage hierarchical model, necessary to estimate G-E correlation effects in controls 
effectively. It is proposed as a tool to account for population-based G-E correlation, one of the 
biggest concerns in studies of G×E interactions. It is well known that the Gaussian family is a 
self-conjugate with respect to a Gaussian likelihood function. Therefore, choosing a normal 
distribution as a prior probability distribution for the mean of G-E correlations ensures that the 
posterior distribution is also normal. We assumed normal distributions at both stages, 
benefitting from the resulting analytical normal form of the posterior distribution and also from 
the closed form of the posterior variance of G-E correlation estimates. This is in contrast to 
EHB-GECHI. Our novel approach controls type I error substantially better than EHB-GECHI and 




hyperparameter estimation, as it requires only one common parameter to be estimated, 
gathering information on the whole available data in contrast to only three hyperparameters for 
EHB-GECHI. It is easily extendable to handle multilevel or continuous genotype and exposure 
variables, as this works in the same manner as shown for EHB-GECHI in Chapter 4. We 
implemented both EHB-GECHI and EHB-GENN in an R package that has been named EHBg×e. 
Performing an extensive simulation study, we evaluated properties of the EHB-GENN approach. 
Based on the observed results, we recommend performing EHB-GENN to test for the interaction 
when a large number of G-E correlation signals with moderate to high effect size are expected 
to exist in the study sample. We also suggest applying EHB-GENN in studies with frequent 
exposure variable, so that the strata are large enough for the hyperparameter estimation. EHB-
GENN can be applied for significance testing in GWAS to search for G×E interaction signals 
without assuming G-E independence. This is in contrast to the case-only or Mukherjee’s 
empirical Bayes tests. It maintains adequate power and almost always performs better than the 
case-control or Murcray’s two step tests. Case-control or Murcray’s two step also do not require 
any assumption of G-E independence. 
Joint tests are performed to detect variants that have moderate marginal effects on an outcome, 
differing according to an environmental factor that would be potentially missed by the main 
effect genome-wide analysis or pure interaction analysis. EHB-GENN can easily be used to 
construct a joint test for genetic marginal and G×E interaction effect, similar to the joint tests 
proposed by Dai and colleagues (Dai, Logsdon et al. 2012). In contrast to the CO test that was 
employed in Dai’s 2 df test construction, our EHB-GENN approach, as well as its joint version, 
do not require any assumption of G-E independence, which can be critical in the context of a 
large-scale genome-wide association study. Therefore, we constructed the joint EHB-GENNJ 





Our work was motivated by lung cancer GWAS data from the ILCCO/TRICL consortium with 
smoking being the established environmental risk factor. With the aim of identifying promising 
association signals for lung cancer, we conducted a statistical analysis on four lung cancer 
GWAS datasets. We replicated previous findings, namely two known SNPs on chromosome 
15q24-25 that belong to the nicotine acetylcholine acceptor subunit CHRNA3 and 
AGPHD1genes with slightly lower p-values than previously reported and described signals in 
our data worth further investigation, e.g. SNPs located in TERT and ENOX1 genes. Nowadays, 
TERT is one of the most interesting genes in the study of lung cancer risk. SNP rs2736100 in 
the TERT gene was reported as being in association with adenocarcinoma risk on the basis of 
a large genome-wide association study involving 13,300 cases and 19,666 controls of European 
descent and 3,333 subjects with adenocarcinoma among them (Landi, Chatterjee et al. 2009). 
The same variant was found to influence the risk of lung cancer in two meta-analyses; the first 
with 16 pooled GWASs involving 14,900 cases and 29,485 controls (Timofeeva, Hung et al. 
2012) and the second with 21 pooled GWASs involving 11,645 cases and 14,954 controls 
(Truong, Hung et al. 2010). To date, none of the single case-control GWAS were able to find 
these SNPs without requiring huge datasets and meta-analytical approaches. In our study with 
the joint test, we identified this SNP with p-value 8.5×10-6 based on only 1,989 cases and 2,625 
controls in the CE-IARC data with the moderate-heavy smoking model. For the same data, the 
variant has a p-value of 2.5×10-4 when testing for G×E interaction with classic CC test and a 
p-value of 1.6×10-3 when testing for genetic main effect. As a result, it was previously missed 
by both interaction and main effect tests in our data. This demonstrates that joint tests are useful 
in the identification of missing genetic main effect signals and require considerably smaller 
sample size than compared to meta-analytic approaches. This can be crucial in many situations 




Both EHB-GENN and EHB-GENNJ tests indicated a novel association signal of SNPs rs7982922, 
rs10492572, and rs10492573, located on the ENOX1 gene on chromosome 13q14. ENOX 
proteins (ENOX1, ENOX2 and ENOX3) are a unique family of cell surface proteins, playing an 
essential role in the enlargement phase of cell growth (ENOX1) and unregulated cancer cell 
growth (ENOX2). Both ENOX1 and ENOX2 are found in the sera of cancer patients. These 
proteins highly relate to each other and in fact share 64% of identity and 80% of similarity in 
humans (Morré and Morré 2012). Deletion of three distinct regions on chromosome 13 
including the 13q14 region in which ENOX1 is located was reported for NSCLC (Tamura, 
Zhang et al. 1997). This suggests that ENOX1 variants, namely rs7982922, rs10492572, and 
rs10492573, might form an interesting signal for the risk of lung cancer development. 
Future research is necessary to study these signals in more detail with regard to their functions 
and molecular biology, as well as to replicate these association results in other studies of 
Europeans or other populations. 
A meta-analysis across more GWASs based on the joint testing techniques and allowing for 
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